CHICAGO
13TH INTERNATIONAL MUSCULOSKELETAL CONGRESS

www.wfh.org/msk2013

Chicago, U.S.A.

April 18-21, 2013

Organized by:
In collaboration with:

FINAL PROGRAM AND ABSTRACTS
50 YEARS OF ADVANCING TREATMENT FOR ALL

Join the World Federation of Hemophilia as we mark 50 years of serving the global bleeding disorders community.

www.wfh.org/50

The WFH is grateful to our corporate partners for their support of the WFH 50th anniversary.

Baxter
Bayer
Biogen Idec Hemophilia
Biotest
BPL
CSL Behring
Green Cross
Grifols
Kedrion
LFB
Novo Nordisk
Pfizer
Sanquin
Greetings

Dear colleagues and friends,

On behalf of the musculoskeletal executive committee of the World Federation of Hemophilia (WFH), it is a great pleasure and privilege to welcome you to the “Windy City” of Chicago, Illinois. This WFH 13th International Musculoskeletal Congress marks the first time that the U.S.A. has hosted a WFH Congress.

We are very pleased to continue the tradition of communication and collaboration among the many orthopedic surgeons, rehabilitation specialists, hematologists, and other professionals, from more than 50 countries, who specialize in the treatment and care of people with bleeding disorders.

Together, all attendees, both experts and novices, will have the opportunity to collaborate, network, learn, and discuss new treatment developments. In sharing their global perspectives, the experience of all will be enriched.

As a testament to our goal to provide a highly scientific meeting, we are pleased to report that we have received a total of 76 abstract submissions that will be shared with attendees in the form of 20 oral presentations, and 48 poster presentations.

Just as we promote a comprehensive team to care for our patients, this meeting was planned using a team approach between the WFH musculoskeletal executive committee, the National Hemophilia Foundation of the U.S.A., and our local host, Len Valentino, MD.

In the spirit of teamwork, collaboration and learning, we encourage you to have a productive congress. We invite you to meet old friends, and make new ones, as we come together with the common goal of caring for the world’s people with bleeding disorders. Enjoy the social time at Congress and all that Chicago has to offer: world-class dining, theatre, museums, music, sports, and shopping.

Welcome again and thank you very much for coming!

Angela Forsyth, PT, DPT
Chair, musculoskeletal executive committee
General Information

Congress information .................................................................................................................................5
About Chicago ...............................................................................................................................................6
Social program...........................................................................................................................................7
Acknowledgements .....................................................................................................................................8
Committees ..................................................................................................................................................8

Program

At a glance ...................................................................................................................................................9

Congress sessions
Professional development workshops........................................................................................................11
Friday, April 19 ...........................................................................................................................................12
Saturday, April 20 ......................................................................................................................................14
Sunday, April 21 .......................................................................................................................................16

Abstracts

Professional Development – Physiotherapy ................................................................................................17
PDW-01: Global Physiotherapy Initiative – an update .............................................................................17

Session A1 - State of the Art
A1.3: Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood induced joint damage in a murine model of hemophilia .................................................................17
A1.2: IPSG scoring system ..........................................................................................................................17
A1.3: Wound healing in hemophilia ..........................................................................................................17
A1.4: Osteoporosis .....................................................................................................................................18

Lunch Symposium – How we manage inhibitor patients with musculoskeletal problems:
A continuous patient journey ....................................................................................................................18

Surgical options .......................................................................................................................................18

Session A3: Surgery Tips and Clips
A3.1: Avoiding non-union in subtalar joint fusion .....................................................................................19
A3.2: The arthritic knee with flexion contracture: Steps to achieve extension during total knee replacement (TKR) .........................................................................................................................19
A3.3: Hemophilic chronic synovitis: Therapy of hemarthrosis using endovascular embolization of knee and elbow arteries .................................................................................................................19
Table of Contents

Session A4: Free Papers 1
A4.1: Total knee replacement in patients with inherited bleeding disorders: Early results ................................................................. 19
A4.2: Accelerated discharge programs post total knee replacements (TKR): Are these suitable for people with hemophilia (PWH)? A review of cases at the Haemophilia Comprehensive Care Centre, Belfast, Northern Ireland ........................................................................... 20
A4.3: Total ankle replacement in patients with severe hemophilic arthropathy .................................................................................... 20
A4.4: Outcomes of total knee arthroplasty (TKA) in the hemophilia population: A meta-analysis ................................................................. 21
A4.5: Radiosynoviorthesis with three types of radiopharmaceuticals: Results in 400 patients ........................................................................ 21
A4.6: A fusion protein of IL4 and IL10 (IL4-10 synerkine) is equally effective in protecting cartilage from blood-induced damage compared to the individual components .................................................................................................................... 22
A4.7: Subchondral cyst in people with hemophilia (PWH) treated with bone substitute (OH apatite coralline) ................................................................................................................................. 22
A4.8: Knee flexion contracture treated with botulinum toxin type A in people with hemophilia (PWH) ........................................................................ 23
A4.9: Orthopedic surgery in patients affected by von Willebrand disease (VWD) and rare bleeding disorders .................................................................................................................................................................... 23
A4.10: Cartilage damage biomarkers are increased after a joint bleed; an explorative human and canine in vivo study ......................................................................................................................... 23

Session B1: Plenary
B1.1: The World Federation of Hemophilia research agenda ......................................................................................................................... 24

Session B2: Crossfire Session: Biological Therapies
B2.1: Biological therapies – The theory ............................................................................................................................................... 24
B2.2: Biological therapies – The theory: Why not .................................................................................................................................................. 24
B2.3: Biological therapies – The reality ......................................................................................................................................................... 25
B2.4: Biological Therapies – The reality: Why not .................................................................................................................................................. 25

Session B3: Muscle Bleeding
B3.1: Muscle bleeding – Diagnostics: How and when? ................................................................................................................................. 25
B3.2: Muscle bleeds and low-intensity pulse ultrasound (US) therapy .................................................................................................. 25
B3.3: Compartment syndrome ............................................................................................................................................................................................ 26
B3.4: Muscle bleed: Medical management .................................................................................................................................................... 26
B3.5: Conservative management ............................................................................................................................................................................... 26

Session B4: Free Papers 2
B4.1: Altered muscle strength and architecture influences motor performance in boys with severe hemophilia and ankle joint hemarthrosis ................................................................................................................. 26
B4.2: Dance-based exercise therapy for patients with hemophilia ................................................................................................................. 27
B4.3: Differences in physical activity and sedentary behavior between young hemophiliacs with and without arthropathy ......................................................................................................................................................... 27
Table of Contents

B4.4: Associations of quality of life, pain, and self-reported arthritis with bleed rate and hemophilia treatment centre (HTC) and healthcare practitioner utilization: Global results from the Hemophilia Experiences, Results and Opportunities (HERO) Study...............28

B4.5: Should osteoporosis screening be a routine standard in hemophilia care: a multi-centre study and review of the literature? .................................................................28

B4.6: Correlation of Haemophilia Activities List (HAL) and musculoskeletal physical assessment in a cohort of 95 severe hemophilia patients ..............................................................28

B4.7: Associations between physical activity risk level, treatment regimen and hemophilia treatment centre (HTC) and healthcare professional utilization: Results from the Hemophilia Experiences, Results and Opportunities (HERO) Study .......................................................29

B4.8: Deferasirox prevents cartilage destruction following hemarthrosis in hemophilic mice .........29

B4.9: Healing defects in a hemarthrosis model are improved by extending factor IX activity during healing .....................................................................................................................30

B4.10: Sequential changes during intra-articular wound healing examined in hemophilic and normal mouse joints ........................................................................................................30

Session C1: Plenary .............................................................................................................................30
C1.1: Outcome measures ....................................................................................................................30

Poster Abstracts

Poster Session 1 ..................................................................................................................................31
Poster Session 2 ..................................................................................................................................39

Speaker Index ........................................................................................................................................51

Poster Index ........................................................................................................................................52
Congress Information

Congress Venue
The WFH 13th International Musculoskeletal Congress is being held at the Westin Michigan Avenue Chicago.

Accessibility
The WFH is committed to providing equal access and an inclusive experience, in all aspects of business, including its meetings and events, to participants who have limited mobility and other medical considerations related to a bleeding disorder or other medical condition. The WFH has made every effort possible to overcome barriers that could obstruct access to the meetings and events associated with the Congress, however, unforeseen circumstances can arise. The WFH would be grateful to hear of any such instances, so it can make suitable improvements.

Cellular Phones and Pagers
As a courtesy to all congress attendees and speakers, cellular phones, pagers, and other electronic devices must be operated in the silent/vibrate mode within educational sessions. Devices that beep and ring are strictly prohibited. No cellular phone conversations are permitted within the meeting rooms.

Duplication/Recording
Audio-taping, video recording, digital taping, or any other form of duplication, is strictly prohibited in the session halls.

Smoke-free Policy
The 13th International MSK Congress has been declared a smoke-free event. Please note that smoking is not permitted anywhere inside the confines of the Westin Michigan Avenue Chicago.

Certificate of Attendance
Each delegate will receive a certificate of attendance, along with his/her name badge. Should your certificate contain errors, kindly report this to the Congress registration desk, located in front of the exhibitions area.

Badges
Congress participants, speakers, and exhibitors must wear their name badges for entry into the congress sessions. Entrance to sessions and social event on Thursday night is limited to badge holders only.

The following is an explanation of the different coloured name badges:

<table>
<thead>
<tr>
<th>Color</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLUE</td>
<td>Delegate/AHP</td>
</tr>
<tr>
<td>BLUE/ORANGE</td>
<td>Speaker</td>
</tr>
<tr>
<td>GREEN</td>
<td>Exhibitor</td>
</tr>
<tr>
<td>RED</td>
<td>WFH staff, executive, travel grants, musculoskeletal committee</td>
</tr>
<tr>
<td>SILVER</td>
<td>On site</td>
</tr>
<tr>
<td>CLEAR</td>
<td>Accompanying person</td>
</tr>
</tbody>
</table>

Congress Evaluation
A Congress evaluation will be placed in each delegate bag. Your valuable feedback will help us in planning our future congresses. All evaluation forms that are completed and returned to the registration desk will be eligible for a draw to win an iPod touch. The draw will take place during the general assembly on Sunday, April 21, 2013. Winner must be present to receive the prize.

Congress Bag
Each delegate will receive a congress bag at registration. As all delegate bags are identical, it is strongly recommended that you personalize your own bag with a business card or bag tag.

Continuing Medical Education Credits (CME)
Delegates wishing to apply for CME credits may stop by the congress registration desk, to register for the accreditation certificate. This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME), through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and of the World Federation of Hemophilia.

The PIM, accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 13 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Coffee & Tea Break
For registered participants wearing their name badges, coffee and tea during the breaks are included in the fee.

Dress Code
Dress code during the congress is smart casual.

Registration
The registration area during the Congress is located on level 2, in front of the Ontario/Erie room.

Registration/information desk schedule:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, April 18</td>
<td>12:00 – 16:30</td>
</tr>
<tr>
<td>Friday, April 19</td>
<td>8:00 – 16:30</td>
</tr>
<tr>
<td>Saturday, April 20</td>
<td>8:00 – 16:30</td>
</tr>
<tr>
<td>Sunday, April 21</td>
<td>8:30 – 11:30</td>
</tr>
</tbody>
</table>

Congress Organizing Secretariat
13th International MSK Congress Secretariat and Housing Bureau

World Federation of Hemophilia
1425 René-Lévesque Blvd. West, Suite 1010
Montréal, Québec Canada H3G 1T7
Tel: +1 (514) 394-2837
Fax: +1 (514) 875-8916

About Chicago
The Chicago area serves as a centre for many key industries and is home to 29 Fortune 500 headquarters, 12 Financial Times Global 500 headquarters, and 400+ major corporate headquarters. Plus, its central location makes it easily accessible from almost anywhere in the world.

Language: English

Time: Central (GMT –5)

Electricity: 110 volts AC, 60Hz. Plugs are of the flat two-pin type. European electrical appliances not fitted with dual-voltage capabilities will require a plug adaptor, best purchased before arrival in the U.S.A.

Currency: U.S. Dollar

Credit Cards: Most major credit cards are accepted throughout the U.S.A., including American Express, Diners Club, MasterCard and Visa. Visitors are advised to carry at least one major credit card, as it is common to request prepayment or a credit card imprint for hotel rooms and car hire, even when final payment is not by credit card.

Travellers cheques: U.S. Dollar cheques are widely accepted.

Currency exchange: Hotels do not, as a rule, exchange currency and only a few major banks will exchange foreign currency, so it is advisable to arrive with U.S. dollars, or exchange foreign currency at the airport upon arrival.

Social & Business Customs
Performing Arts / Theater
Chicago's theatre scene has everyone watching. Broadway in Chicago boasts many mega-hit musicals every year, and you'll find cutting-edge drama at the Goodman, Steppenwolf, or Lookingglass theatres.

Shopping
Chicago is where a shopper's fantasy comes true. Imagine a place with world-class department stores, every kind of boutique, specialty shops, and fabulous discount shopping. One important Chicago destination is The Magnificent Mile, along Michigan Avenue. In this eight-block stretch, hundreds of stores offer luxury items, beautiful bargains, and everything in between. Or check out Oak Street, an international style centre with high-end stores and salons.

Gastronomy and Nightlife
Chicago is home to four AAA Five-Diamond restaurants, which is the second most of any city in the U.S. The city is also famous for its deep-dish pizza and Chicago-style hot dogs. Downtown, and in Chicago's 77 neighborhoods, countless ethnic restaurants are ready to introduce you to new tastes. Chicago is also home to a number of celebrity chefs, several of whom have made appearances on —or won—competitive reality cooking shows. After dinner, check out Chicago's great nightlife. At legendary lounges, piano bars, and other great venues, the city pulses with the beat of countless live performances of jazz, mainstream and indie rock, folk and country, world music, and—of course—blues. After all, Chicago is the official home of the blues.
Climate & Clothing
There is a wide variation between hot summers and freezing winters, especially in the north of the state. The highest humidity is in the summer, near the Great Lakes.

The average weather in Chicago in April is:

Average high temperature 14°C / 57°F
Average low temperature 4°C / 39°F

Public Transportation
The Chicago Transit Authority (CTA) offers fast, direct train service from airports to downtown along convenient bus and train lines to major attractions and provides custom trip planning for groups.

Taxis/Water taxis
There are thousands of taxi cabs in Chicago. Fares begin at $3.75 and increase $0.20 for each 1/9th of a mile.

Social Program

**WFH 50TH ANNIVERSARY AND WELCOME COCKTAIL**
Following the opening ceremony, delegates will be directed to the Michigan room for the WFH 50th anniversary and welcome cocktail. Light snacks and refreshments will be served and delegates will have the chance to connect with old friends and acquaintances. The evening will conclude at 19:30.

**DATE:** Thursday, April 18, 2013
**TIME:** 18:00–19:30
**VENUE:** Michigan Ballroom (L2)
**DRESS:** Smart Casual
**COST:** Complimentary for registered attendees

**FAREWELL DINNER**
A fun evening is in store at the House of Blues for all guests attending the farewell dinner. American comfort cuisine and entertainment have been planned for the evening. Pre-paid tickets for this evening will be distributed at registration. Tickets will be available for purchase on site, at the registration desk, for $75 USD, until Friday, April 20, or while quantities last. Join us and let music and food feed your soul.

**DATE:** Saturday, April 20, 2013
**TIME:** 18:45–23:00
**VENUE:** The House of Blues
**DRESS:** Casual Chic
**ON SITE COST:** $75 USD
Acknowledgements
The congress organizer for the WFH 13th International Musculoskeletal Congress would like to thank the following companies for their significant contributions:

Platinum Sponsors:

Silver Sponsor:

Exhibitor:

Committees

WFH musculoskeletal organizing committee
Angela Forsyth, U.S.A., chair
Mauricio Silva, U.S.A., senior vice-chair
Neil Frick, NHF vice-president for research and medical information
Assad Haffar, WFH regional program manager, deputy director
Maria Milagros Salas, WFH congress & meetings manager – Musculoskeletal Congress 2013 project manager

WFH musculoskeletal executive committee
Angela Forsyth, U.S.A., chair
Mauricio Silva, U.S.A., senior vice-chair
Nicholas Goddard, U.K., junior vice-chair
Pamela Narayan, India, secretary
Lily Heijnen, the Netherlands, member at large

WFH musculoskeletal program committee
Angela Forsyth, U.S.A.
Nicholas Goddard, U.K.
Lily Heijnen, the Netherlands
Pamela Narayan, India
Len Valentino, U.S.A.
Helene Lussier, WFH congress & meetings manager, scientific program

WFH musculoskeletal abstract review committee
Mauricio Silva, U.S.A.
Nicholas Goddard, U.K.
Pamela Narayan, India
Lily Heijnen, the Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday, April 18</th>
<th>Friday, April 19</th>
<th>Saturday, April 20</th>
<th>Sunday, April 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–10:30</td>
<td>State of the Art session</td>
<td></td>
<td>Plenary: WFH Research Agenda</td>
<td>Plenary: Outcomes Measures</td>
</tr>
<tr>
<td></td>
<td>NFkB target genes in BUD (G. Jayandharan)</td>
<td>IPSG scoring system (M. Manco-Johnson)</td>
<td>(David Lillicrap)</td>
<td>(Nancy Young)</td>
</tr>
<tr>
<td></td>
<td>Wound healing (M. Hoffman)</td>
<td>Osteoporosis (M. Simpson)</td>
<td>Crossfire Session</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biological therapies:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The theory/The reality</td>
<td></td>
</tr>
<tr>
<td>09:00–10:00</td>
<td>Plenary: WFH Research Agenda</td>
<td></td>
<td>Biological therapies:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary: Outcomes Measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary: Outcomes Measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Live Surgery Stream with Panel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematologist (L. Valentino)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Orthopedist (L. Solimeno)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physiatrist (L. Heijnen)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physiotherapist (P. McLaughlin)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–12:00</td>
<td>Crossfire Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biological therapies:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The theory/The reality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–16:30</td>
<td>Registration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–14:00</td>
<td>Industry Lunch Symposium (Novo Nordisk)*</td>
<td>How we manage inhibitor patients with musculoskeletal problems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–16:00</td>
<td>Professional Development – Physiotherapy</td>
<td>Global Physiotherapy Initiative</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>International project updates</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Next steps for physiotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Open Forum: To rest or not to rest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30–15:30</td>
<td>Ortho: Surgery Tips and Clips</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The subtalar joint (J. Luck)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The arthritic knee (A. Llinás)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic synovitis (H. Caviglia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00–17:10</td>
<td>Free Papers 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00–15:30</td>
<td>Muscle Bleeding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic: How and when? (D. Stephensen)</td>
<td>Use of ultrasound (A. Sabbour)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Compartment syndrome (N. Goddard)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical management (M. El-Ekiaby)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conservative management (L. Chen)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30–19:30</td>
<td>Opening Ceremony and Welcome Cocktail</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| * This activity is jointly sponsored/co-provided by the Postgraduate Institute for Medicine, The Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Supported by an educational grant from Novo Nordisk.
Professional Development Workshops (PDW)
13:00–16:00

PDW – Physiotherapy

Physiotherapy issues and developments
Room: Great Lakes D-E
Co-chairs: Pamela Narayan, India, and Lily Heijnen, the Netherlands
13:00-13:15 Welcome and introductions • Lily Heijnen, the Netherlands
13:15-13:45 Global Physiotherapy Initiative • Piet de Klein, the Netherlands
13:45-14:10 International physiotherapy projects
    St. Petersburg, Russia • Angela Forsyth, U.S.A.
    Cairo, Egypt • Adly Sabbour, Egypt
    Lithuania • Natasa Jankovic, Serbia
    Serbia • Natasa Jankovic, Serbia, and Lily Heijnen, the Netherlands
14:10-14:20 Next steps • The training team
14:20-15:00 Open forum: to rest or not to rest
    Introduction and procedures • Pamela Narayan
    The concept of rest: What do we mean by it? • David Stephensen, U.K.
    The impact of too little rest on the bleeding joint? • Rohini Dange, India
    The impact of too much rest on the bleeding joint? • Silvana Toledo, Uruguay
15:00-15:15 Break
15:15-16:00 Group discussions and conclusions • Audience and chairpersons

PDW – Orthopedic

Orthopedic issues and developments
Room: Great Lakes A-B
13:00-13:15 Welcome and introductions • Mauricio Silva, U.S.A.
13:15-13:45 Joint replacement registry • Nicholas Goddard, U.K.
13:45-14:15 Brainstorming session:
    Educational projects: Development of an image bank • Mauricio Silva, U.S.A.
    Other projects • Audience
14:15-14:30 WFH orthopedic fellowship program: A progress report • Mauricio Silva, U.S.A.
14:30-15:00 Treatment guidelines of hemophilia • Mauricio Silva, U.S.A.

Poster Presentation Highlights
16:00–16:15
Best of abstract selected posters
Room: Great Lakes A-B
Chair: Mauricio Silva, U.S.A.

Opening Ceremonies and Welcome Reception
17:30–19:30
Room: Great Lakes A-B
Master of Ceremonies: Assad Haffar, WFH
Opening remarks • Angela Forsyth, WFH musculoskeletal chair
Greetings from the NMO host • Val Bias, U.S.A.
Message from the WFH vice-president, medical • Alok Srivastava, WFH
Keynote Speech: 50th anniversary of the World Federation of Hemophilia • Alain Weill, WFH president
Friday, April 19

Congress Sessions
9:00–10:30

**A1 – State of the Art**

Room: Great Lakes Grand Ballroom

- NFkB target genes in BIJD · Giridhara Rao Jayandharan, India
- IPSG scoring system · Michael Manco-Johnson, U.S.A. (TBC)
- Wound healing · Maureane Hoffman, U.S.A.
- Osteoporosis · Mindy Simpson, U.S.A.

Refreshment Break and Poster Viewing
10:30–11:00
Room: Ontario/Erie

Congress Sessions
11:00–12:30

**A2 – Live Surgery and Panel Discussion**

Room: Great Lakes Grand Ballroom
Co-chairs: Mauricio Silva, U.S.A. and Greig Blamey, Canada

Panel
- Hematologist: Len Valentino, U.S.A.
- Orthopedist: Luigi Piero Solimeno, Italy
- Physiatrist: Lily Heijnen, the Netherlands
- Physiotherapist: Paul McLaughlin, U.K.

Lunch Symposium
12:30–14:00

**How We Manage Inhibitor Patients with Musculoskeletal Problems: A Continuous Patient Journey**

Room: Michigan Ballroom
Chair: Len Valentino, U.S.A.

- Case study introduction · Len Valentino, U.S.A.
- Surgical options · Carlos Rodriguez-Merchán, Spain
- Physiotherapy interventions · Nichan Zourikian, Canada

Congress Sessions
14:30–15:30

**A3 – Surgery Tips and Clips**

Room: Great Lakes Grand Ballroom
Co-chairs: Natasa Jankovic, Serbia, and Luigi Piero Solimeno, Italy

- The subtalar joint: Tips to decrease the risk of non-union after fusion · James Luck, U.S.A.
- The arthritic knee with flexion contracture: Steps to achieve extension during TKR · Adolfo Llinás, Colombia
- Chronic synovitis: Is embolization a better solution than synovectomy? · Horacio Caviglia, Argentina
Refreshment Break and Poster Viewing
15:30–16:00
Room: Ontario/Erie

Congress Sessions
16:00–17:10

**A4 – Free Papers I**

Room: Great Lakes Grand Ballroom

*Co-chairs: Greg Blamey, Canada, and Adolfo Llinás, Colombia*

**A4.1: Total knee replacement in patients with inherited bleeding disorders: Early results**

_**P. Ambroziak***, P. Zbikowski1, J. Windyga1, I. Kotela1,3
1Central Clinical Hospital of the Ministry of Interior, Warsaw; 2Institute of Hematology and Transfusion Medicine, Warsaw; 3The Jan Kochanowski University in Kielce, Kielce, Poland_

**A4.2: Accelerated discharge programs post total knee replacements (TKR): Are these suitable for people with hemophilia (PWH)? A review of cases at the Haemophilia Comprehensive Care Centre, Belfast, Northern Ireland**

_**L. Sayers**, D. Beverland2, C. Connolly2, G. McAlinden2, G. Benson3
1Haemophilia Comprehensive Care Centre, Bridgewater Suite, Belfast City Hospital; 2Musgrave Park Hospital, Stockmans Lane, Belfast BT12BN, Belfast, Northern Ireland_

**A4.3: Total ankle replacement in patients with severe hemophilic arthropathy**

_**A. Strauss**, G. Goldmann4, M. Wessling1, M.C. Mueller1, J. Oldenburg1, D. Wirtz1, P.H. Pennekamp1_

1Department of Orthopedics and Trauma Surgery and, 2Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany

**A4.4: Outcomes of total knee arthroplasty (TKA) in the hemophilia population: A meta-analysis**

_**M. Moore**, P. Tobase, D. Allen, B. Smoot_

University of California, San Francisco Medical Center, San Francisco, U.S.A.

**A4.5: Radiosynoviorthesis with three types of radiopharmaceuticals: results in 400 patients**

_**L.F.D. van Vulpen***, S. Augusto Lopes Souza1, B. Gutfilen1, M. Albernaz2, D. Regina Della Riva3, M. Benedito Correa Gabriel1, P.M. Pinheiro Perri1, A. Rebelo1, A. Bordim1, R. Gomes2, E. Pimentel da Silva1, L. Barboza da Fonseca1_

1Universidade Federal do Rio de Janeiro, Rio de Janeiro; 2Hemoceimento do Mato Grosso, Cuiaba, Brazil

**A4.6: A fusion protein of IL4 and IL10 (IL4-10 synerkine), is equally effective in protecting cartilage from blood-induced damage compared to the individual components**

_**L.D. van Vulpen***, S.E.R. van Meegeren1,2, S.A.Y. Hartgring1,2, C. Steen-Louws1,3, S.C. Mastbergen1, C.E. Hack1,3, J.A.G. van Roon1,2, F.P.J.G. Lafeber1_

1Rheumatology & Clinical Immunology; 2Haematology and Van Creveld Clinic; 3Immunology, University Medical Center Utrecht, the Netherlands

**A4.7: Subchondral cyst in people with hemophilia (PWH) treated with bone substitute (OH apatite coralline)**

_**H. Caviglia***, C. Daffunchio1,2, G. Galatro1,2, G. Cambiaggi1,2, N. Moretti1, M. Candela1,3
1Fundación de la Hemofilia; 2Hospital Juan A. Fernandez, Servicio de Ortopedia y Traumatologia; 3Academia Nacional de Medicina, Buenos Aires, Argentina

**A4.8: Knee flexion contracture treated with botulinum toxin type A in people with hemophilia (PWH)**

_**L.P. Solimeno***, G. Pasta1, S. Siboni2, E. Biguzzi2, C. Mistretta2, F. Peyvandi3_

1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico; 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy

**A4.9: Orthopedic surgery in patients affected by von Willebrand disease (VWD) and rare bleeding disorders**

_**L.P. Solimeno***, G. Pasta1, S. Siboni2, E. Biguzzi2, C. Mistretta2, F. Peyvandi3_

1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico; 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy

**A4.10: Cartilage damage biomarkers are increased after a joint bleed; an explorative human and canine in vivo study**

_**L.F.D. van Vulpen***, M.E.R. van Meegeren1,2, G. Roosendaal3, S.C. Mastbergen1, F.P.J.G. Lafeber1_

1Rheumatology & Clinical Immunology; and 2Haematology and Van Creveld Clinic, University Medical Center Utrecht, the Netherlands
Saturday, April 20

Congress Sessions
9:00–10:00

**B1 – Plenary**
Room: Great Lakes Grand Ballroom
Chair: Magdy El-Ekiaby, Egypt
WFH research agenda · David Lillicrap, Canada

**Refreshment Break and Poster Viewing**
10:00–10:30
Room: Ontario/Erie

**Congress Sessions**
10:30–12:00

**B2 – Crossfire Session: Biological Therapies**
Room: Great Lakes Grand Ballroom
Co-chairs: Nicholas Goddard, U.K., and Pamela Narayan, India

The theory: Why and why not · Paul Monahan, U.S.A., Len Valentino, U.S.A.
The reality: Why and why not · Ulrike Reiss, U.S.A., Carlos Rodriguez-Merchán, Spain

Lunch
12:00–13:00

Poster Viewing
13:00–14:00

Congress Sessions
14:00–15:30

**B3 – Muscle Bleeding**
Room: Great Lakes Grand Ballroom
Co-chairs: Piet de Kleijn, the Netherlands, and James Luck, U.S.A.

Diagnostics: How and when · David Stephensen, U.K.
Use of ultrasound to manage muscle bleeds · Adly Sabbour, Egypt
Compartment syndrome: Surgical management · Nicholas Goddard, U.K.
Medical management · Magdy El-Ekiaby, Egypt
Conservative management · Lixia Chen, China

**Refreshment Break and Poster Viewing**
15:30–16:00
Room: Ontario/Erie
B4:1: Altered muscle strength and architecture influences motor performance in boys with severe hemophilia and ankle joint hemarthrosis  
**D. Stephensen**, W.I. Drechsler, O.M. Scott  
1School of Health, Sport and Bioscience, University of East London, London; 2Kent Haemophilia Centre, Canterbury, U.K.

B4:2: Dance-based exercise therapy for patients with hemophilia  
**D. Zepe**, S. van Ravenstein, T. Hilberg  
Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany

B4:3: Differences in physical activity and sedentary behavior between young hemophilic patients with and without arthropathy  
1School of Health, Sport and Bioscience, University of East London, London; 2Kent Haemophilia Centre, Canterbury, U.K.

B4:4: Associations of quality of life, pain, and self-reported arthritis with bleed rate and hemophilia treatment centre (HTC) and healthcare practitioner utilization: Global results from the Hemophilia Experiences, Results, and Opportunities (HERO) Study  
**A. Forsyth**, C. Guelcher, A. Buzzi, T. Wisniewski, D. Cooper, A. Iorio  
1Rush University Medical Center, Chicago, U.S.A.; 2Children's National Medical Center, Washington, DC, U.S.A.; 3Fondazione Paracelsio Onlus, Milan, Italy; 4Novo Nordisk Inc., Princeton, U.S.A.; 5McMaster University, Hamilton, Canada

B4:5: Should osteoporosis screening be a routine standard in hemophilia care: a multi-centre study and review of the literature?  
**A. Wells**, P. Prouse, J. Mainwaring, J. Simmonds, P. McLaughlin, P. Chowdary  
1Haemophilia, Haemostasis & Thrombosis Centre, Basingstoke & North Hampshire Hospital, Basingstoke; 2Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London; 3University of Hertfordshire, Hatfield, U.K.

B4:6: Correlation of Haemophilia Activities List (HAL) and musculoskeletal physical assessment in a cohort of 95 severe hemophilia patients  
**P. McLaughlin**, P. Chowdary  
Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, Pond St, London, U.K.

B4:7: Associations between physical activity risk level, treatment regimen and hemophilia treatment centre (HTC) and healthcare professional utilization: Results from the Hemophilia Experiences, Results, and Opportunities (HERO) Study  
**A. Forsyth**, F. Quero, A. Stain, L. Pericleous, D. Cooper, A. Iorio  
1Rush University Medical Center, Chicago, U.S.A.; 2Children's National Medical Center, Washington, DC, U.S.A.; 3Kiddies Health Care Inc., Toronto, Canada; 4Novo Nordisk Inc., Princeton, U.S.A.; 5McMaster University, Hamilton, Canada

B4:8: Deferasirox prevents cartilage destruction following hemarthrosis in hemophilic mice  
**L. Nieuwenhuizen** et al.  
1Hematology & Van Creveldkliniek; 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

B4:9: Healing defects in a hemarthrosis model are improved by extending factor IX activity during healing  
**P. Monahan** et al.  
1Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; 2Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; 3Department of Hematology, Peking Union Medical College Hospital, Beijing, China; 4Department of Biomedical Engineering and Radiation Oncology, University of North Carolina, Chapel Hill, U.S.A.

B4:10: Sequential changes during intra-articular wound healing examined in hemophilic and normal mouse joints  
**P. Monahan** et al.  
1Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; 2Department of Medicine, Peking Union Medical College, Beijing, China; 3Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.

**Farewell Dinner**  
18:45–23:00
Sunday, April 21

Congress Sessions
9:00–10:00

**C1 – Plenary**
Room: Great Lakes Grand Ballroom
Chair: Pamela Hilliard
*Outcome Measures* - Nancy Young, Canada

**Refreshment Break and Poster Viewing**
10:00–10:30

Congress Sessions
10:30–12:00

**C2 – Crossfire Session**
Room: Great Lakes Grand Ballroom
Co-chairs: Lily Heijnen, the Netherlands, and Gian Luigi Pasta, Italy

- **Inhibitor patient endoprosthesis or conservative** - Michael Heim, Israel, Nicholas Goddard, U.K.
- **Ice vs no ice** - Greig Blamey, Canada, Nichan Zourikian, Canada

**Annual General Assembly**
12:00–13:00
A Global Physiotherapy Initiative (GPI) was started in 2007. It is based on the principle of training the trainers, in close cooperation with WFH coordinators, regional NMOs, and local medical and paramedical professionals. Emphasis is on training the local trainers, combined with training and implementing basic physiotherapy on the spot. The intention is to set up and stabilize a regional network, in three steps: 1) One-day symposium (attract medical doctors and physiotherapists), 2) Site visits, to encourage the role of the physiotherapist inside the HTCs; 3) International course: one-day symposium and two-day workshops, organized by the local trainer for colleagues from that region. Results will be given from two pilot projects (Russia and Egypt) of which only one enrolled into an Arabic physiotherapy network. The Balkans and Baltic region will have their third step this year. All three existing regions produced trainers, not originating from developed countries, as well as implemented physiotherapy care. Finding tailored solutions for each HTC in this implementation process – with a proper set up, communication, and the cooperation of hematologists and physiotherapists – is still a challenge. But when it works, people with hemophilia (PWH) worldwide will benefit, running towards optimal functional capabilities and, thus, better quality of life.

Keywords: Global Physiotherapy Initiative – an update

A1.1

Nuclear factor (NF)-kB and its associated pathways are major molecular regulators of blood induced joint damage in a murine model of hemophilia

D. Sen1, A. Chapla1, N. Walter2, V. Daniel3, A. Srivastava1,4, G.R. Jayandharan1,4

Departments of 1Hematology; 2General Pathology & Forensic Medicine; 3Orthopedics; and 4Centre for Stem Cell Research, Christian Medical College, Vellore, Tamil Nadu, India

Background: Hemophilic arthropathy results from recurrent joint bleeds (hemarthrosis) in patients with hemophilia. The identity of the molecular mediators, which are activated upon exposure to blood, and the ensuing mediators of inflammation and articular damage are not completely characterized. The present study was thus designed to understand the major molecular regulators of blood induced joint damage in a murine model of hemophilia A.

Methods and Results: A sharp-injury model of hemarthrosis that recapitulated the histomorphologic features of both acute hemarthrosis and chronic arthropathy, seen after single- or multiple- articular bleeds, respectively, was used. A global gene expression array on joint-specific RNA isolated 3h post-injury revealed nuclear factor-kappa B (NF-κB) as the major transcription factor triggering inflammation. Since a number of genes encoding various cytokines, growth factors, and hypoxia-regulating factors are known to be activated by NF-κB and many of these are part of the pathogenesis of various joint diseases, we reasoned that NF-κB associated pathways may play a crucial role in blood-induced joint damage. To further understand how the transcriptional potential and activity of this factor is regulated upon bleeding, we did a targeted screening of NF-κB associated pathways between 1h and 90 days after injury. After a single-articular bleed, distinct members of the NF-κB family (NF-κB1/NF-κB2/RelA/RelB) and their responsive pro-inflammatory cytokines (IL-1β/IL-6/IFNγ/TNFα) were significantly up-regulated (>2 fold, p<0.05) in injured vs control joints at the various time-points analyzed (1h/3h/7h/24h). On multiple injury models (day 30/60/75/90), downstream targets of NF-κB, that contribute to hypoxia (HIF-1α, 3.3-6.5 fold), angiogenesis (VEGF-α, 2.5-4.4 fold), and chondrocyte damage (matrix metalloproteinase-13, 2.8-3.8 fold) were significantly (p<0.05) elevated in the injured joints. Many key micro RNAs (miR) with documented roles in NF-κB activation (miRs-9 and 155), inflammation (miRs-16, 155 and 182), and apoptosis (miRs-19a, 155 and 186) were also differentially expressed after joint bleeding (~4 to +13-fold), indicating that the small RNAs could modulate the arthropathy phenotype. Conclusions: These data suggest that NF-κB associated signaling pathways are involved in the development of hemophilic arthropathy. Further ongoing studies by specific blocking of NF-κB alone or in combination with other key targets such as HIF-1α, VEGF-α, or MMP-13, or modulating the expression of miRNAs (eg. miR-155) in the hemarthrosis models, will shed further mechanistic insights into this phenomenon.
Osteoporosis

M.L. Simpson

Rush University, Chicago, IL, U.S.A.

Bone mineral density (BMD) is determined by peak bone mass and the rate of bone loss. Peak bone mass is reached in the third decade of life and is influenced by genetics, nutrition, body weight, and weight-bearing physical activity. Bone mass remains relatively constant until bone loss begins later in life. Accelerated bone loss can occur resulting in lower peak bone mass if it occurs early in life or progressive bone loss. Osteoporosis is characterized by reduced mass and impaired quality or structural integrity of bone, increasing the risk of fracture. This may be achieved by failure to achieve optimal bone strength (low peak bone mass), excessive bone resorption, or defective bone formation.

DEXA is a screening tool for osteoporosis by attempting to measure BMD. Treatment is generally focused on promoting increasing bone mass or anti-resorptive medications. Osteoporosis is an underestimated problem in individuals with hemophilia. Repeated studies have shown a correlation with hemophilia and reduced bone density and/or osteoporosis, compared to controls. Contributing factors in this population may include avoidance of weight-bearing physical activity as a child or adolescent, prolonged immobilization, presence of comorbid infections, including HIV and hepatitis C, and the presence of excess iron from intra-articular bleeding. Treatment strategies in this population include weight-bearing physical activity, treating joint disease to maintain mobility, adequate calcium and vitamin D supplementation, and the possible use of antiresorptive medications.

Improved screening for early detection in this high risk population is needed.

Keywords: osteoporosis, bone mineral density, DEXA
A3.1
Avoiding non-union in subtalar joint fusion

J.V. Luck, Jr.
UCLA/Orthopaedic Hospital Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A.

Hemophilic arthropathy of the ankle is often associated with arthropathy of the subtalar joint (STJ). Recurrent bleeding and chronic hemorrhagic synovitis primarily affect the posterior facet. Early involvement is most easily detected at the posterior margin of the posterior facet on lateral ankle X-ray. STJ involvement is evident in about 50% of hemophilia patients who are candidates for ankle fusion. Symptoms of STJ involvement are pain in the region of the sinus tarsi that is aggravated by inversion and eversion. On physical exam, rocking the STJ with the ankle in full flexion, compressing the posterior margin of the posterior facet, will often produce crepitus and reproduce the pain. In these patients, it is important to include fusion of the STJ with the ankle fusion. More rarely, arthropathy of the STJ is present without ankle involvement. The incidence of non-union of the STJ is slightly higher than that for the ankle. In our study, reported at the WFH 2012 World Congress in Paris, the incidence of tibiotalar non-union was 3.7% compared to 5.6% for the STJ. However, these non-unions had stable fibrous union and none required revision surgery. Several techniques can be utilized to help facilitate union in STJ arthrodesis. Our approach focuses on the posterior facet. After thorough debridement and curettage, the opposing bony surfaces are “fish-scaled” with a ¼” osteotome to create interdigitating surfaces. Stable fixation and compression of those surfaces is accomplished with two cancellous small fragment screws. When the ankle is included, an anterior plate is utilized with three screws across the STJ. It is essential that the posterior facet be well opposed and compressed prior to placing the anterior plate. Otherwise the anterior screws may actually hold the STJ apart. Immobilization in a short leg cast, non-weight bearing until the x-rays show early consolidation, is important. The time to solid fusion will usually be longer than for ankle fusion alone.

Keywords: hemophilic arthropathy, joint fusion

A3.2
The arthritic knee with flexion contracture: Steps to achieve extension during total knee replacement (TKR)

A. Llinás
Fundación Santa Fe De Bogotá, Colombia

Abstract unavailable

A3.3
Hemophilic Chronic Synovitis: Therapy of hemarthrosis using endovascular embolization of knee and elbow arteries

H. Caviglia1, E. Galli1, A. Baques1, N. Moretti1, M. Candela1
1Hospital de Agudos Juan A. Fernandez; 2Fundación de la Hemofilia de Buenos Aires; Academia Nacional de Medicina, Buenos Aires, Argentina

Purpose: Hemarthrosis in patients with hemophilia is a condition that leads to joint damage and disabled patients. Selective embolization of the knee and elbow arteries can prevent bleeding episodes. The aim of this study is to evaluate the decrease of bleeding in the affected joint before and after selective arterial embolization. Materials and Methods: We performed 30 procedures in 27 hemophilic patients; including 23 knee, and 7 elbow procedures. To evaluate the efficacy of selective embolization of knee and elbow arteries in people with hemophilia, we analyzed the number of bleeding episodes for 12 months before the procedure, compared with the amount of episodes that occurred 3, 6 and 12 months after embolization. Results: Twenty-nine out of 30 procedures were classified as successful. The median of 1.25 episodes per month (range 0-3) observed before the procedure was reduced to 0 (range 0–1.67) (p<0.001) at 3 months, 0.17 (range 0–1.67) (p<0.001) at 6 months, and 0.33 (range 0–1.67) (p=0.024) at 12 months. Three patients remained free of bleeding events for more than six months. Additionally, after the procedure there was a significant reduction in factor VIII usage that sustained up to 12 months after the procedures. No serious adverse events were observed. Conclusions: Selective angiographic embolization of knee and elbow arteries is a feasible procedure that can prevent repetitive bleedings, which would translate into better joint outcomes for these patients.

Keywords: hemophilia, arterial embolization, hemorrhosis, interventional radiology

Session A4 – Free Papers 1

A4.1
Total knee replacement in patients with inherited bleeding disorders: Early results

P. Ambroziak1, P. Zbikowski1, J. Windygą3, I. Kotel’1,3
1Central Clinical Hospital of the Ministry of Interior, Warsaw; 2Institute of Hematology and Transfusion Medicine, Warsaw; 3The Jan Kochanowski University in Kielce, Kielce, Poland

E-mail: pawel.ambroziak@wp.pl

Introduction: The prospective trial aimed at assessing early results of total knee replacement (TKR) in patients with hemophilia A and von Willebrand disease compared to a group operated due to primary degenerative joint disorder (DJD). The evaluation covered postoperative blood loss, pre- and postoperative clinical outcomes, level of pain, and range of motion (ROM).

Methods: The study group: 27 patients – (30 knees) operated for hemophilic arthropathy. Hemophilia A – 24 patients, including 1 with high-titer inhibitor. Von Willebrand disease – 3 patients: Routine administration of antithrombotic prophylaxis with nadroparin in patients with additional risk factors for venous thromboembolism (VTE). No thromboprophylaxis administered in inhibitor patient. Discharge was followed by outpatient treatment including physiotherapy. The comparison group: 30
patients (30 knees) – requiring TKR for primary DJD. WOMAC Osteoarthritis Index and Knee Society Score for clinical evaluation and Visual Analogue Score (VAS) for pain evaluation were used. Pre- and postoperative ROM and postoperative blood loss were assessed. Radiographic evaluation was at outpatient visits during follow-up that lasted 12 months. Results: Clinical results in the study and comparison groups were good and satisfactory. Considerable pain reduction was observed. Results were comparable in both groups and its improvement was statistically significant. The mean ROM improvement in the study group was 24° and, in the comparison group, -13°. Postoperative blood loss was comparable: 423.67 ml in the study group and 453.50 ml in the comparison group. No symptomatic VTE complications occurred. Conclusion: TKR in patients with inherited bleeding disorders is a very demanding procedure and requires particular surgical and hematological expertise. Early clinical results are promising and comparable to group operated for primary DJD. Pain alleviation and improvement in locomotor abilities were significant despite only minor increase in ROM. Postoperative blood loss was acceptable and comparable in both groups.

Keywords: TKR, hemophilia A.

A4.2
Accelerated discharge programs post total knee replacements (TKR): Are these suitable for people with hemophilia (PWH)? A review of cases at the Haemophilia Comprehensive Care Centre, Belfast, Northern Ireland

L. Sayers1, D. Beverland2, C. Connolly3, G. McLinder4, G. Benson1
1Haemophilia Comprehensive Care Centre, Bridgewater Suite, Belfast City Hospital; 2Musgrave Park Hospital, Stockmans Lane, Belfast BT9 7JB, Belfast, Northern Ireland

E-mail: fionnuala.sayers@belfasttrust.hscni.net

Background: Musgrave Park Hospital, Belfast, operates an accelerated discharge program post TKR for all patients including those with a history of hemophilia, contrasting with reported detail of other hemophilia patients in the UK. Methods: Retrospective review of PWH A or B, post TKR, at Musgrave Park Hospital (July 2002 – July 2012). Information collected using case note review, Belfast Orthopaedic Information System, and patient questionnaire. Results: 15 cases (9 patients): severe hemophilia A (n=8); severe hemophilia B (n=1); Primary n=9; revision n=6. Mean age was 48 years (36-74). Seven patients were Hep C+ve, two of whom were HIV+ve. Two were not affected. Patients received the standard post-operative inpatient care. Factor cover was managed by the Haemophilia Comprehensive Care Team. Mean factor use during the perioperative period was 73,971 IU (48,000IU – 107,000IU). Mean length of stay (post-op) was five days (2-12) with 13 discharged directly home. Forty per cent of these were discharged by day 3. Of the two cases transferred to Belfast City Hospital at day 2, one was discharged day 6 postoperatively without further problems. The other had significant co-morbidities and was ultimately discharged home 25 days post-surgery. Overall, patient satisfaction was good. Twelve were very satisfied with surgery in terms of pain relief, ability to return to work and ability to perform their usual leisure activities. There were three early complications. One popliteal artery occlusion requiring further surgery and two bleeds following discharge. Late complications included one popliteal aneurysm, one infection requiring two-stage revisions, and one loss of joint range.

Discussion: This review demonstrates that PWH can safely participate in an accelerated discharge program. Recent years have seen a reduction in the mean length of stay required (Fig.1). Multicentre review of current practice, together with previously identified predictors of protracted admission, may help to identify those PWH most suited to this approach.

Keywords: accelerated discharge, total knee replacement

A4.3
Total ankle replacement in patients with severe hemophilic arthropathy

A. Strauss1, G. Goldmann2, M. Wessling1, M.C. Mueller1, J. Oldenburg3, D. Wirtz1, P.H. Pennekamp1
1Department of Orthopedics and Trauma Surgery and, 2Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany

E-mail: andreas.strauss@ukb.uni-bonn.de

Objectives: Arthropathy of the ankle is a frequent complication in hemophilic patients. Therapeutic approaches for surgical interventions in cases of advanced joint destruction include arthrodesis or endoprosthesis. There is only very limited literature data available on total ankle replacement (TAR) in hemophilia patients. The objective of this study is to evaluate the results after TAR in patients suffering from advanced hemophilic

FIGURE 1: MEAN LENGTH OF STAY (post-op)

FIGURE 2: DISCHARGED (day post-op)
arthropathy. Methods: In a retrospective study, results after TAR (type: Hintegra) were evaluated in 10 patients (11 endo-prostheses) with severe (n=8) or moderate (n=2) hemophilia. All patients suffered from severe knee arthropathy with a Petteerson score of ≥ 10. Nine patients were positive for hepatitis C, five were HIV-positive. Mean follow-up was 2.6 years (range, 1.2 – 5.0 years). Range of motion (ROM), AOFAS ankle-hindfoot score, pain status (visual analogue scale, VAS) as well as patient satisfaction was determined prior to surgical intervention and every six months postoperatively. The data were statistically analyzed using SPSS Version 21.0. Results: The 3-year survival rate following implantation was 81.8 %. In two cases, deep prosthesis infection occurred leading to the removal of the implant. In the remaining eight patients (nine implants), the mean AOFAS ankle-hindfoot score improved significantly from 21.5 to 68.0 (p<0.0005), the VAS score decreased significantly from a mean of 7.6 to 1.9 (p<0.0005). ROM did not increase significantly, i.e. from 23.2 to 25.0 degrees. At final follow-up, all patients were satisfied with the surgical result. Radiological controls did not suggest any signs of prosthetic loosening. Conclusions: TAR constitutes a therapeutic alternative to arthrodesis in cases of advanced hemophilic arthropathy, providing good pain reduction and high patient satisfaction. Marginal postoperative increase in range of motion may be explained by pre-existing soft tissue scarring caused by repetitive bleeding events in hemophilic arthropathy. Due to the increased risk of infection and a lack of long-term results, TAR in patients suffering from severe hemophilia should be indicated carefully.

Keywords: arthropathy, TAR, hemophilia

A4.4
Outcomes of total knee arthroplasty (TKA) in the hemophilia population: A meta-analysis

M. Moore, P. Tobase, D. Allen, B. Smoot
University of California, San Francisco Medical Center, San Francisco, U.S.A.
E-mail: mfmmlmu@gmail.com

Background/Objective: People with hemophilia (PWH) experience end-stage joint disease due to repeated hemorrhosis. In this review, we examined the available literature on total knee arthroplasty (TKA) outcomes in PWH. Methods: A literature review was performed to identify studies with functional outcomes after TKA in PWH published between 1980 and 2012. Inclusion criteria were studies with greater than five TKAs in PWH, reported Hospital for Special Surgery Knee Score (HSSKS), knee range of motion (ROM), and complication rates. Variables such as inhibitor status, hemophilia severity, and HIV status were not criteria for inclusion or exclusion. A meta-analysis was performed on extracted mean and standard deviation data to create a single group effect size and 95% confidence interval for the HSSKS, ROM data, and complication rate with subcategories for infection and revision rate. Results: Eleven studies met inclusion criteria; seven of eleven had sufficient data for meta-analysis review. 216 TKAs in 158 PWH were analyzed with a mean follow-up of 5.4 years (SD 1.4). TKA in PWH demonstrated statistically significant ROM improvements: 6.67 degrees improvement of the flexion contracture (-.94 SE, CI -1.34 to -.54), and 5.10 degrees increase into flexion (.44 SE, CI .22 to .66). HSSKS is a validated outcome tool for the TKA population. 36.8 point increase in the HSSKS score was reported among subjects (4.00 SE, CI 1.99 to 6.00). 20 revisions out of 216 TKAs were reported due to aseptic loosening, infection, and excessive hemorrhaging. Conclusions: Total knee arthroplasty is an effective procedure for reducing the effects of hemophilic arthropathy; ROM deficits, and functional deficits. PWH have less ROM gains; however, functional gains reflected via the HSSKS demonstrate TKA improves overall function. This study provides guidelines on expectations post-TKA in PWH based on seven retrospective studies.

Keywords: Hemophilia; Total Knee Arthroplasty

A4.5
Radiosynoviorthesis with three types of radiopharmaceuticals: results in 400 patients

S. Thomas1,2, S. Augusto Lopes Souza1, B. Gutifilen3, M. Albernaiz1, D. Regina Della Riva1, M. Benediio Correa Gabriel1, P.M. Pinheiro Perri1, A. Rebolo1, A. Bordim1, R. Gomes2, E. Pimentel da Silva1, L. Barboza da Fonseca2
1Universidade Federal do Rio de Janeiro, Rio de Janeiro; 2Hemocentro do Mato Grosso, Cuiaba, Brazil
E-mail: sylviahemato@gmail.com

Chronic synovitis has major importance in hemophilia care. Radiosynoviorthesis (RS), the intra-articular injection of radiopharmaceuticals (RP), represents an effective and minimally invasive treatment for refractory synovitis. Some characteristics influence RP choice, such as particle size, tissue penetration depth, and availability. Accordingly, yttrium-90 citrate (C.90Y), yttrium-90 hydroxyapatite (HA-90Y), and samarium-153 hydroxyapatite (HA-153Sm) have been used in Brazil and the objective of this study is to compare the results achieved by these RP. A total of 400 patients with 697 joints were treated in two centres. Six months pre- and post-RS it was compared: number of joint bleeds, range of motion (ROM) and pain (WFH scale). Outcomes were classified as Failure: <50% bleeding reduction; Good: bleeding reduction 50%-75% plus improvement in ROM and pain; and
Excellent: bleeding reduction >75% plus improvement in ROM and pain. We found statistically significant differences between the three RP in knees, favoring C-90Y. Hence C-90Y compared to HA-153Sm showed OR=9.4 and 7.399, respectively regarding good and excellent outcomes. Differences between the three RP were not statistically significant regarding elbows and ankles. Even properly located inside the joints, RS with 2 mCi of HA-90Y caused cutaneous burn in two ankles (0.5%) of two patients (0.3%), one requiring surgery after five months of evolution; none have presently severe sequelae, eight months post-RS. All three RP achieved reduction of hemarthroses in different percentages. We concluded that 90Y labeled RP, having high tissue penetration depth (mean 3.6 mm, max 11 mm), should be utilized in knees, while HA-153Sm, presenting lower penetration depth (mean 0.7 mm, max 3.1 mm), seems suitable for medium-sized joints. RS is an important therapy for hemophilic synovitis, and centres must count on RP adequate to each case.

**Key word:** radioisynoviorthesis

### A4.6

A fusion protein of IL4 and IL10 (IL4-10 synerkine), is equally effective in protecting cartilage from blood-induced damage compared to the individual components

L.F.D. van Vulpen1,2, M.E.R. van Meegeren1,2, S.A.Y. Hartgring3, C. Steen-Louws1,3, S.C. Mastbergen4, C.E. Hack1,3, J.A.G. van Roon1,3, F.P.J.G. Lafeber1

1Rheumatology & Clinical Immunology; 2Haematology and Van Creveld Clinic; 3Immunology, University Medical Center Utrecht, The Netherlands

**E-mail:** L.F.D.vanvulpen-2@umcutrecht.nl

**Objective:** Recombinant human IL4, IL10, or the combination, protects cartilage from blood-induced damage in vitro. To overcome low bioavailability of IL4 and IL10 in vivo, a fusion protein is developed: IL4-10 synerkine. This study investigates whether the IL4-10 synerkine protects against blood-induced cartilage damage similarly as the combination of the individual components. **Methods:** Human cartilage explants were exposed to 50% v/v whole blood for four days and simultaneously to a broad concentration range (0-10ng/mL) of the IL4-10 synerkine. Effects of 10 ng/mL IL4-10 synerkine were compared to the same concentrations of the individual cytokines and the combination. Cartilage matrix proteoglycan turnover was assessed after a recovery period of 12 days. Moreover, the influence of IL4-10 synerkine and its individual components on levels of IL1 and IL6 were investigated in a four-day 50% v/v whole blood culture. **Results:** A clear dose-response curve by adding IL4-10 synerkine was observed, leading to full normalisation of proteoglycan synthesis rate and release at higher concentrations. The results were similar to the effect of the two individual cytokines (see figure). Addition of IL4-10 synerkine reduced IL1 and IL6 production in whole blood cultures, similar to the combination of IL4 plus IL10. **Conclusion:** The IL4-10 synerkine strongly protects against blood-induced cartilage damage in vitro, presumably, at least in part, by reduction of IL1 production. Considering better bioavailability and application of this synerkine compared to the individual cytokines, testing the IL4-10 synerkine in an in vivo model of blood-induced cartilage damage is warranted.

**Keywords:** arthropathy, Synerkine

### A4.7

Subchondral cyst in people with hemophilia (PWH) treated with bone substitute (OH apatite coralline)

H. Caviglia1,2, C. Daffunchio3,4, G. Galatro1,2, G. Cambiaggi1,2, N. Moretti5, M. Candela1,3

1Fundación de la Hemofilia; 2Hospital Juan A. Fernandez, Servicio de Ortopedia y Traumatología; 3Academia Nacional de Medicina, Buenos Aires, Argentina

**E-mail:** dafunca@hotmail.com; mmendoza@biblostravel.com

**Introduction:** Subchondral cysts usually can be progressive and lead to joint destruction. **Materials and Methods:** 37 patients with 49 subchondral cyst were treated. 34 patients suffering from hemophilia A and three from hemophilia B. Four patients presented inhibitors; one was low responder. The mean follow up was nine years (1-18). Most affected bones were the tibia and talus. The lesions were treated when the injury was greater than 15% of the area of the affected joint. The treatment consisted of aspiration of the cyst and filling with coralline hydroxyapatite. **Results:** 48 cysts cured (p<002); one cyst with extensive tibial lesion recurred at three years and 30% of its original size. The patient underwent surgery and was filled again with coralline hydroxyapatite and finally healed. None of the patients required a TKR in the affected joint. The outcome was similar in patients with and without inhibitors. **Relevance and applicability to hemophilia care:** This method of treatment has prevented the progression of joint damage. More than 15 years of experience with the method has proven effective and inexpensive. **The originality of the work:** This is the longest series of subchondral cysts treated with aspiration and filling, using a bone substitute such as coralline hydroxyapatite. This study demonstrates that the coralline hydroxyapatite is an adequate bone substitute; it is suitable for use in patients with hemophilia.

**Keywords:** subchondral cyst, bone substitute

**FIGURE 1:** Effect of the IL4-10 synerkine compared to IL4 and IL10 on cartilage proteoglycan synthesis rate (n=8). Median values ± interquartile range are depicted. Hash tags indicate a statistically significant difference compared to 50% v/v blood (p<0.05), asterisks indicate a statistically significant difference compared to control cartilage (p<0.05).
Knee flexion contracture treated with botulinum toxin type A in people with hemophilia (PWH)

H. Caviglia1,2, C. Daffunchio1,2, C. Galatro1,2, M. Moretti2, L.P. Solimeno1, G. Pasta1,2
1Centro Ortopedico e Traumatologico; 2Academia Nazionale di Medicina, Buenos Aires, Argentina

Introduction: Knee flexion contracture is a frequent complication in patients with hemophilia A or B. High frequency of joint bleeding, frequently associated with chronic joint damage, is the cause of this contracture. Intra-articular botulinum toxin is used to correct knee flexion contracture. However, its use in hemophiliac patients is not well documented.

Methods: A retrospective analysis was performed on knees of 13 hemophiliac patients treated with botulinum toxin at the Orthopaedic Unit of the Policlinico IRCCS of Rome between 2007 and 2012. Only knees with flexion contracture of at least 20° were treated. The number of injections of botulinum toxin was 1-3, depending on contracture amplitude. The average follow-up was 6.5 months (range 2-18).

Results: Seven patients had hemophilia A and six had hemophilia B. The average age was 35 years (range 14-65). The average degree of knee flexion contracture before injection was 35° (range 20-50). The average degree of knee flexion contracture after the last injection was 10° (range 5-30), with a mean improvement of 25° (range 10-45°). The difference was statistically significant (p <0.001).

Conclusion: Intra-articular botulinum toxin is a safe, easy-to-apply procedure for the correction of knee flexion contracture in hemophiliac patients. It improves the quality of life of these patients.

Keywords: Hemophilia, botulinum toxin, knee flexion contracture, hemophiliac patients

Orthopedic surgery in patients affected by von Willebrand disease (VWD) and rare bleeding disorders

L.P. Solimeno1, G. Pasta1, S. Siboni2, E. Biguzzi3, C. Mistretta2, F. Peyvandi3
1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico; 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Policlinico; 3Academia Nazionale di Medicina, Buenos Aires, Argentina

Introduction: Orthopedic surgery in patients with von Willebrand disease (VWD) and rare bleeding disorders (RBDs) requires careful planning and management. The aim of this study is to describe the experience of orthopedic surgery in such patients.

Methods: Retrospective analysis of orthopedic surgery performed between January 1981 and November 2012 at the Orthopedic Unit of the Policlinico IRCCS of Rome. Data were collected from the medical records of patients who underwent orthopedic surgery for VWD or RBDs. The outcome of surgery was evaluated in terms of success rate and complications.

Results: Of the 71 orthopedic procedures, 12 were minor surgeries (seven hand surgeries, five others) and 59 were major surgeries (19 arthroplasty, 19 arthroscopic procedures, 21 others procedures). The median age of the patients at surgery was 47 years (range: 10-78) and the median follow-up time was 37 months (range: 1-384). The most frequent RBDs were FVII (11/22) and FXI (7/22) deficiency. Bleeding complications occurred in five procedures (7%). No late bleeding problems were recorded. Only three patients received prophylaxis with low molecular-weight heparin (LMWH).

Conclusion: Orthopedic surgery performed in a specialized hemophilia centre is a safe procedure.

Keywords: Orthopedic surgery, von Willebrand disease, rare coagulation disorders

Cartilage damage biomarkers are increased after a joint bleed; an explorative human and canine in vivo study

L.F.D. van Vulpen1,2, M.E.R. van Meegeren1,2, G. Roosendaal3, S.C. Mastbergen1, P.P.J.G. Lafeber1
1Rheumatology & Clinical Immunology; and 2Haematology and Van Creveld Clinic, University Medical Center Utrecht, the Netherlands

Introduction: Cartilage damage biomarkers (uCTX-II, sCOMP, sC1,C2, sCS846) are associated with overall radiographic joint damage. This study investigates for the first time whether these biomarkers can sense cartilage degradation immediately after a joint bleed.

Methods: uCTX-II, sCOMP, sC1,C2, and sCS846 levels were measured in hemophiliac patients (n=8) at three time points: within 2 days, after 3-5 days, and about 90 days after a joint bleed (considered as baseline). Similar, a joint bleed was induced in dogs (n=7) by intra-articular autologous blood injections over 5 days. The same biomarkers were measured before the experimental joint bleed, immediately after this bleeding episode, and 5 and 90 days later.

Results: In hemophiliac patients, the levels of all four biomarkers were elevated 3-5 days after a joint bleed, compared to baseline (p<0.05). A combined score of the four biomarkers, 3-5 days after the bleed, increased compared to levels directly after the bleed (p=0.024). In dogs, 5 days after the bleed, the biomarkers were increased, except for sCOMP; uCTX-II and the combined score were significantly different compared to the levels directly after the induced bleed (p=0.007 and p=0.02). At 90 days, the levels were similar to the pre-bleeding levels. Conclusion: This study demonstrates that joint tissue damage biomarkers increase already after a single joint bleed, both in an experimental and clinical setting. A combined score could be used to detect cartilage degradation immediately after a joint bleed, supporting early cartilage damage after a single bleed.

Keywords: Cartilage damage, biomarkers
Abstracts

Session B1 – Plenary

B1.1
The World Federation of Hemophilia Research Agenda

D. Lillicrap
Queen’s University, Kingston, Canada

The World Federation of Hemophilia (WFH) has a longstanding history of excellence in supporting the care of persons with inherited bleeding disorders, worldwide. This program of activities has provided access to care in many countries where treatments were not previously available. Alongside these enhancements to global treatment access, the inherited bleeding disorder community has witnessed significant advances in translational initiatives to further improve diagnostic and therapeutic approaches. With this background, the WFH has initiated a new program of activity focused on the support of research into clinical outcomes for inherited bleeding disorders. This program will be supported by new sources of funding, and is intended to run as a complementary program to the existing WFH activities focused on advocacy and clinical care. The new research program will initially comprise two distinct but overlapping foci of investigation: an enhancement of the intramural Global Survey data collection and an extramural grant competition intended to support a small number of projects aimed at novel aspects of clinical outcome evaluation. The initial stages of assessing the current limitations and potential future enhancements of the Global Survey are already underway, and new components of this process are being discussed with the WFH Data and Demographics Committee. The ultimate intention is that this collation of global data could be used by extramural researchers to address specific clinical outcome questions. The second component of the new WFH Research Program will also be launched in 2013, and will provide opportunities for extramural investigators to obtain support for innovative projects whose objective is to provide new information relating to clinical care outcomes.

Session B2 – Crossfire Session: Biological Therapies

B2.1
Biological therapies – The theory

P.E. Monahan, J. Sun, N. Narkbunnam
Department of Pediatrics, The Harold R. Roberts Hemophilia Treatment Center and The Gene Therapy Center at the University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.

The standard of care for hemophilia therapy is infusion of coagulation factor protein, using recombinant proteins when possible. This therapy maintains and/or restores the potential for secondary hemostasis. The physiologic effects of hemophilic bleeding are not confined to detrimental anemia or mass effect of unchecked hemorrhage, however. Intra-articular bleeding, in particular, is associated with a cascade of inflammatory and neoangiogenic effects that mediate degradation of joints and bone long after hemostasis has been restored. Evidence is accumulating that even after hemostasis has been achieved, the continued support of thrombin-generating potential helps normalize events in the prolonged period of wound repair. One potential advantage of using complex biological therapies such as virus-mediated or cell-mediated nucleic acid therapies (gene therapy) is the chance to support optimal wound healing, along with optimal prophylaxis via endogenous clotting factor production following transgene delivery. Specific therapies to oppose inflammatory cytokines, including Interleukin 6 (IL-6) receptor antagonists and TNF-alpha receptor antagonists based on engineered immunoglobulins, have become important in the management of inflammatory joint disease, including both childhood and adult rheumatoid arthritis. In mouse models of hemophilia A and B, short-course specific inhibition of these inflammatory cytokines, as an adjunctive approach along with replacement of hemostasis, has been demonstrated to improve the protection from synovitis, when compared to clotting factor alone. These biologics were more effective than non-specific small molecule anti-inflammatory agents, such as corticosteroids, in these models. Alternative biologic agents that have shown promise in animal models include cytokines that oppose inflammation and neoangiogenesis.

B2.2
Biological therapies – Why not

L.A. Valentino, L. Boggio, N. Hakobyan and M. Simpson
Rush University Medical Center, Chicago, IL, U.S.A.

The treatment of hemophilia has progressed significantly since the first written description of the affliction, found during the second century in the Babylonian Talmud, when nothing more than mechanical pressure and hopes for divine intervention were practiced. Later descriptions of the homeopathic remedies used by Leopold and Alexis – who suffered from the “Royal disease” around 1900 – and the injection of a series of ever more pure products to replace missing or defective coagulation factor VIII and IX, respectively available in abundance (in countries willing and able to pay for these drugs). The currently available products are highly effective and able to control hemorrhage with one, or at most, two injections in more than 90% of all bleeding episodes. The products are capable of preventing hemorrhage when administered in the absence of bleeding in virtually all children without existing joint disease, and even in many adolescents and adults with pre-existing joint damage. Importantly, these products are able to prevent hemorrhage during surgical procedures in nearly all cases. In each of these scenarios, the mainstay of treatment is replacement of the missing coagulation factor activity to correct the error of nature. Four very important issues face the hemophilia community today when considering treatment of hemophilia: These include: 1) development of new products with sustained duration of action, capable of reducing the frequency of administration; 2) development of therapeutic strategies to circumvent the need for intravenous delivery of replacement products; 3) development of therapies that are less immunogenic; and 4) two items of critical importance to
Abstracts

the global hemophilia community: cost and accessibility of the treatments. Herein, each of these issues will be discussed briefly and highlights of the progress made to date in each of these areas will be provided. These achievements underscore the need for caution when considering biological therapies, including gene transfer and use of bioactive molecules, both of which have the potential for serious and considerable deleterious effects on patients with hemophilia. The risks and benefits as well as the costs to the patient and to society must be part of the equation when evaluating any novel therapy. At this time, the evidence argues against the clinical use of biological therapies in patients with hemophilia.

B2.3

Biological therapies – The reality

U. Reiss

St. Jude’s Children’s Research Hospital, Memphis, TN, U.S.A.

Abstract unavailable

B2.4

Biological Therapies – The reality: Why not

E.C. Rodriguez-Merchán

Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain

Nowadays, the most usual surgical procedures for treating articular cartilage defects (cartilage repair) include abrasion chondroplasty, microfracture, mosaicplasty, autologous chondrocyte implantation (ACI), and matrix-induced ACI. In small defects (<2–4 cm²), osteochondral autograft or microfracture are the recommended options. In large defects (>2–4 cm²), ACI, or osteochondral allograft are indicated. However, so far we have not applied these techniques in hemophilic patients because inflammatory conditions and advanced degenerative change (>50% joint space narrowing) are contraindications for cartilage repair. Thus, prevention of cartilage damage is paramount in hemophilia [1]. Newly developed techniques, mainly those based on cell therapy that use bioreactors, growth factors, mesenchymal stem cells (MSC) and genetically-modified cells, still are under investigation. The aim of cell therapy is restoration of function through the repair of damaged tissue or the stimulation of growth factor synthesis. MSCs hold promise for the repair of joint cartilage given their differentiation capacity and the therapeutic effect induced by a more natural and biologic restoration. The use of bioreactors and growth factors, which stimulate cartilage formation, may optimize such strategies in the context of reimplantation of chondrocytes, differentiated MSCs and cartilage progenitor cells. Implantation of autologous chondrocytes or MSCs was, up to now, able to address only highly localized chondral lesions. Adequate control of the differentiation process, as well as the use of growth factors and appropriate bioreactors, could transform cell-based therapies into a more efficient and longer term treatment, even for patients with hemophilia. We still have a long way to go before use of biological therapies in hemophilic arthropathy. Raising false expectations in hemophilia patients should be avoided [2].

References

Session B3 – Muscle Bleeding

B3.1

Muscle bleeding – Diagnostics: How and when?

D. Stephensen

School of Health, Sport and Bioscience, University of East London, London, U.K.

Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, U.K.

Approximately 20% of all bleeding episodes in individuals with hemophilia occur into muscle. Following joint bleeds, it is the second most frequent consequence of hemophilia and, like joint bleeding, is more common in the lower limb than the upper limb. A recent 12–month study of bleeding patterns in children and adults with severe hemophilia found that the order of muscle bleeding frequency was the forearm, thigh, lower leg, foot, hand, back, groin, upper arm, buttock and iliopsoas, with the forearm and thigh muscle groups accounting for 40% of muscle bleeding episodes (Stephensen et al., 2009). An understanding of the hierarchical macro and microscopic structure, mechanics, and diverse function of human skeletal muscle is key to evaluating muscle bleeding. Whole muscle is composed of bundles of muscle fascicles, which are composed of individual muscle fibres that contain myofibrils arranged side by side in parallel, which are further subdivided into sarcomeres arranged end-to-end in series. Sarcomeres are composed of two sets of overlapping myofilaments, thick myosin filaments, and thin actin filaments that are the basic contractile components of muscle. Detailed clinical examination, together with imaging techniques, can determine the site and extent of bleeding, evaluate the stage of healing and response to treatment, and guide rehabilitation and return to physical activity.

B3.2

Muscle bleeds and low-intensity pulse ultrasound (US) therapy

A. Sabbour

Physical Therapy, Cairo University, Cairo, Egypt

The muscles most commonly affected are in the calves, thighs, upper arms, front of the hips, and forearms. Bleeding into the muscle can go unnoticed for some time before discomfort develops. Some bleeds will cause the limbs to swell and become warm and painful to the touch. Bruising can occur if the bleed is near the skin surface. In deeper muscles, the swelling may press on nerves or arteries, which will cause tingling and numbness. Muscle hemotoma represents 10–25% of bleeds in patients with severe hemophilia. There is limited consensus on diagnostic or treatment strategies and little knowledge about the natural history of muscle hemotoma and optimal treatment goals. Low-intensity
pulsed ultrasound (LIPUS) has gained much attention for patients with musculoskeletal disorders, which occur through a variety of biological and physical mechanisms, include muscle relaxation, reduced swelling, and pain relief. Most knowledge of the effects of US on living tissue has been gained through in vitro studies and animal models, but relatively little in vivo evidence that these effects actually occur has been published. This paper is presented as a literature review of the physiology of muscle bleeds and the influence LIPUS exerts on cells and molecules involved in such bleeding process. Keywords: Ultrasound therapy, muscle bleeding, hemophilia

B3.3 Compartment syndrome
N. Goddard
Royal Free Hospital, London, U.K.
Abstract unavailable

B3.4 Muscle bleed: Medical management
M. El Ekiaby
Faculty of Medicine, Cairo University, Cairo, Egypt
Muscle hematomas (MH) represent 10-25% of all bleeds in patients with severe hemophilia. In a cross-sectional survey of current practice in the management of MH, with participation from 22 consultants, the respondents reported 492 MH/year, corresponding to an average of 25/centre, most associated with trauma. Iliopsoas (55%), calf (18%), and thigh (18%) bleeds were scored as most serious. Half of respondents distinguished between contusion and strains, whereas the majority (68.2%) did not categorize bleedings as intra- or inter-muscular, although 77.3% routinely used ultrasound. Although the outcome of treating muscle hematomas has improved in the past 20 years, with fewer patients suffering long-term disability, this has not been paralleled by greater evidence-based understanding of management strategies, nor a treatment consensus among hemophilia treaters. A cross-sectional survey on the management of MH in patients with severe hemophilia, including those with inhibitors, revealed no consensus in diagnosis, timing, type and dosing of treatment, nor in the initiation and appropriate modalities of physiotherapy. Insufficient treatment of MH – or poor response to treatment – can lead to serious and debilitating complications, including re-bleeding, infection, compartment syndrome, joint contractures, pseudotumours, myositis ossificans, functional loss, and decreased range of motion (ROM). In patients with severe hemophilia and inhibitors, MH, such as iliopsoas bleeds, can be life- or limb-threatening. In conclusion, there is a need for further studies on the pathology, diagnosis, and importance of early treatment to achieve rapid control of bleeding, as well as rehabilitation following MH in patients with hemophilia. A prospective international multicentre registry of current management of MH seems desirable to get more data. Optimized and systematic diagnosis may facilitate a better strategy regarding type and timing of physiotherapy.

B3.5 Conservative management
L. Chen
Peking Union Medical College Hospital, Beijing, China
Abstract unavailable

Session B4 – Free Papers 2

B4.1 Altered muscle strength and architecture influences motor performance in boys with severe hemophilia and ankle joint hemarthrosis
D. Stephensen1,2, W.I. Drechsler1, O.M. Scott1
1School of Health, Sport and Bioscience, University of East London, London; 2Kent Haemophilia Centre, Canterbury, U.K.
E-mail: david.stephensen@nhs.net

Introduction: It has been shown that the muscles of young hemophilic boys with a history of ankle joint bleeding are smaller and weaker than their unaffected peers. Alterations in balance and gait have also been reported. This study explores the influence of muscle architecture of the lateral gastrocnemius (LG) muscle on ankle plantar flexor (APF) muscle strength and biomechanical walking patterns in 19 typically developing boys (G1), aged 7-12 years, and 19 age and size-matched hemophilic boys (G2). Methods: LG cross-sectional area (CSA), thickness (MT), fascicle length (FL), and pennation angle (PA) using ultrasound imaging, APF strength utilizing an isokinetic dynamometer, and function of the knee and ankle during walking, using a 3D motion-capture system, was recorded. Results: CSA and MT of LG together with strength of the APF were significantly smaller in G2 when compared to G1. Strength correlated most strongly with BMI in G1 (r=0.62, p<0.05) and with age in G2 (r=0.65, p<0.01). Associations between MT and ankle joint motion differed between groups at the beginning (p<0.05, Fig 1) and end of stance (p<0.05). Reduced FL was associated with larger knee flexion moments in G2 but smaller moments in G1 (p<0.05). Relationships between reduced APF strength, ground reaction forces, and knee flexion moments (Fig 2) were significantly stronger in G2 than G1 (p<0.05). Clinical Relevance: Biomechanical function of the ankle and knee joints of hemophilic boys who have a history of ankle joint bleeding appears to be related to APF muscle strength deficits and adaptations in muscle architecture.

![Fig. 1. Scatter plot showing significantly different relationship between lateral gastrocnemius (LG) thickness and peak ankle plantar flexion (PF) angle during walking in typically developing boys (G1) and hemophilic boys (G2).](image.png)
Abstracts

B4.2

Dance-based exercise therapy for patients with hemophilia

D. Czepa, S. van Ravenstein, T. Hilberg
Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany
E-mail: czepa@uni-wuppertal.de

The use of methods derived from creative arts has not been considered in hemophilia treatment. The aim of this study was to investigate the expectations for a dance-based exercise therapy (DbET) for patients with hemophilia (PWH) and the extent of its acceptance. The one-hour DbET was offered to 30 PWH (HI30: 49±11; 30-67 years). For the evaluation of expectations, questionnaires were created and filled out by participants before and after the intervention. Additionally, 19 PWH (HF) and 20 controls without hemophilia (KF), who did not participate in the intervention, were also questioned. The results illustrate that controls without hemophilia (KF), who did not participate in the intervention, were mainly due to pain (HI30: 40%; HF: 29%; KF: 0%) and lack of time (HI30: 30%; HF: 57%; KF: 56%). Finally, 24 out of 30 PWH (HI24) completed the DbET. All HI24 met their expectations. Thirty-eight per cent felt limited by hemophilia while carrying out the exercises. Twenty-nine per cent perceived the intervention as moderately difficult or not difficult. The majority were able to follow the exercises well (96%) and did not overstrain physically (92%), nor mentally (87%); also 79% did not have pain and felt comfortable physically. Twenty-three of HI24 (96%) can envision a continuation of the DbET. The experience with the DbET was predominantly positive. It represents an alternative exercise program for PWH.

Keywords: exercise therapy

B4.3

Differences in physical activity and sedentary behavior between young hemophiliacs with and without arthropathy

P. Sala1, X. García-Massó2, A. Valencia3, C. Peiró-Velert4, S. Pérez-Alenda3, A. Valencia4, F. Querol1,4

Objective of the work: The aim of this study is to compare the amount of physical activity (PA) in people with hemophilia (PWH), with arthropathy (AR) and without arthropathy (NA) both on weekdays and weekends. Methods: 41 patients with hemophilia, 12 with AR and 29 without NA participated in this study. Each participant wore a triaxial accelerometer ACTigraph GT3X (Actigraph, Fort Walton Beach, FL, U.S.A.). Data were saved in a hard disc for subsequent analyses. All the variables complied with the assumption of normality (K–S normality test). Differences among groups regarding energy expenditure and time spent in sedentary activities were assessed by Student's t-tests for independent samples. Bonferroni correction (a / number of comparisons) was applied to avoid increasing the possibilities of Type I errors. The effect-size (r) was calculated for each comparison. Results of the intervention: No significant differences were found in time spent in SB on weekdays. However, on weekends significant differences were shown (P<.03) with AR patients spending more time in SB than NA (no arthropathy) patients. Regarding Light PA (LPA), significant differences were found on weekdays (P<.01), so that participants with healthy joints engaged longer than AR participants (Figure 1). No significant differences appeared in time spent in LPA on weekends. Discussion and conclusions: Both AR and NA accumulated more minutes of LPA on weekdays can be related to the time spent at school. However, no significant differences were found on weekends in LPA level. This may be due to the sedentary lifestyle acquired by young PWH with similar or equal quality of life as their healthy peers. Today, PWH showed a similar quality of life as their healthy peers and this fact may develop SB in these patients as a result of the same lifestyle as the general population.

Keywords: hemophilia and physical activity

FIGURE 1. Differences in physical activity levels and sedentary behavior between weekdays and weekend in PWH with and without arthropathy; AR, Arthropathy; NA, no arthropathy; WD, weekdays; WE, weekend; LPA, light physical activity; SB, sedentary behavior. *Significant differences (P > 0.05).
B4.4

Associations of quality of life, pain, and self-reported arthritis with bleed rate and hemophilia treatment centre (HTC) and healthcare practitioner utilization: Global results from the Hemophilia Experiences, Results and Opportunities (HERO) Study

A. Forsyth1, C. Guelder2, A. Buzzi3, T. Wisniewski4, D. Cooper5, A. Iorio6

1Rush University Medical Center, Chicago, U.S.A.; 2Children’s National Medical Center, Washington, DC, U.S.A.; 3Fondazione Paracelso Onlus, Milan, Italy; 4Novo Nordisk Inc., Princeton, U.S.A.; 5McMaster University, Hamilton, Canada

E-mail: dcoop@novonordisk.com

Objective: To examine associations of quality of life (QoL)/pain and self-reported arthritis with bleed rate and HTC/hospital utilization among adults with hemophilia (“adults”) in the HERO Study. Methodology: Adults ≥18 years completed a 5-point Likert scale on pain-interference over the prior four weeks, a health-related visual analog scale (VAS, 0-100, coded as an 11-point categorical response) and a standard QoL assessment [EQ-5D-3L mobility, usual activities, self-care and pain/discomfort]. Data from eight countries with home treatment are presented. Results: 515 adults responded, 46% with self-reported arthritis. Adults with self-reported arthritis were older (median 41 vs 35 years); median age increased with worsening EQ-5D disability and pain-interference. Employment and the percentage reporting “good” VAS scores (80-90) declined with worsening EQ-5D, pain-interference, and arthritis. Median annual bleeding rates were higher with more EQ-5D disability/pain, pain interference, and arthritis. Adults with disability/pain reported higher mean number of HTC visits/year. Percentages reporting the greatest pain interference were highest amongst those with more EQ-5D disability and arthritis. Amongst adults without self-reported arthritis, 39% reported moderate/extreme pain-interference. Nurse and social worker involvement increased in adults reporting difficulties with self-care (45%-79% and 16%-50%), pain/discomfort (48%-61% and 14%-32%), pain-interference (48%-61% and 14%-28%), or arthritis (45%-61% and 14%-27%). Physiotherapist involvement was moderate (32%-46%) and did not differ with disability, pain-interference, or arthritis. Conclusions: Increased disability and pain were associated with increased age, lower employment, more bleeds, and more HTC visits. Additional physiotherapy involvement/follow-up might be helpful in adults with arthropathy; this could be evaluated in a prospective study.

Keywords: arthritis, quality of life

B4.5

Should osteoporosis screening be a routine standard in hemophilia care: a multi-centre study and review of the literature?

A. Wells1, P. Prouse1, J. Mainwaring1, J. Simmonds3, P. McLaughlin2, P. Chowdary2

1Haemophilia, Haemostasis & Thrombosis Centre, Basingstoke & North Hampshire Hospital, Basingstoke; 2Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London; 3University of Hertfordshire, Hatfield, U.K.

E-mail: anna.wells@hhft.nhs.uk; helen_lambourne@baxter.com

Introduction: It has been shown that bone mineral density (BMD) may be lower in people with hemophilia. The impact of joint health and activity levels on BMD has not been analyzed thoroughly in the current literature, and a comparison of results to control subjects is needed. Primary objectives: To test the hypothesis that BMD is lower in people with severe hemophilia than in healthy controls and in those people with more severely affected joints or lower activity levels. Method: In this case-control study, 40 patients with severe hemophilia A (aged 18-70) were recruited from 2 hemophilia centres in the U.K. A group of 40 age, sex and ethnicity-matched control participants were recruited. All participants had a bone density scan (DEXA) of the lumbar spine and hip. A musculoskeletal joint score was used to assess joint impairment. Activity levels were assessed using the hemophilia activities list (HAL). Results: 3% of cases were osteoporotic, 42% were osteopenic. No control participants were osteoporotic, 84% of cases had low vitamin D levels and 86% of controls had low vitamin D. Joint score range 0-56, and activity score range 41.1-100 in case participants. No controls had any joint impairment. Discussion: Results show that people with a higher joint score and a lower activity score have lower BMD. Interestingly, vitamin D levels do not appear to correlate with BMD levels.

Keywords: osteoporosis screening, joint score

B4.6

Correlation of Haemophilia Activities List (HAL) and musculoskeletal physical assessment in a cohort of 95 severe hemophilia patients

P. McLaughlin, P. Chowdary

Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, Pond St, London, U.K.

E-mail: p.mclaughlin@nhs.net

Joint assessment is an integral part of the clinical review of hemophilia patients to monitor joint health and physical function. The self-perceived evaluation of function, as reported by the HAL is also essential in ascertaining the overall musculoskeletal health status in hemophilia patients. A retrospective review of clinic attendances identified 95 individuals (aged 18-83), with severe hemophilia, who had completed a HAL and on whom the Colorado Half-Point Physical Examination joint score had been done. The median, 10th and 90th centile ranges are presented for the scores: Total joint score: 21.5 (0.4, 52), upper limb (UL): 2.75 (0, 15), lower limb (LL): 16 (0, 38.5), total HAL: 76.8 (37.9, 98.1), HAL complex LL: 62.2 (15.6, 100), HAL arms: 80 (35,100), HAL household: 90 (44.7, 100). The most affected joint in this cohort was the ankle. The elbow and knee were similarly affected. There was a high correlation between the total joint score and total HAL (R=0.67), and between LL and HAL complex LL activities
Associations between physical activity risk level, treatment regimen and hemophilia treatment centre (HTC) and healthcare professional utilization: Results from the Hemophilia Experiences, Results and Opportunities (HERO) Study

A. Forsyth1, F. Querol2, A. Stain3, L. Pericleous4, D. Cooper3, A. Iorio6

1Rush University Medical Center, Chicago, U.S.A.; 2University Hospital La Fe, Valencia, Spain; 3Kiddies Health Care Inc., Toronto, Canada; 4Novo Nordisk A/S, Bagsvaerd, Denmark, 5Novo Nordisk Inc., Princeton, U.S.A.; 6McMaster University, Hamilton, Canada

E-mail: dcoo@novonordisk.com

Objective: To examine associations among physical activity risk level (lower/medium/higher) and bleed rate, pain, and resource utilization. Methods: Data from eight countries with home treatment were descriptively analyzed for associations between activity risk levels and bleeding rate and HTC and healthcare professional utilization, taking into account absence or presence of inhibitors and treatment regimen. Results: Adults with hemophilia (“adults”, n=383) and parents of children with hemophilia (“children”, n=422) receiving on-demand or prophylaxis treatment responded; most (315 adults, 391 children) had no inhibitors. Adults who reported higher-risk activities tended to be on prophylaxis, and were on average younger and more likely to be employed. In children, median age increased with increasing activity risk. Mean, but not median, annual bleeding rate was higher for adults reporting higher-risk activities. Bleed frequency decreased with increasing activity risk for children with inhibitors treated on-demand, but increased for those receiving prophylaxis. In adults without inhibitors, the percentages reporting no/little pain interference increased with activity risk. Median HTC visits per year for adults without inhibitors did not differ by activity risk. For children without inhibitors, HTC visits/year decreased with higher-risk activity. In adults without inhibitors on prophylaxis, nurse and social worker involvement in management increased with increasing activity risk, with little change in physiotherapist involvement. Physiotherapy involvement increased with increasing activity risk for children with hemophilia on prophylaxis. Conclusions: Adults reporting higher-risk activity tended to be on prophylaxis and were employed with little-to-no pain interference. The number of HTC visits/year was generally lower with higher-risk activity for children without inhibitors.

Keywords: HAL, joint scores

B4.8

Deferasirox prevents cartilage destruction following hemarthrosis in hemophilic mice

L. Nieuwenhuizen1,2, G. Roosendaal1, K. Coeleveld3, D. Biesma1, F. Lafeber4, R. Schutgens1

1Hematology & Van Creveldkliniek, 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

E-mail: l.nieuwenhuizen@umcutrecht.nl

Introduction: Joint bleedings in hemophilia result in iron-mediated synovitis and cartilage destruction. It was evaluated whether deferasirox, an iron chelator, was able to prevent the development of hemophilic synovitis and cartilage destruction. Methods: Hemophilic mice were randomly assigned to oral treatment with deferasirox (30mg/kg) or its vehicle (control) (30mg/kg). After two months of pretreatment, the right knees of hemophilic mice were punctured to induce hemarthrosis. The mice were sacrificed after another five weeks of treatment. Post-mortem, knee joints were isolated and sectioned for histology. Hemophilic synovitis and cartilage destruction were determined by two blinded observers, according to Valentino and Glasson, respectively. For hemophilic synovitis, sections of tissue were stained with hematoxylin-eosin and scored for evidence of synovial hyperplasia, vascular hyperplasia, hemosiderin depositions, intra-articular erythrocytes, and synovial villi. For cartilage destruction, sections of tissue were stained with safranin O and the intensity of safranin O staining was scored according to Glasson, which is directly proportional to the proteoglycan content in the cartilage, which is a measure of cartilage destruction. The maximum score of the Valentino score is 10, and the maximum score of the Glasson score is 6. An increase in Valentino and Glasson scores represent an increase in hemophilic synovitis and cartilage destruction, respectively. Treatment with deferasirox was compared with control. Categorical data were analyzed by loglinear analysis and Pearson Chi-Square. Results: Treatment with deferasirox (823mg/ml ±56) resulted in a statistically significant (p<0.01) decrease in plasma ferritin levels, as compared to the control group (1220ng/ml ±114). The presence of hemosiderin was statistically lower (p=0.04) in the deferasirox group, compared to the control group. Signs of hemophilic synovitis, as assessed by the Valentino score, were not different (p=0.52) when comparing the control group to the deferasirox group: 1 (12.4% vs 7.7%), 2 (16.7% vs 11.5%), 3 (12.5% vs 38.5%), 4 (29.2% vs 19.2%), 5 (16.7% vs 11.5%), 6 (4.2% vs 7.7%), and 8 (8.3% vs 3.8%). Deferasirox treatment resulted in a statistically significant (p<0.01) reduction in cartilage destruction, as assessed by the Glasson score, when comparing the control group to the deferasirox group: 2 (4.2% vs 65.4%), 3 (4.2% vs 26.9%), 4 (20.8% vs 7.7%), 5 (54.2% vs 0%), 6 (12.5% vs 0%), and 7 (4.2% vs 0%). Conclusions: Treatment with deferasirox prevented cartilage destruction following the induction of hemarthrosis in
heamophilic mice. The data presented herein support the need for further investigation of the potential role for iron chelation in the treatment of joint bleedings in hemophilia. This is of particular interest in the event of a hemorrhage despite prophylactic treatment with factor replacement.

**Keywords:** hemarthrosis, hemophilic mice, iron chelation

### B4.9

**Healing defects in a hemarthrosis model are improved by extending factor IX activity during healing**

P. Monahan¹⁻³, J. Sun¹, B. Hua¹⁻³, E. Livingston⁴, A.G. Lau, T. Bateman⁴, M. Echam³, M. Hoffman⁶, D. Monroe⁵

¹Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; ²Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; ³Department of Hematology, Peking Union Medical College Hospital, Beijing, China; ⁴Department of Biomedical Engineering and Radiation Oncology, University of North, Chapel Hill, U.S.A., ⁵Haemostasis Biology, Novo Nordisk, Denmark, ⁶Department of Pathology, Duke University, Durham, NC, U.S.A., ⁷Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, U.S.A.

**E-mail:** paul_monahan@med.unc.edu

**Objective:** Wound healing requires interactions between coagulation, inflammation, angiogenesis, cellular migration, and proliferation. We examined healing following hemarthrosis in FIX⁻/⁻ mice. We also examined whether extended factor IX activity, achieved by glycopegylation of factor IX (N9-GP; NovoNordisk), when compared to recombinant factor IX (rFIX, BeneFIX; Pfizer) normalizes defects in this wound model. **Methods:** A unilateral joint hemorrhage was induced in FIX⁻/⁻ or WT mice by needle puncture of the knee joint capsule. Following wounding, FIX⁻/⁻ mice were treated intravenously with either normal saline, with N9-GP 250 U/kg, or with rFIX 250 U/kg. Two weeks following induction of hemarthrosis joints were collected, the articulating bones evaluated with micro-computerized tomography (MCT), and tissue histology evaluated. **Results:** Hemarthrosis resulted in severe synovitis in untreated hemophilic mice (Valentino synovitis grade 5.9 on scale of 0 to 10), compared to WT mice (0.87 of 10). A single 250 U/kg dose of rFIX minimally protected the joint (mean synovitis grade 3.7), compared to 250 U/kg N9-GP (mean synovitis grade 1.8). Histologic parameters of healing, including neoangiogenesis, macrophage infiltration/residence, and iron deposition were improved by N9-GP when compared to unmodified rFIX. By MCT, a quantitative calculation of bony degradation at the articular surface demonstrated N9-GP and WT groups to be similar, but significant roughening of bony contours in the other groups. **Conclusion:** Compared to a single dose of conventional rFIX, extending factor IX activity following the time of wounding significantly improves wound healing in hemophilia B mice, as achieved using an equivalent dose of N9-GP.

**Keywords:** wound healing, hemarthrosis

### B4.10

**Sequential changes during intra-articular wound healing examined in hemophilic and normal mouse joints**

P. Monahan¹⁻³, J. Sun¹, B. Hua¹⁻³

¹Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.; ²Department of Medicine, Peking Union Medical College, Beijing, China; ³Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.

**E-mail:** paul_monahan@med.unc.edu

**Objective:** Observing cutaneous wound healing in hemophilic mice suggests that, in the absence of normal hemostasis, healing abnormalities exist and persist long after bleed cessation, even if hemostasis is restored at the time of wounding. We used a mouse model of hemarthrosis to test the hypothesis that wound healing within the blood-exposed joint is altered in hemophilia, harmonizing changes in this model with those previously described in the dermal wound. **Methods:** Intra-articular hemorrhage was induced in the knee joint of factor IX deficient mice (FIX⁻/⁻) or hemostatically normal (WT) mice. Mice were sacrificed serially at days 1, 3, 5, 7, 10, 14, 28 and 56 to examine gross histopathology and specific staining. **Results and Relevance:** Wound healing in WT mice was characterized by absent iron deposition, minimal angiogenesis, no apoptosis in articular cartilage chondrocytes, and a macrophage infiltration that peaked by day 3 and returned to baseline by day 28. FIX⁻/⁻ mice developed marked iron deposition, neoangiogenesis and chondrocyte apoptosis, all of which persisted from week 1 to week 8 of observation. Time to peak macrophage population of the joint was delayed (day 7) and did not normalize by week 8. A single "on-demand" dose of FIX, given following hemorrhage and sufficient to restore hemostasis, did not protect against subsequent wound healing abnormalities. Healing did respond in a dose-dependent fashion to prolonged periods of FIX replacement as protein infusion or from AAV.FIX gene therapy. This model may be useful for the investigation of therapeutic approaches to normalize wound healing in hemophilia.

**Keywords:** wound healing, animal models

---

**Session C1 - Plenary**

### C1.1

**Outcome measures**

**Nancy L. Young**

Laurentian University, Sudbury, Canada

Outcomes are hidden in plain sight. They are integrated in every aspect of life, but they are often overlooked. This session will elucidate the various aspects of outcomes from diverse perspectives. The goal is to encourage participants to become familiar with a variety of outcomes, in the context of hemophilia, and consider capturing these systematically to inform decision making. This session will provide a historical background on outcomes measurement. It will examine the various perspectives, including those of the patient, family, clinical team, healthcare
Utility of arthroscopic debridement in chronic arthropathy in hemophilic patients

Unidades Médicas de Alta Especialidad, Hospital de Traumatología, Mexico

E-mail: armandohdezsal@prodigy.net.mx

Introduction: Hemophilia is a blood coagulation disorder that causes recurrent joint bleeding, most often in the knee. This condition causes the destruction of the joint and functional incapacity. For adult hemophilic patients with grade III-IV AH knee arthropathy requiring a total knee arthroplasty that cannot be performed due to the patient’s age, arthroscopic debridement can be of great value. With this procedure, we perform the removal of the meniscal remains of chronic lesions, osteophytes, and intra-articular bodies; shaving of the cartilage; and resection of the hypertrophic synovial and intercondylar sulcus plasty. This increases mobility and walking, reduces pain and bleeding due to mechanic causes, and improves the patient’s performance for about two to five years. Objective: Reporting the usefulness of arthroscopic debridement in severe knee arthropathy helps us to improve the patient’s conditions and postpone the need for a total knee arthroplasty. Method: We report 20 cases of arthroscopic debridement for severe arthropathy in patients with hemophilia A and B, with a range of age between 20-30 years, in Traumatology Hospital Victorio de la Fuente Narváez, IMSS, City of México. Conclusion: Arthroscopic debridement in severe hemophilic arthropathy improves the patient’s condition because it diminishes pain and bleeding due to mechanic causes, increases knee mobility arches, and postpones the need for total knee arthroplasty. Keywords: knee arthropathy, arthroscopic debridement.

Repeated autologous intra-articular blood injections as an animal model for joint pain in hemophilic arthropathy

M. Boettger1,2,3, S. Krucker1, M. Gajda4, H. Schaible1, T. Hilberg2
1Institute of Physiology 1 - University Hospital, Friedrich-Schiller University, Jena; 2Department of Sports Medicine - University Wuppertal, Wuppertal; 3Current address - Bayer Pharma AG, Wuppertal; 4Institute of Pathology, University Hospital Jena, Jena, Germany

E-mail: hilberg@uni-wuppertal.de

Introduction: Hemophilic arthropathy following recurrent joint bleeds is one of the major disease-related complications in people with hemophilia (PWH), leading to mostly chronic joint pain. Since many antinociceptive principles interfere with the clotting system, PWH are restricted in treatment options, thereby defining a medical need for novel therapeutic principles. Testing these, however, lacks the availability of an animal model for joint pain in hemophilic arthropathy. Aim: In this study, we thus aimed at validating the rat model of repeated autologous intra-articular blood injections for pain-related behaviour. Methods: During an observation period of 50 days, groups of animals were injected weekly into one knee joint with either whole blood or cellular/plasma components. Results: Injections induced primary hyperalgesia starting after the third injection, accompanied by mild functional gait changes and joint swelling. Secondary hyperalgesia and quantitative gait disturbances were not observed. This phenotype was most prominent in whole-blood injected animals, with effect sizes of cells and plasma being additive. In order to differentiate hemophilia-related arthropathy from traumatic joint bleeding, another group was injected with whole blood only once, which did not cause any alterations. Conclusion: Repeated autologous intra-articular injections of blood showed a time course, inflammatory response, and reduction in pain thresholds similar to the signs and symptoms observed in PWH. Therefore, this model may be utilized in the future for testing novel antinociceptive principles in hemophilia-associated joint pain. Keywords: animal models, arthropathy.

Arthroscopic treatment of hemophilic ankle arthropathy

G. Pasta1, M. Mancuso3, E. Cristini1, P. Gozzini1, E. Santiagoostino1, L. Solimeno1
1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico; 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy

E-mail: gianluigipasta@yahoo.it

Background: From early childhood, joints are the most common bleeding site in people with hemophilia. Hemarthroses tend to recur at the same site (target joint) causing structural damage that gradually involves synovium, cartilage, and bone, leading to chronic hemophilic arthropathy with crippling and deformities. Although primary prophylaxis has radically decreased the
number of target joints in hemophilic patients, the ankle joint seems to be an exception to the rule, and information regarding the arthroscopic management of hemophilic ankle arthropathy is limited. **Aim:** Description of arthroscopic treatment of hemophilic ankle arthropathy. **Methods:** Retrospective data collection regarding orthopedic surgery between January 1990 and December 2012. Bleeding frequency, radiographic scores, range of motion (ROM) measures, and pain (using VAS) were recorded preoperatively and at follow-up (i.e. at the time of data review). Outcome measures included length of hospitalization, length of follow-up, occurrence of adverse events, need for additional intra-articular intervention, and patient satisfaction. **Results:** Data are reported on 67 procedures performed in 63 patients affected by hemophilia A (59 patients) and B (four patients), three patients with inhibitors at surgery. The median age of the patients at surgery was 20 years (range: nine to 61) and the follow-up time ranges between one to 264 months. Joints showed a bleeding frequency decline. Median arc of motion was stable or improved in the years after surgery. No complications were registered. Radiographic scores worsened slightly or slowly. **Conclusion:** The procedure can be performed safely on an outpatient basis, but an experienced treatment team is of utmost importance in determining a good outcome.

**Keywords:** arthroscopy, ankle, hemophilia

**P1.04**

**Standardized ultrasonography of joints and correlation with joint function in children and young adults with hemophilic arthropathy - first results of a clinical pilot trial at a German treatment center**

M. Sigl-Kraetzig1,2, A. Seuser3, M. Wendel1

1IPFW - Institute for pediatric research and further education, Blaubeuren; 2Pediatrician practice and haemophilia treatment center, Blaubeuren; 3Institute for motion analysis (IBQ), Bonn, Germany

Email: sigl@gerinnungspraxis-ulm.de

**Introduction:** Sonography is used in routine clinical practice to examine joint bleedings or signs of hemophilic arthropathy (HA) with effusion, synovitis, cartilage defects, or subchondral bone damage in patients with bleeding disorders. For the presentation of synovitis or effusions, as a sign of activity and defects of the articular cartilage, or subchondral bone as a sign of progression of HA, standardized sonographic section planes are available. In this study, the sono graphic findings are correlated with data from an ultrasonic motion-analysis of the knees and the results of an orthopedic examination. **Materials and Methods:** First experiences were made in a group of 26 young German patients (three to 28 years, median 13.1) with hemophilia A, B, or von Willebrand’s disease. A standardized ultrasonography of the elbow, knee, and ankle joints with a Zonare z.one ultrasound machine (transducer L14-5w) and, simultaneously, a clinical examination and a motion analysis of the knees were performed. Joint ultrasound characteristics were scored. Motion analysis of the knees were done with the Ultrasound-Topometer and scored also. The scores and the results of the orthopedic examination were correlated. **Results:** The results of various studies indicate an age-dependent correlation of ultrasound and motion analysis. Joint sonography shows some changes before detection in clinical examination. **Summary:** Initial studies of correlating a standardized ultrasonography of disease activity, in HA and joint function analysis, showed age-dependent promising results. These results were encouraging to examine the correlation now in a larger group of young patients in Germany (HämarthroSonoPilotTrial).

**Keywords:** ultrasound, synovitis, joint function

**P1.05**

**Early complications after total knee replacement in people with hemophilia**

P. Zbikowski1, P. Ambroziak1, J. Windyga3, A. Misiak3, M. Marawski1, J. Kotela1,3

1Central Clinical Hospital of the Ministry of Interior, Warsaw; 2Institute of Hematology and Transfusion Medicine, Warsaw; 3The Jan Kochanowski University in Kielce, Kielce, Poland

E-mail: p.zbikowski@gmail.com

**Introduction:** Total knee replacement is an accepted method of treatment for hemophilic arthropathy. Nevertheless, the rate of complications in hemophilic patients is still higher than in osteoarthritis. Between 2010 and 2013, 70 total knee replacements (three revisions) were done in patients with severe bleeding disorders. Five complications requiring operative treatment occurred in postoperative months (7.1%). Case 1: Superficial skin necrosis treated successfully with the split skin graft and platelet-rich plasma gel. Case 2: Early joint infection with skin necrosis. In the first stage, early debridement with implant preservation was performed without effect. Secondly, open revision with implants removal and application of spacers with antibiotics was done and was complicated by skin and soft tissue necrosis affecting extensor apparatus. Debridement was performed and the defect was covered with rotation myocutaneous flap from the calf. Case 3: Pertiarticular pseudoaneurysm. The pseudoaneurysm appeared as a pulsating mass at the lateral aspect of the operated knee. Doppler sonography and arteriography revealed inferior lateral genicular artery bleeding. Intravascular coiling of the pseudoaneurysm was performed with good effect. Case 4: Prolonged intra-articular bleeding after revision surgery with extensive approach and spacer removal. Despite several aspirations in the postoperative period growing hemarthrosis was noted. Sonography and arteriography revealed a group of small bleeding arteries in the popliteal region. Several injections with thrombin were done with partial effect. Vessels that did not respond underwent intravascular coiling that eventually stopped bleeding. **Conclusion:** The risk of early bleeding and infectious complications in patients with hemophilia undergoing total joint replacement remains remarkable.

**Keywords:** hemophilia, complications
P1.06
Simultaneous bilateral knee arthroplasty in hemophilia patients: report of two cases
Unidades Médicas de Alta Especialidad, Hospital de Traumatología, México
E-mail: armandohdezsal@prodigy.net.mx

Introduction: Adult hemophilic patients usually have severe joint destruction due to hemophilic arthropathy, leading to pain and dysfunction of one or more joints, with the need of joint replacement. The knee is the most commonly affected joint but, frequently, multiple joints are affected. Therefore to optimize the use of deficient factor concentrates, to reduce costs, to have a global functional recovery, to facilitate pain control, and to reduce the rehabilitation period, multiple surgical procedures are indicated in the hemophilic patient. The advantages of performing the simultaneous bilateral arthroplasty, in addition of the above mentioned, are the execution of only one surgical event, a maximum of two hours of anesthesia, and the reduction of surgical stress in the patient by accomplishing both joint replacements, with two surgical teams working at the same time, compared with a bilateral arthroplasty in two stages or to perform them in different surgeries. Objective: Report two cases of bilateral total knee arthroplasty performed simultaneously with two orthopedic surgical teams in hemophilia patients. Methods: Report two cases of bilateral total knee arthroplasty performed simultaneously in the Traumatology Hospital Victorio de la Fuente Narvaez, México D.F. in two patients with severe hemophilia (one with hemophilia A and VHC infection, one with hemophilia B). There is only one case reported of bilateral total knee arthroplasty. Conclusion: There is a reduction in hospitalization costs and factor concentrates consumption by performing only one surgical event, as well as a short hospitalization, quick deambulation, opportune rehabilitation, and less psychological impact in the patients.

Keywords: arthropathy, simultaneous bilateral arthroplasty

P1.07
Functionality and quality of life of hemophilic persons undergoing a bilateral total knee arthroplasty
C. Lorenzo1, T. Prado2, A. Wolf2, L. Rocha Loures Pacheco2
1Hemepar - Haemocentre from Paraná, Brazil; 2UFPr- Federal university from Paraná, Curitiba, Brazil
E-mail: lorenzato.claudia@gmail.com

Subject: Assessing the functionality and quality of life of hemophilic patients undergoing a bilateral total knee arthroplasty. Material and methods: Analytical and cross-sectional study, with hemophilic patients that underwent arthroplasty at Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil, in the period from 1997 to 2011. The medical records were analyzed and patients were called for interview and assessment of functionality using FISH, of quality of life using SF-36, and of range of motion. Results: There were 13 male patients, with mean age 38.91 years (SD 9.20); nine with hemophilia A and four with hemophilia B; 12 were severe and one was moderate. The quality of life assessment resulted in better scores on social functioning, followed by role emotional and mental health; the worst were bodily pain, followed by role physical and physical functioning. The FISH assessment resulted in better performance in activities such as bathing, dressing, eating, and grooming; the worst were running, chair, and stairs (12 to 14 steps). Most patients did not have full extension of knees (0°), staying with attitude in fixed flexion average of 9.23°. (SD 8.86) in the right knee and 8.85°. (SD 8.20) in the left knee. The average range of flexion movement was 88.46°. (SD 21.35) in the right knee, and 79.23°. (SD 18.35) in the left knee.

Keywords: knee arthroplasty, health evaluation.

P1.08
Surgical synovectomy in pediatric patients with severe factor VII deficiency
S. Peltier, S. Kearney, M. Heisel-Kurth
Children’s Hospitals and Clinics of Minnesota, Center for Bleeding and Clotting Disorders, Minneapolis, MN, USA
E-mail: skye.peltier@childrensminn.org

Background: Severe congenital factor VII deficiency is extremely variable in its presentation and bleeding phenotype. We present the cases of two female siblings with severe factor VII deficiency who developed ankle hemarthrosis, chronic synovitis, and arthropathy. While infusion of recombinant factor VIIa (rFVIIa) was successful in achieving hemostasis acutely, daily prophylaxis did not appear to alter the progression of synovitis and destructive arthropathy. Case Presentation: The older sibling presented at age four following a left ankle injury. She was subsequently diagnosed with severe factor VII deficiency, due to recurrent swelling of the ankle. Despite daily prophylaxis, intermittently for three years, physiotherapy, and conservative orthopedic interventions, she continued to have progression of bilateral ankle synovitis, with bony changes, and underwent ankle synovectomies at age seven and eight. The younger sibling was diagnosed secondary to oral bleeding. At age 5, she presented with a new gait abnormality not associated with injury or obvious ankle swelling. MRI revealed synovitis in the left ankle without bony changes. She was placed on daily prophylaxis and synovectomy was done within two months. Conclusion: Arthropathy does occur in congenital factor VII deficiency and established guidelines for treatment and prophylaxis do not exist. Daily rFVIIa prophylaxis did not alter the progression of synovitis and arthropathy in the older sibling. Based on this experience, synovectomy was performed on the younger sibling much earlier. Surgical synovectomy was successful in stopping further bleeding episodes. However, follow-up is required to ascertain if this will arrest the progression of hemophilic arthropathy.

Keywords: synovectomy, pediatrics, arthropathy
P1.09
The economic effect of tandem arthroscopic synovectomy for hemophilic patients
Y. Inagaki1, Y. Tanaka1, K. Maruta1, Y. Sakamoto1, T. Kuniti1, K. Vemastu1, A. Taniguchi1, M. Ogawa1, H. Nakat1, S. Omokawa1, K. Nozomi1, M. Shima1
Departments of 1Orthopaedic Surgery; 2Pediatrics; 3Rehabilitation, Nara Medical University, Kashihara, Japan
E-mail: eternalbluem9@yahoo.co.jp

Objective: Arthroscopic synovectomy is an effective technique for hemophilic articular synovitis, especially in Japan, where synovectomy using radioactive material is not approved. However, orthopedic procedures, including arthroscopic synovectomy, require expensive drugs. Recently, we devised "tandem" arthroscopic synovectomy in which upper extremity arthroscopy and lower extremity arthroscopy are performed simultaneously to reduce medical cost. The objective of this work is to report the economic effect of our procedure. Method: Four "tandem" arthroscopic synovectomies for 12 joints (two shoulders, two elbows, seven ankles and one metatarsal joint) of four hemophilic patients were performed at our institute. All patients suffered from hemophilia A and two were inhibitor positive. Average operation time was 180 minutes with no perioperative complications. The medical cost for four "tandem" arthroscopic synovectomies, and hypothetical cost for 12 separated arthroscopic synovectomies, were compared. Results: To perform "tandem" arthroscopic synovectomies, 58,500 units of factor VIII concentrate, 46,000 units of factor VIII concentrate, 48 mg of epatocog alpha followed by 32,000 units of anti-inhibitor coagulant complex, and 235 mg of epatocog alpha were needed for patients 1 to 4, respectively. Thus, calculated medical cost reduced by our procedure was 93,071,480 yen, in total. Relevance and applicability: Arthroscopic synovectomy requires expensive drugs, although it is very effective for hemophilic articular synovitis. "Tandem" arthroscopic synovectomy can reduce much medical cost, compared to separated procedures. Originality of the work: To the best of our knowledge, this work is the first report about economic effect of "tandem" arthroscopic synovectomy.

Keywords: "tandem" arthroscopic synovectomy, economic effect

P1.10
Radiosynoviorthesis in the treatment of chronic hemophilic synovitis
I. Szerbi1, L. Bartha2, L. Nemes3
1Uzsoki Hospital, Orthopaedic Dept.; 2Semmelweis University Orthopaedic Clinic, 3National Haemophilia Center and Haemostasis Department, Budapest, Hungary

Aim: to present our promising results with radiosynoviorthesis in the treatment of hemophilic joints in Hungary. Material and method: Hemophilic hip, knee, and ankle joints have been treated with radiosynoviorthesis method at our department since 2003. Hip and ankle joints are treated with 110 MBq of rhenium-186 sulfide isotope in colloidal suspension, while yttrium-90 isotope, in colloidal suspension is used for knee joints. Isotope implantations are performed in a very sterile environment, in an operating room. Local anesthesia with 1% lidocaine is used for the procedure. There were no cases of injury caused by leakage of the isotope. The patients are admitted to the hospital for three days. Bed rest and immobilization of the joints with brace is prescribed, for the same time period, to reduce extra-articular migration of the radiopharmaceutical. Hip joint is not braced. Results: We observed overall reduction in joint bleeding frequency, from 18.7 to 2.4 per year, post radiosynoviorthesis. Similar results were obtained in patients with advanced osteoarthritis and in inhibitor cases. There was a significant reduction in pain in all joints. Average range of motion was maintained or increased from five to 15 degrees of motion one year post radiosynoviorthesis, in most joints. Radiosynoviorthesis was successful in 88% of the patients one year after isotope implantation. Conclusion: Radiosynoviorthesis represents an important alternative for the treatment of chronic hemophilic synovitis, markedly reducing joint bleeding frequency and pain, irrespective of the stage of arthritis and inhibitor status.

Keywords: radiosynoviorthesis, inhibitor

P1.11
Our experience with arthroscopic synovectomy of the hemophilic knee joint
L. Bartha1, L. Nemes2, I. Szerbi3
1Semmelweis University Department of Orthopaedics; 2National Haemophilia Center and Haemostasis Department, State Health Center; 3Uzsoki Hospital, Department of Orthopaedics, Budapest, Hungary

The most frequently observed target joint in hemophilia is the knee. The success rate synovectomy in controlling recurrent bleeding is high; however, significant loss of motion frequently results. Open or arthroscopic knee synovectomy requires an experienced, multidisciplinary collaboration (hematologists, orthopedic surgeons, and physiotherapists) in a dedicated hemophilia treatment centre. Method: Between 1997 and 2012, we performed 72 surgical procedures, of which 30 were knee synovectomies. Among these, 28 were arthroscopic knee synovectomies, combined with joint debridement. Two other knee synovectomies were performed by open surgical procedure. Preoperatively, all patients had experienced an average of three bleeding episodes into the affected joint per month, and had been unresponsive to at least three months of intensive replacement prophylaxis. In parallel to intensive replacement therapy, traditional LMWH prophylaxis was also used in all of the cases. Results: The frequency of bleeding episodes decreased in all cases; however, the average loss of range of motion in the knee was 17 degrees. We have observed five hemorrhagic complications in the postoperative period, but no infections or appearance of new inhibitors occurred after surgery. The average age of the patients at the time of the knee synovectomy was 37 years and the average length of follow-up was 5.65 years (range, one to 16 years). Conclusion: It was concluded from our study that bleeding frequency and the pain associated with persistent synovitis in the hemophilic knee can be effectively influenced by knee synovectomy. All of our patients required less factor replacement to control bleeding after synovectomy, although almost all of our patients experienced a certain degree of loss of motion in the operated knee.

Keywords: arthroscopic synovectomy, knee joint
P1.12

Joint distraction results in clinical and structural improvement of hemophilic ankle arthropathy: a series of three cases

L.F.D. van Vulpen1,2, M.E.R. Van Meegeren1,2, K. van Veghel1, P. de Kleijr2, P.M. van Roermund1, D.H. Biesma1, G. Roosendaal1, S.C. Mastbergen1, F.P.J.G. Lafeber3

1 Rheumatology & Clinical Immunology; 2 Haematology and Van Creveld Clinic; 3 Orthopaedic Surgery, University Medical Center Utrecht, the Netherlands

E-mail: l.f.d.vanvulpen-2@umcutrecht.nl

Objective: In ankle osteoarthritis, joint distraction is found to be very effective in diminishing pain and improving joint function and results in actual joint tissue repair. With this treatment, a prosthesis or arthrodesis can be delayed at least five years, which is especially of value for younger patients. In severe hemophilic ankle arthropathy (HAA), the standard surgical treatment options are arthrodesis and total ankle replacement, both treatments having their specific complications. In this study, joint distraction for HAA was explored for the first time. Methods: Three HAA patients were treated with joint distraction using an Ilizarov external fixator for 10-15 weeks. After 1.7-3.4 years, clinical outcomes were evaluated in retrospect with different questionnaires: hemophilia activities list (HAL), impact on participation and autonomy (IPA), and the Van Valburg pain score. Postoperative ankle joint mobility was measured. Structural changes were assessed on X-ray by the Pettersson score and joint space width (JSW), and on MRI. Results: All patients reported a clear improvement for self-perceived functional health: mean HAL sum score improved from 44±28.4% to 73±17.7% (p=0.04), IPA, and Van Valburg pain score (pre-treatment 80±5.0%; post-treatment 23±15.3% (p=0.016). Partial ankle joint mobility was preserved. The Pettersson score slightly improved in two patients. The mean JSW increased from 2.3±1.8mm to 3.4±1.0mm (p=0.07), and the MRI score improved (pre-treatment 12.0±3.5; post-treatment 8.0±4.4; p=0.020). Conclusion: Although retrospective in nature, this study suggests that joint distraction is a promising treatment for individual cases of HAA, without additional risk of bleeding during treatment. These results warrant further prospective studies.

Keywords: arthropathy, distraction

P1.13

Musculoskeletal status of adult Saudi patients with severe hemophilia

A.K. Almomen1, F. Aljassir2, M. Alfarhan3, T. Owaidah1, K. Alsaleh1, H. Saad1, J. Kaid3

1 Center of Excellence in Thrombosis and Hemostasis, College of Medicine; 2 Department of Physical Therapy, King Khalid University Hospital; 3 Department of Radiology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

E-mail: akalmomen@gmail.com

Background: Arthropathy of various degrees is a common complication of severe hemophilia, due to repeated spontaneous or traumatic bleeding episodes. Regular prophylactic administration of clotting factor concentrates can effectively prevent such complications. Objective: To assess the musculoskeletal status of adult Saudi patients with severe hemophilia prior to the establishment of a comprehensive hemophilia care centre. Methods: We carried out a full physical musculoskeletal examination, functional assessment, and radiological reporting of knees, ankles, and elbows of five adult male patients, aged 23-42 years. Results: We found 10 of 30 affected joints, one patient with three affected joints, three patients with two affected joints each, and one patient with one affected joint, all with severely impaired functions. MRI imaging indicated that all affected joints scored 3-5, according to the Arnold-Hilgartner Classification, where zero is normal and five is complete joint destruction. Conclusion: Adult Saudi patients with severe hemophilia suffer from advanced arthropathy. There is a great need to establish a comprehensive hemophilia care centre, then provide orthopedic surgery and rehabilitation for affected patients, and prophylaxis to patients with severe hemophilia.

Keywords: arthropathy, prophylaxis

P1.14

Peripelvic myositis ossificans in a hemophilic adolescent

D.V. Petratos1, H. Pergantou1, G. Matsinos1, H. Platokouki1, J. Anastasopoulos2

1 Haemophilia Centre/Haemostasis Unit, and 2nd Orthopaedic Department, Aghia Sophia Children’s Hospital, Athens, Greece

E-mail: haemofilia@paidon-agiasofia.gr

Although intramuscular hematoma is a common manifestation in people with hemophilia, the incidence of myositis ossificans in adolescents with hemophilia is extremely low. The case of a 16-year-old boy with severe hemophilia A, who presented with a 3-month-duration right hip pain and major gait disturbance, is described. Radiographs revealed the presence of an ischiofemoral bony bridge. CT scan with 3D reconstruction not only confirmed the diagnosis of myositis ossificans (MO) but also showed the exact location of the bony mass in the substance of the hip external rotators. Because of the painful and severely impaired motion of the hip joint, urgent surgical resection was performed. Unfortunately, recurrence of the MO, after 10 months, resulted in gradually increased difficulty with walking and the adolescent underwent a second operation. At 10 months
follow-up, the patient presented with a painless full range of motion of the hip joint and the pelvic x-ray showed no signs of recurrence. Juxtaarticular cases of MO in adolescents with hemophilia that severely impair the motion of the adjacent joint should be treated with early surgical intervention, while postoperative maintenance of sufficient levels of factor VIII is of great importance. In order to minimize the risk of permanent stiffness of the joint and disability of the patient, the degree of "maturation” of the MO should not be a contraindication.

**Keywords:** myositis ossificans, heterotopic ossification, hemophilia

### P1.15

**ACL reconstruction in active athlete with factor VII deficiency: Case report**

J. Walawski, Tomasz Wisnuk, M. Górska-Kosicka

1 MSW Hospital Lublin; Private Practice Ortomix, Lublin; 2Orthopaedic and Traumatology Department, Medical University, Lublin; 3Department of Disorders of Haemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw Poland

Email: jacwal@interia.pl

Uncontrolled bleeding during or after orthopedic surgery remains a major concern for surgeons, as it may jeopardize the outcome and could require re-intervention to secure hemostasis. This problem is particularly relevant for patients with bleeding disorders. This may raise a fear leading to avoidance of performing elective surgical procedures in those patients. Factor VII (FVII) deficiency is a rare bleeding disorder, which ranges in clinical severity from life-threatening to asymptomatic forms. Surgical bleeding is among the most frequent symptom in this disorder.

A 25-year-old, healthy active athlete was diagnosed with an anterior cruciate ligament (ACL) lesion. Routine preoperative laboratory tests revealed prolongation of prothrombin time (PT). A factor VII (FVII) deficiency was diagnosed (FVII level 8%). Standard, arthroscopic anatomical single-bundle ACL reconstruction using hamstrings was performed. The procedure was carried out under hemostatic coverage of activated recombinant factor VII (rFVIIa). RFVIIa was administered in three doses on surgery day and every 12 hours for the next two to seven days. The pre-surgery dose was 30 µg/kg. The subsequent doses were 15µg/kg. Care was taken to limit the procedure time and carry meticulous hemostasis. No excessive bleeding was observed during and after the operation. Standard rehabilitation protocol was introduced. No complication was noted during the procedure and rehabilitation. After six months, the patient returned to the same sport activity level. ACL reconstruction in athletes is possible, in routine surgical protocol, for the factor VII deficient patients.

**Keywords:** ACL injury, FVII deficiency

### P1.16

**Surgical and non-surgical management of pelvifemoral bone bridges in patients with hemophilia**

S. Aydogdu, K. Kavaklı, C. Balkan, G. Saydam

Departments of: 1Orthopaedics; 2Pediatric Haematology, Ege University Hospital Izmir, Turkey

Email: semih.aydogdu@ege.edu.tr

Pelvic bone bridges (HBF) have been infrequently described in patients with hemophilia. Spontaneous or post-traumatic intramuscular bleedings have been blamed as causative factors since they follow some specific muscle excursions. Sometimes they can extend from one bone to another, form complete or incomplete bone bridges, and block the natural joint motion. We present three cases (one of them previously reported) of HBF, in people with hemophilia, extending from the proximal femur to the pelvic bones. Patients were 15, 17, and 21 years-old. Two cases had hemophilia B and one had hemophilia A. The right side was affected in two cases and the left in one. In two cases, HBF was located in the quadratus femoris (QF) muscle (posterior to the hip joint), and in the rectus femoris muscle (anterior to the hip) in the last case. HBFs in the QF did not form a complete bone bridge and caused only limited discomfort without compressing the surrounding soft tissue, particularly the sciatic nerve. In one case, spontaneous regression of HBF occurred within six months. Therefore, management, consisting of regular observation, avoidance of overuse and trauma, and a controlled exercise program, was enough for two QF muscle HBFs. On the contrary, the case with HBF in the RF muscle had a complete bone bridge formation, which completely blocked hip joint motion and was located between the iliac bone and the anterior aspect of the femur. We had to surgically remove the extraarticular bone bridge formation. The patient regained joint motion immediately and almost completely. The perioperative course of the patient was uneventful. The last case is under close observation for the future course. Pelvimoral bone bridges may be encountered infrequently in people with hemophilia and can be managed by taking into account the patient's discomfort and the clinical-radiographic course of the HBF.

**Keywords:** periarticular heterotopic, hemophilia A, hemophilia B

### P1.17

**Hemostatic management of children with severe hemophilia A, B, and von Willebrand disease (VWD) and high responding inhibitors undergoing orthopedic surgeries**


1Haemophilia Centre/Haemostasis Unit, 2nd Orthopaedic Department, Aghia Sophia Children’s Hospital, Athens, Greece

Email: haemofilia@paidon-agiasofia.gr

Hemostatic monitoring of surgical interventions in patients with hemophilia A (HemA), hemophilia B (HemB) and VWD type III and high responding inhibitors is not feasible with replacement therapy. **Patients/Methods:** Management of five orthopedic interventions in four patients with alloantibodies to FVIII (n=2), FIX (n=1) and VWF (n=1) is presented. **Results:** Type of surgeries: 1) Chemical synovectomies with rifampicin at three target joints, under bypassing agent infusions. The same procedure was applied for four consecutive weeks to each patient. All synovectomies
resulted in significant reduction of hemarthroses in the affected joints. 2) Drainage of a post-traumatic compartment syndrome of the right forearm, requiring the concomitant use of two bypassing agents in order to control oozing from the surgical site. The outcome was complete recovery after adequate physiotherapy. 3) Excision of a left knee tumor in a boy with alloantibodies to VWF under concomitant use of a bypassing agent and continuous infusion (CI) of recombinant FVIII (rFVIII) devoid of VWF. No drug-related adverse event occurred. A Kaposis-form hemangioendothelioma was revealed in biopsy and the patient followed a physiotherapy course in order to be mobilized under prophylaxis. Details on patients’ characteristics, surgical procedures, inhibitor titres, perioperative management, and outcomes are shown in the following table. Conclusion: Hemostatic management of orthopedic surgeries, in children with hemophilia or VWD and high titre inhibitors, is challenging and requires adequate amounts of concentrates in order to attain successful hemostasis and ensure uneventful outcome.

### Table: Elective orthopedic surgery in hemophilic patients with inhibitors

<table>
<thead>
<tr>
<th>Case</th>
<th>Disorder</th>
<th>Age</th>
<th>Inhibitor titre at surgery</th>
<th>Type of intervention</th>
<th>Pre-operative treatment</th>
<th>Day 1</th>
<th>Day 2 onwards</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Severe hemA</td>
<td>14y</td>
<td>8 BU 1.2 BU</td>
<td>1) Synovectomy of right knee 2) Synovectomy of left elbow</td>
<td>90μg/kg rFVIII</td>
<td>90μg/kg rFVIII every 2-3-4 hours</td>
<td>90μg/kg rFVIII every 6-8-12 hours for 2 days</td>
<td>Good post-operative hemostasis Reduction of joint bleeds</td>
</tr>
<tr>
<td>2</td>
<td>Severe hemB</td>
<td>12y</td>
<td>46 BU</td>
<td>Synovectomy of left knee</td>
<td>90μg/kg rFVIII</td>
<td>90μg/kg rFVIII every 2-3-4 hours</td>
<td>90μg/kg rFVIII every 6-8-12 hours for 2 days</td>
<td>Good post-operative hemostasis Reduction of joint bleeds</td>
</tr>
<tr>
<td>3</td>
<td>Severe hemA</td>
<td>4y</td>
<td>7.8 BU</td>
<td>Decompression of post-traumatic compartment syndrome of the right forearm. Symptoms caused by paralysis of median and ulnar nerves</td>
<td>200μg/kg rFVIII</td>
<td>90μg/kg rFVIII every 2 hours</td>
<td>90μg/kg rFVIII every 2 hours and after day 4 tapering for 15 days + pd- aPCC (50IU/kg) every 12 hours for 3 days</td>
<td>Decompression of the right forearm and good hemostasis at surgical site. Full recovery after 3-month -physiotherapy</td>
</tr>
<tr>
<td>4</td>
<td>VWD type III</td>
<td>8y</td>
<td>0.6 BU Historical titre 6BU</td>
<td>Excision of left knee tumor</td>
<td>60 IU/kg rFVIII followed by CI 250IU/kg/h + a single dose of rFVIII (90μg/kg)</td>
<td>CI of rFVIII</td>
<td>CI of rFVIII + rFVIIa every 2-3-4 hours for 2 weeks</td>
<td>Uneventful surgery Mobilization under physiotherapy Biopsy of tumor: Kaposis-form hemangioendothelioma</td>
</tr>
</tbody>
</table>

**P1.18**

**Elective orthopedic surgery in hemophilic patients with inhibitors**


**Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico; 1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy**

**E-mail:** gianluigipasta@yahoo.it

**Background:** Orthopedic surgery in patients who developed an inhibitor against FVIII/FIX, the most common and most serious complication of replacement therapy in patients with hemophilia A or B, represents a surgical challenge, and information regarding the management of orthopedic surgery in such patients is limited. **Aim:** Description of elective orthopedic surgery in hemophilic patients with inhibitors from a single centre. **Methods:** Retrospective data collection regarding orthopedic surgery between January 1997 and December 2012. Forty-four procedures were performed in 22 patients affected by severe hemophilia A with inhibitor. Outcome measures included length of hospitalization, length of follow-up, occurrence of adverse events, need for additional intra-articular intervention, and patient satisfaction. **Results:** Of the 44 orthopedic procedures, four were minor surgery (surgical treatment of flat foot) and 40 were major surgeries (19 replacement surgeries, 10 arthroscopic procedures, 11 others procedures). Thirty-nine procedures were performed in high-responder patients. Recombinant factor VIIa was used for 36 major surgeries (90%). The median age of the patients at surgery was 32 years (range: 5-70), and the follow-up time ranges between three to 180 months. **Conclusion:** To date, no routine laboratory assay has proven to be helpful for dose optimization of either aPCC or rFVIIa treatment hence careful clinical follow-up is mandatory in order to avoid bleeding complications. Nevertheless, such procedures in hemophilic patients with inhibitors have to be limited to experienced hemophilia centres and surgeons.

**Keywords:** elective orthopedic surgery, hemophilia, inhibitors

**P1.19**

**The diagnosis of acute compartment syndrome (ACS) in hemophilia**

**S. Classey**

Guy’s and St. Thomas’ Foundation Trust Hospital, London, UK

**E-mail:** Stephen.classey@gstt.nhs.uk

ACS is caused by a restriction of capillary blood flow within a fascial compartment with potential limb-life-threatening
P1.20

Surgical resection of a pseudotumour in Myanmar

S. Htut1, K. Thu Tun1, A. Myo Thant1, K. Nwe Oo3, A. A. Khaing2

1Department of Orthopaedics, Yangon Orthopaedic Hospital; 2 Department of Haematology, Yangon Children Hospital, Yangon, Myanmar

E-mail: sawhtut28@gmail.com

Objective: To showcase a dedicated team’s effort in alleviation of severe pain and discomfort of a young boy with severe hemophilia B in a country with minimal hemostatic replacement therapy.

Methods: Myanmar has come out of isolation and is engaging with the rest of the world. The healthcare system is seeing the fruits of the interaction. Donation of clotting factor concentrate, and the pharmaceutical companies’ showing corporate social responsibility, has made this happen: “Surgical resection of a pseudotumour in a young hemophilia B patient”. The methodology is “seizing the opportunity” and the working of a team of paediatricians, orthopedic surgeons, pathologists, and other healthcare professionals. The patient was treated surgically by using both volar and dorsal approach and a pseudotumour was removed without requirement of bone graft. The surgery has been videotaped and the final result of the young boy is shown. It portrays the skills of the surgeons, the dedication of the team, and the capability to work together for the “best care of the patients,” as can be given with whatever is available. It also illustrates the need of corporate social responsibility by pharmaceutical companies in helping WFH to close the gap in hemophilia care globally.

Results: At three-month follow-up, normal healing occurred and no recurrence was observed. The patient was completely asymptomatic.

Conclusion: Hemophilia patients, even in places with resource limitations, deserve the treatment needed for them, so that they can have an improved quality of life. This can be made possible when all caring people work together.

Keywords: pseudotumour, hemophilia B

---

P1.21

A case study of hemophilia: Alfred P.

R.J. Atwood

Hemophilia of North Carolina, Morrisville, N.C., USA

E-mail: atwoodr@earthlink.net

A patient with hemophilia has not been recognized for his role in advancing medical care through the application of X-rays. In 1897, Dr. J.E. Shaw of Bristol, England, was first to publish X-rays of hemophilic arthropathy in knees and elbows. The patient was a 30-year-old man named Alfred P. who had previously been reported as a case study in hemophilia. Historical research using original and secondary source material uncovered the family and medical history of Alfred P. along with a copy of the original x-ray of his swollen knee. Alfred P. is due proper acknowledgment as the first person with hemophilia to consent to an x-ray examination of his joints.

Keywords: history, X-rays

---

P1.22

Factors influencing functional independence score in hemophilia


1Orthopedic Department, Ghaem Hospital; 2Sheikh Hospital for Children; 3Orthopedic and Trauma Research Center, Ghaem Hospital Mashhad University of Medical Sciences, Mashhad, Iran

E-mail: r_mahdavian_nz@yahoo.com

Background: Functional independence score in hemophilia (FISH) is a measurement tool to assess disability in patients with hemophilia. Scores ranging from one to four are given for each of eight parameters. Different factors can influence on the function of hemophilic persons after a therapeutic intervention. Methods and Materials: Demographic data and treatment modalities were collected together with FISH questionnaires in a cross-sectional study on a total of 153 patients, comprising 113 patients with hemophilia A and 32 with hemophilia B. Results: The mean age of patients with hemophilia A and B was 25.1±15.4 and 22.8±11.9, respectively. Furthermore, the mean FISH score of patients with hemophilia A and those with hemophilia B was 27.7±4.6 and 28.1±4.5, correspondingly. No significant difference was observed between hemophilia A and B regarding FISH score (p=0.671), but there was significant difference in FISH score between patients with and without inhibitor (p=0.029). Moreover, there was no significant difference between prophylactic and on-demand groups in hemophilia type A patients regarding FISH score (p=0.977). A significant difference was observed between severe type, and mild and moderate types of hemophilia regarding FISH Score (0.037). As well as this, a wide disparity was detected between patients with and without hepatitis C regarding FISH score (0.000). Conclusion: FISH score is a simple means of measuring disabilities: the more severe the hemophilia, the more disabled the patient. Furthermore, if factor deficiency can be diagnosed early on and the patient receives prophylactic treatment, the least disability can be predicted for the patient.

Keywords: hemophilia; FISH score
**P1.23**

**Interdisciplinary musculoskeletal clinic for persons with inherited bleeding disorders (PWBD)**


Hamilton Niagara Regional Bleeding Disorders Program, Hamilton Health Sciences, Hamilton, Canada

**E-mail:** strike@hhsc.ca

**Background:** Notwithstanding the progressive adoption of pharmacological prophylaxis, the assessment and management of joint disease remains an integral aspect of comprehensive care for persons with inherited bleeding disorders (PWBD). Given current fiscal restraints, it has been suggested that new models of care may better allow for fiscally responsible health outcomes.

**Objective:** To develop an interdisciplinary musculoskeletal clinic (IDMC) for PWBD. **Methods:** An interdisciplinary team, including hematology, orthopedics, physiotherapy, prosthetics/orthotics, nursing, and program administration was created. Patients requiring joint health assessment and management were referred to the bi-annual IDMC at their annual review. Functions provided in the IDMC include orthopedic assessment, recommendations for surgical intervention, factor replacement, intra-articular joint injection, bracing/orthotics, and physiotherapy. **Results:** The IDMC demonstrated several beneficial outcomes for PWBD including: Intervventional procedures were discussed and performed by orthopedic surgery, in the clinic, with factor replacement recommendations provided by hematology and administered by nursing staff; When indicated, goals for physiotherapy and bracing/orthotics were evaluated with the patient and an interdisciplinary team to streamline service delivery and follow-up; Enhanced communication among team members and the PWBD, facilitating accountability, patient self-efficacy, and autonomy. **Conclusions/Future Directions:** In our experience, the IDMC provided patient-focused care with reduced fragmentation and duplication. Future needs include evaluating the cost-effectiveness of this model of care, the impact on quality of life/disease management for PWBD, provider satisfaction, administrative outcomes, including wait times and the psychosocial/financial impact of joint disease on PWBD with the inclusion of social work as a member of the interdisciplinary team.

**Keywords:** interdisciplinary care, orthopedics

**P1.24**

**Efficacy and safety of rFVIIa, used as comparator in development of a new rFVIIa analogue: data from a phase 3 trial on vatreptacog alfa in hemophilia patients with inhibitors**

**J. Windyga**, J. Mahlangu, F. Abdul Karim, Tatiana Andreeva, Marina Economou, Silke Ehrenforth, Steven Lentz, on behalf of the adept™2 investigators

**Aim:** To report the efficacy and safety of rFVIIa in Adept™2, a phase 3, multi-centre, double-blind, cross-over trial on the treatment of bleeds in inhibitor patients aged ≥12 years. Bleeding episodes were randomized (3:2) to vatreptacog alfa (1-3 doses × 80 µg/kg) or rFVIIa (1-3 × 90 µg/kg). Local standard of care was used if hemostasis was not achieved after three doses. Effective bleeding control was defined as no additional hemostatic medication within 12 hours. Safety assessments included immunogenicity (development of vatreptacog alfa/rFVIIa neutralizing antibodies) and adverse events. A total of 227 bleeds in 57 patients were treated with rFVIIa; 205 were joint or muscle bleeds treated at home. There were 3.98±3.4 (mean±SD; range 1-16) bleeds/patient. Time from bleeding onset to first injection was 1.3±3.8 hours. Effective bleeding control was achieved in 93% of all bleeds treated with 1-3 doses of rFVIIa. Vatreptacog alfa efficacy was also 93%. rFVIIa efficacy was comparable for muscles, joints, and mucocutaneous bleeds. Bleeds treated after two hours responded as well as bleeds treated within two hours. Only 15 AEs (in 6.6% rFVIIa-treated bleeds), of which five were serious AEs (2.2%), were reported. General safety assessments showed no safety signals to rFVIIa. Adept™2, the largest global, randomized trial in inhibitor patients, confirmed the well-established safety and efficacy profile of rFVIIa with a 93% success rate. Late-treated bleeds (>2 hours) responded as well as early-treated bleeds (≤2 hours).

**Poster Session 2**

**P2.01**

**The effect of a home-based exercise program on postural balance in children with hemophilia: two case studies**

**F. Melo Bessa De Souza**, B. Romanelli Ortiz, M. VerÁssimo Oliveira, C. Mendes Carmo, P. Villa, C. Tanaka

**1Physical Therapy Service, Clinical Hospital; 2Hemophilia Center, Clinical Hospital, University of Sao Paulo, Sao Paolo, Brazil**

**E-mail:** bessa_fisioterapia@yahoo.com.br

**Objective:** The objective of this study was to evaluate the effects of a home-based exercise on postural balance in children with hemophilia. **Method:** Two children with hemophilia A, with a previous history of at least four lower limb joint bleeds over the past six months, participated in this study. The joint condition was evaluated by HIJHS 2.1 and the postural control was assessed during quiet standing with (I) eyes-open/stable surface, and (II) eyes-open/foam surface. A (III) condition was assessed using...
unexpected perturbation using an external device. Sway area of center of pressure displacement (COP) were analyzed for conditions (I) and (II) and COP-displacement in anterior-posterior (AP) direction for condition (III). Children and parents received a booklet with instructions of a home-based exercise program to be accomplished over a six-week period, three times a week. After this period, they were similarly re-evaluated. Results: Both participants improved the variables analyzed after the 6-week program. Conclusion: These case-reports suggest that a home-based exercise program could improve postural control in children with hemophilia. Applicability to hemophilia care: The understanding of the real effect of exercises can help physiotherapists to improve the already available booklets of home exercise that are distributed in hemophilia centers, especially in developing countries, where the distance between the hemophilia centers and patients’ home is a barrier to optimum care.

<table>
<thead>
<tr>
<th>Condition I sway area (cm²)</th>
<th>Initial</th>
<th>After 6 weeks</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.06</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>1.55</td>
<td>0.47</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition II sway area (cm²)</th>
<th>Initial</th>
<th>After 6 weeks</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.17</td>
<td>2.71</td>
<td></td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>0.93</td>
<td>2.25</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition III COP-AP (cm)</th>
<th>Initial</th>
<th>After 6 weeks</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41.4</td>
<td>77.7</td>
<td></td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>38.4</td>
<td>61.2</td>
<td></td>
</tr>
</tbody>
</table>

Keywords: postural balance, hemophilia

P2.02

Physiotherapy is an important element of modern hemophilia treatment

S. Halimeh 1,2, M. Rosenthal 1
1GZRR Coagulation Centre Rhine/Ruhr; 2GZRR Coagulation Centre Rhine/Ruhr, Duisburg, Germany

E-mail: susan.halimeh@gzrr.de

Introduction: Patients with hemophilia suffer from joint bleedings, which can lead to arthropathy. The administration of factor concentrate is primary to prevent these bleeds. Thus, we are investigating if there is an additional benefit by subsidiary measures. We offered these patients physiotherapy in our centre and investigated them systematically. Methods: 44 patients (age four – 62 years) were interviewed about quality of life and their pain sensation before and after one year of physiotherapy. We used also the substitution calendar as a data source. Twenty-nine patients (66%) were treated prophylactically and 15 patients (34%) were treated on demand. For the data analysis, we used SPSS (version 21.0) with algebraic sign test by the scaled sizes and CHI2-test by the dichotomous sizes. Under physiotherapy, the well-being has increased. Pain could be diminished 2.6 scale points in the mean. Analgesics use was reduced one scale point in the mean. The number of bleeds decreased and additional concentrate administration could be reduced. During the physiotherapy, all kind of injuries were less frequent than before. Conclusions: Individualized physiotherapy can raise the quality of life of a patient with hemophilia through increase of the physical function, prevention of bleeds and injuries, and also pain reduction. Besides, this cost can be reduced as there is less coverage of factor concentrate. These results can only be achieved if the physiotherapy is adjusted on the status of the individual joint.

<table>
<thead>
<tr>
<th>Mean comparison</th>
<th>Number n</th>
<th>1. Survey 2011</th>
<th>2. Survey 2012</th>
<th>Improvement</th>
<th>Equal</th>
<th>Degradation</th>
<th>Significance p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical well-being of children/adolescents (scale-score: 1-5)</td>
<td>22</td>
<td>4.00 (0.68)</td>
<td>4.25 (0.64)</td>
<td>10</td>
<td>10</td>
<td>2</td>
<td>0.04</td>
</tr>
<tr>
<td>Physical function of adults (Scale-score: 1-5)</td>
<td>22</td>
<td>3.88 (1.03)</td>
<td>4.21 (0.79)</td>
<td>11</td>
<td>9</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Pain (maximum scale value: 0-10)</td>
<td>44</td>
<td>5.84 (2.98)</td>
<td>2.20 (2.42)</td>
<td>41</td>
<td>3</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Analgesics use (0=none – 5=several times daily)</td>
<td>44</td>
<td>1.45 (1.52)</td>
<td>0.43 (0.90)</td>
<td>21</td>
<td>17</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Number of bleeds (Jan.-Aug.)</td>
<td>44</td>
<td>2.95 (3.63)</td>
<td>0.66 (1.55)</td>
<td>21</td>
<td>23</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Additional factor concentrates (Jan.-Aug.)</td>
<td>44</td>
<td><strong>Yes (64%)</strong></td>
<td><strong>No (73%)</strong></td>
<td>16</td>
<td>28</td>
<td>0</td>
<td>0.002</td>
</tr>
<tr>
<td>Events of injuries (Jan.-Aug.)</td>
<td>44</td>
<td><strong>Yes (64%)</strong></td>
<td><strong>No (73%)</strong></td>
<td>16</td>
<td>28</td>
<td>0</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Keywords: physiotherapy, quality of life
P2.03
Effects of cold application on pain sensitivity in hemophilia knee: Results of a randomized controlled study

D. Czepa, J. Kirstein, S. Krueger, F. Stauber, H. Stephan, T. Miloszewski, T. Hilberg
Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany
E-mail: czepa@uni-wuppertal.de

Hemophilic arthropathy is usually accompanied by chronic pain. Cryotherapy is a common procedure in pain treatment, although its practice has hardly been substantiated by studies. The aim of this randomized controlled study was to investigate effects of cold application on pain sensitivity (PS) in hemophilia patients. A total of 51 adults with severe hemophilia A (H) and 20 controls without hemophilia (C) were included. Out of these, 15 H and 10 C underwent a 20-minute cooling of both knees in constant 15°C circulating water using Hilotherm® (with intervention) and were compared to 16 H and 10 C, who had on a room-temperate cuff (without intervention). PS threshold was assessed by means of a force algometer on knees before intervention, immediately after intervention, at two and at 24 hours after intervention. Also, the skin temperature (ST) was examined using an infrared thermometer. ST decreased by 2°C immediately after cold application in both groups with intervention (p≤0.01). In H with intervention, no significant changes were determined in PS in knees (left: 50±15 vs. 49±15 Newton (N); right: 46±13 vs. 49±16N) (p>0.05). In contrast, C with intervention showed a decrease in PS (left: 75±30 vs. 89±29N; right: 78±28 vs. 89±26N) (p≤0.01). Values of groups without intervention did not change regarding ST and PS (p>0.05). The study has shown that the use of cold application on knees lowers skin temperature; however, it does not lower pain sensitivity in hemophilia patients. Therefore, cryotherapy should be reconsidered in the treatment of chronic pain in hemophilic arthropathy.

Keywords: pain, temperature, arthropathy

P2.04
Muscle strength, architecture, and neuromuscular function in adolescent boys with hemophilia following lower limb joint hemarthrosis

L.B. Suckling1, D. Stephensen1, 2, M.C. Cramp1, W.I. Drechsler4
1 School of Health, Sport and Bioscience, University of East London, Stratford, London, UK; 2 Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, United Kingdom
E-mail: l.suckling@uel.ac.uk

Objective: Muscle strength deficits have previously been reported in young children (seven to 11 years) with hemophilia. To date, muscle strength, along with muscle architecture and neuromuscular function in adolescents, have not been explored. The aim of this study was to evaluate differences in muscle strength, architecture, and neuromuscular function in a group of boys with hemophilia and age and Tanner stage-matched typically developing boys. Methods: Fourteen boys aged 11-18 years with severe hemophilia (G1) were recruited from five hemophilia centres in the U.K. Eight boys had experienced lower limb joint bleeds in the previous 12 months (median: 1, IQR: 0-2 bleeds). Typically, developing boys (G2) were recruited from a local primary school. Maximum isometric and isokinetic muscle strength, muscle architecture, voluntary activation, and surface electromyogram (EMG) parameters of the knee extensors (KE) and ankle plantarflexors (APF) were examined. Results: Preliminary analysis has shown no significant group differences for normalized muscle strength, muscle architecture, and EMG parameters for both the KE and APF (p > 0.05). In G1, muscle strength of the KE (r = 0.70, p < 0.01, Fig. 1) and APF (r = 0.69, p < 0.01, Fig. 2) was significantly associated with six-minute timed walk performance. Conclusion/Relevance: The lack of significant differences in muscle measures may be due to factors such as sample size and the proportion of boys with no recent history of bleeds. The observed significant relationships suggest that strength is still an important indicator in adolescent hemophilic boys. Further planned analysis will address these points.

Keywords: muscle strength, neuromuscular function
Abstracts

P2.05
Effectiveness of joint traction and PNF in hemophilic arthropathy of the elbow

R. Cuesta-Barriuso1, M. Moreno-Moreno2, D. Garcia-Diego3,4
1Department of Physiotherapy, Faculty of Medicine, University of Murcia, Murcia; 2Service of Hematology, University Hospital Virgen de la Arrixaca, Murcia; 3Spanish Federation of Haemophilia, Madrid; 4Instituto Universitario Ortega y Gasset, Madrid, Spain

E-mail: ruben.cuestab@gmail.com

Objective: Evaluate the effectiveness of joint traction and proprioceptive neuromuscular facilitation (PNF), to improve range of movement (ROM), the perimeter and strength of biceps, and pain perception in patients with hemophilia (PWH) and arthropathy of elbow. Methods: Randomized trial with two groups: one treated with joint traction and PNF (MT group) and a control group (C group). The intervention lasted 12 weeks (two sessions per week, one hour each session), and elbows were evaluated before and after treatment, and after six months. Eighteen PWH participated in this study: nine in TM group and nine in C group, being evaluated 16 and 14 elbows, respectively. Three blind evaluators assessed: ROM (flexion and extension), biceps perimeter (measuring tape), biceps strength (rupture test, 0-5 points), and perception of pain (visual analog scale, VAS). Results: Table 1 shows the descriptive characteristics of PWH in the study, depending on the group. We observed improvement (p <0.05) on the perimeter of biceps, flexion, and pain perception of elbow in MT group. These findings held after the follow-up period. Table 2 shows the statistical data of post-treatment and follow-up period. Relevance and applicability to hemophilia care: Our results provide improvement in the elbow flexion despite advanced joint damage. PNF is achieved with a gradual increase of the strength of the muscles around the elbow. The elbow pain relief, observed in this study, is a valid tool for the management of this symptom of special concern for PWH.

| TABLE 1. Description of the sample |

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>TM group</th>
<th>C group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>11.67</td>
<td>12.26</td>
</tr>
<tr>
<td>Weight</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Elbow hemarthrosis previous year</td>
<td>0.68</td>
<td>0.71</td>
</tr>
<tr>
<td>Radiological damage</td>
<td>1.62</td>
<td>2.90</td>
</tr>
</tbody>
</table>

| TABLE 2. Means and standard deviations of measured variables in three measurements |

<table>
<thead>
<tr>
<th>Variable</th>
<th>Assessment</th>
<th>TM group (n=16)</th>
<th>C group (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.094 (0.272)</td>
<td>0.000 (0.000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>31.31 (3.474)</td>
<td>31.72 (3.205)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>136.13 (14.181)</td>
<td>140.31 (11.247)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.719 (0.752)</td>
<td>0.344 (0.436)</td>
</tr>
</tbody>
</table>

| Key words: joint traction, hemophilic arthropathy |

(SD: standard deviation; rd: released degrees; Sig.: significance; ES: effect size).

TABLE 3. Parametric analysis of physical and pain variables in the study groups at 3 measurements

<table>
<thead>
<tr>
<th>Group</th>
<th>Assessment</th>
<th>Variable</th>
<th>Mean (SD)</th>
<th>t</th>
<th>rd</th>
<th>Sig.</th>
<th>ES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pre-Post-treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biceps perimeter</td>
<td>-0.393</td>
<td>0.738</td>
<td>-2.132</td>
<td>15</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flexion</td>
<td>-4.189</td>
<td>6.555</td>
<td>-2.552</td>
<td>15</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pain</td>
<td>1</td>
<td>3.670</td>
<td>3.223</td>
<td>15</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Post-treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biceps perimeter</td>
<td>0.756</td>
<td>17.952</td>
<td>1.685</td>
<td>15</td>
<td>0.113</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flexion</td>
<td>0.000</td>
<td>5.566</td>
<td>0.000</td>
<td>15</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pain</td>
<td>0.218</td>
<td>0.446</td>
<td>1.062</td>
<td>15</td>
<td>0.069</td>
</tr>
</tbody>
</table>
Abstracts

P2.06
Improved ambulation and weight-bearing in hemophilia patients with affected lower limbs using the SmartStep™ Gait System

R. Tiktinsky, G. Kenet, M. Heim, U. Martinowitz
National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

E-mail: tikoti@netvision.net.il

Objective: Gait training rehabilitation to improve weight bearing and ambulation on an affected lower limb. The training can be used with hemophilia patients who are post hemarthrosis, pre and post-surgery with joint arthropathy, and joint contractures. Methods: Using the SmartStep Gait System™, a biofeedback and monitoring device. It records and analyzes key gait parameters during functional activities and provides instantaneous audio and visual feedback. The SmartStep is comprised of a pneumatic insole that is placed in the shoe and is connected to two pressure sensors, which measure and transmit the vertical force under the hind foot and foot. The data are received and analyzed by a control unit, which is worn around the ankle and transmitted to computer-running software. For each step, the software provides the peak vertical force over the entire foot, heel and forefoot. Temporal parameters, including the number of strides, velocity, cadence, and timing of the stance and swing phase of each step are also calculated. Treatment sessions began with a gait assessment. Therapy consisted of strengthening exercises, stretching, the use of electrotherapy modalities, weight shift and balance activities. Training and game modes consisting of weight shifts A-P and lateral were also utilized. Post-treatment assessment was then performed. Results: A 40-60% improvement was seen in overall weight bearing and, especially, in hind foot placement. A positive learning curve was observed. The SmartStep can also be used in a home environment for continued improvement. Relevance: Continued improvement of proper gait is an essential aspect of hemophilia care. Due to recurrent bleeds and joint arthropathy, many patients develop gait deviations. These deviations need immediate and exact correction. SmartStep aids the proper steps to gait rehabilitation.

Keywords: gait rehabilitation, biofeedback

Andante Medical Devices Ltd, Omer, Israel
SmartStep

P2.07
Building evidence into practice: proposed evidence-based updates to the Canadian physiotherapists in hemophilia care (CPHC) standards of care

1Hamilton Health Sciences, McMaster Children's Hospital, Hamilton, ON; 2McMaster University, School of Rehab Science, Hamilton, ON; 3Health Sciences North, Sudbury, ON; 4WK Health Centre, Halifax, NS; 5Adult Inherited Bleeding Disorder Program of B.C., St. Paul's Hospital, Vancouver, BC; 6Centre de traitement de l'hémolipie pour l'Est du Québec, CHU de Québec, Québec, QC, Canada

E-mail: strike@hhsc.ca

Background: Research in the field of hemophilia has played a critical role in the management of the disease. As the practice of physiotherapy becomes more evidence-based, the standards of physiotherapy care must also evolve to ensure that persons with hemophilia receive comprehensive treatment. Objective: To evaluate and update the Canadian Physiotherapists in Hemophilia Care (CPHC) Standards of Care against current best evidence. Methods: Medline and Embase were used to identify the current evidence for physiotherapy management of persons with hemophilia. Keywords used were hemophilia and physical therapy, with additional limits restricting results to the English language. Searches of Medline and Embase returned 80 and 265 potential articles, respectively. Articles were reviewed to include only those from which novel standards of care could be developed. Results: The Hemophilia Joint Health Score (HJHS) has been found to be the assessment most widely adopted by physiotherapists to assess for moderate changes in joint status. Current evidence also suggests that physiotherapists play an important role in chronic disease management in the aging population [4,5], as well as in the secondary prevention of obesity, by prompting increased physical activity of patients (i.e. daily exercise, appropriate sport selection) [4,6-9]. Conclusion: Based on current evidence, it is recommended that the CPHC standards of care include: a) use of the HJHS at annual reviews [1-3]; b) education on appropriate sport selection [4,8]; and c) discussion on levels of physical activity [4-9].

Keywords: hemophilia, physiotherapy

References:
Abstracts

P2.08
Physiotherapy, physical activity, and sport in a program of prophylaxis of arthropathy in adult hemophilia patient

S. Pérez-Alenda1,2, F. Querol1,3, L.M. González2, M. Jaca3, J.A. Vila3, C. Aznar2
1University of Valencia; 2Haemostasis and Thrombosis Unit, University and Polytechnic Hospital La Fe, Valencia, Spain

In the hemophilic patient, the quality of life concept implies obtaining and maintaining a good physical condition through a physiotherapy program with physical activities and the practice of low-risk sport, according to the substitutive therapy of the patient. Physical activities, as well as sports have, by themselves, hemorrhagic risks to the musculoskeletal system, especially when the circulating factor levels in plasma are lower (after 24–48 hours of intravenous infusion of the coagulation factor concentrate). In the last trimester of 2011, we added to the established physical activities and sports recommendations a new physiotherapy protocol as part of the secondary prophylaxis program of the adult hemophilic patient. We have evaluated the quality of life pre and post protocol following the Hemophilia Joint Health Score items (version HJHS 2.1). The global physiotherapy protocol is a 3-year-long prospective study. Objectives: Physiotherapy protocol presentation and preliminary results after the first 12 months. Results: It has been evaluated 36 patients (hemophilia A, average age: 33 years, age range: 19–46) and have been revised for evaluating the physical program compliance (Table 1). Conclusions: 1) The prevention of hemophilic arthropathy still is the principal goal of prophylaxis treatment and it is directly related to quality of life. Almost all adult hemophilic patients have hemophilic arthropathy (patients who have not followed the prophylaxis modality of hematologic treatment). The implementation of a more complete “prophylaxis” program, including physiotherapy guidelines, may improve the quality of life level and achieve the basic goal of “hemarthrosis zero”, maintaining factor through physical activity and exercise: the role of physiotherapy. Haemophilia. 2007; 13(Suppl. 2):31–37.

Keywords: physiotherapy, arthropathy

Table 1. Results

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Arthropathy</th>
<th>Physiotherapy Compliance</th>
<th>Sport Compliance</th>
<th>General Gym</th>
<th>Quality of Life Median perception (1-10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe Hemophilia A (n=36)</td>
<td>35</td>
<td>17</td>
<td>18</td>
<td>3</td>
<td>8</td>
</tr>
</tbody>
</table>

P2.09
Incidence of bone mass deficit in the hemophilic patient: aspects related to physiotherapy and quality of life

F. Querol1,3, S. Pérez-Alenda1,2, F. Aparisi3, M. Jaca3, C. Vila3, J.A. Aznar3
1University of Valencia; 2Haemostasis and Thrombosis Unit, and 3Radiology Service University and Polytechnic Hospital La Fe, Valencia, Spain

Introduction: In the general population, as well as in patients with hemophilia (PWH), osteoporosis implies: 1) compromise of bone resistance; 2) chronic pain related to age and degenerative process; and 3) fracture risk. Alternatively, the reduction of functional capacity and even invalidity are inevitable. All of these aspects together with those of hemophilia itself represent an increase in the comorbidity of this disease. Objectives: To provide preliminary results of bone mass values in hemophilic patients and their relation to physiotherapy, arthropathy signs, and influence on quality of life. Methods: This is an observational prospective study, in which the inclusion in the different groups is directly linked to socio-sanitary criteria, such as the arthropathy rate that prevents the practice of an aerobic sport, the proximity to a center controlled by a physiotherapist, or the modality of the factor substitutive therapy. Three groups of hemophilic patients (PWH) were evaluated. Group 1) PWH with a physiotherapy and sport controlled guideline; Group 2) PWH with the same guideline of physiotherapy and sport but without any professional control; Group 3) Control group; Group 4) PWH who do not follow any physiotherapy program. Results: PWH n=53 (Chart 1) average age: 30.2 years, median: 33, age range: 10–45.5. Pettersson score and Gilbert score = hemophilic arthropathy (46 PWH). Densitometry (BMD) = abnormally low values of bone mineral density (Table 1). Conclusions: Osteoporosis is a severe problem that mainly affects aging people, and the present life expectancy of hemophilic patients involves socio-economic/sanitary risks not studied so far. The average age of hemophilic patients worldwide is between 30 and 40 years, so that many age-related pathologies are unknown in these patients who have a specific pharmacologic, physical, or surgical treatment. Osteoporosis is associated directly to the age and the abnormally low values found in hemophilic population: young adults may require protocolized treatments.

Keywords: physiotherapy, BMD

Table 1. Results

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Patients</th>
<th>Clinic Arthropathy</th>
<th>Arthropathy X-r</th>
<th>Osteopenia</th>
<th>Osteoporosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe Hemophilia A</td>
<td>42</td>
<td>41</td>
<td>41</td>
<td>6</td>
<td>15</td>
</tr>
<tr>
<td>Moderate Hemophilia A</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Mild Hemophilia A</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Severe Hemophilia B</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>53</td>
<td>46</td>
<td>46</td>
<td>8</td>
<td>19</td>
</tr>
</tbody>
</table>

Keywords: physiotherapy, BMD
P2.10
Relation of elbow joint bleed and grip strength rehabilitation

R. Dange
Sahyadri Speciality Hospital, Hemophilia Society of Maharashtra, Pune Chapter, India

E-mail: rohidange@gmail.com

Objective: To study the changes in grip strength after an elbow bleed and the effects of treatment strategies. Background: Loads of written work is given to students in India. With limited resources, faster recovery strategy is important to cope with writing work. A valid evaluation of handgrip strength is of great importance in determining the effectiveness of different treatment strategies. It is widely accepted that grip strength provides an objective index of the functional integrity of upper extremity. Many treatment protocols compare the strength of the injured limb to the other or compare with normative data. Is there a relation between elbow bleed and hand function? Anatomically, the elbow complex is designed to serve the hand, 15 muscles that cross the elbow complex also act at either the wrist or shoulder, and therefore the wrist and shoulder are linked with the elbow in enhancing function of the hand. Purpose: 1. Does a bleed affect the grip strength? 2. What best strategies improve grip strength? Method: Grip measured before and, periodically, after a bleed by using handheld dynamometer. Group B given isolated elbow exercises; Group B elbow + upper limb exercises. Results: Both groups A+B are significant at 95% confidence, but if you compare T statistics or P value, group B is more significant than group A, faster recovery + better functional outcome. Conclusion + Discussion: Gives biofeedback, goal planning, treatment guidelines and in estimating the severity of force generating impairments in patients.

Keywords: coping strategies, hand grip strength

P2.11
Post-surgical mobility of total knee replacement in patients with hemophilia (PWH) operated without tourniquet

C. Daffunchio1,3, G. Galatré1,3, N. Moretti1, H. Caviglia1,3, M. Candela1,3, P. Salgado3
1Fundación de la Hemofilia; 2Hospital Juan A. Fernández, Servicio de Ortopedia y Traumatología; 3Academia Nacional de Medicina, Buenos Aires, Argentina

E-mail: dafunca@hotmail.com

Introduction: The literature showed that the post-operative ROM in PWH treated with TKR slightly improved with the procedure. Objective: To evaluate the postsurgical ROM in patients with TKR done without tourniquet. Materials and Methods: From 2001 to 2012, 25 TKAs were performed in 18 patients with severe hemophilia A, seven bilateral and 11 unilateral. Mean age at arthroplasty was 47 years, mean follow-up was five years (range one to 11). All the knees were treated with PCS total knee replacement. For surgeries done without tourniquet, the ROM was evaluated preoperatively and postoperatively every six months. Results: The mean knee flexion improved from 67° to 82°, post op. The mean flexion contracture diminished from 26° to 8°. The mean total ROM increased from 40° preoperatively to 74° at the final follow-up, (P<0.0001) Test student paired test. ROM obtained in six months postoperative was maintained up to the final follow-up. The relevance and applicability to hemophilia care: This study shows that patients undergoing TKR without tourniquet, and treated with an appropriate plan of long-term rehabilitation, achieved marked improvement in ROM.

Keywords: ROM (range of motion), TKR (total knee replacement)

P2.12
Fisiocare: a new approach to physiotherapy based on self-treatment

E. Forneris1, M. Messina2, C. Bruno3, E. Boccalandro3, C. Ettorre3, G. Fasta3, L.P. Solimeno3
1Compound structure Pediatrics and Traumatology, Hospital O.I.R.M.-S. Anna, Turin; 2Transfusion Service, Hospital O.I.R.M.-S. Anna, Turin; 3Traumatology Department; IRCCS Maggiore Hospital Foundation, Milan; 4Haemophilia Centre; Policlínico, Bari- Italy

E-mail: eleforn@libero.it

The objective of the project is to assess the impact of a new approach based on self-treatment, and also to raise awareness and educate the hemophilic population to the “culture of movement”. Methods: Patients will be included after a multidisciplinary assessment (HJHS, postural analysis, bleeding frequency) in order to plan a tailored rehabilitation program. Twelve weekly physiotherapy sessions of 90 minutes will be dedicated to two groups of five patients (adult and pediatric). Afterwards, a self-treatment program will be carried out at home for three months. Once this period will be completed, a re-assessment will be performed. Results: The first data will be made available at the conference. The relevance and applicability to hemophilia care: The Fisiocare project started in two pilot centres (Turin, Bari) and it will be extended throughout the country, particularly in hemophilia centres without regular access to a physiotherapy service, in order to promote a standardized approach of physiotherapy. Our initiative could be proposed as a model. The originality of the work: The project, Fisiocare, is the first national network of physiotherapists involved in hemophilia. This project provides a model for the organization of collective courses of physiotherapy, held by a specialist, in order to administer and teach specific and tailored exercises that every patient can perform in complete autonomy at home.

Keywords: physiotherapy, hemophilia

P2.13
Effectiveness of training program in open waters, pool, and land exercise in adolescents with hemophilic arthropathy

A. Gibraltar Conde*, M. Osorio Guzmán**, M.A. Gutiérrez Aguna***
* UMAE “Dr. Victorio de la Fuente Narváez”. Unity of Physical Medicine and Rehabilitation North, ** UNAM “Facultad de Estudios Superiores Iztacala”, ***Hemophilia Federation of the Republic of Mexico, México

Email: giblitarconde@hotmail.com
Abstracts

Introduction: Swimming is one of the most recommended sports for people with hemophilia. Objective: To evaluate the effectiveness of a training program of swimming in open waters, in the pool, and land exercise. Material and methods: After obtaining informed consent, they included five adolescents who performed a training program that included pool, open waters and land exercises for 10 months. Three measurements were made with scale Hemophilia Joint Health Score (HJHS). Results: of adolescents included, 80% had hemophilia A (moderate and severe) and 20% hemophilia B (severe). The joints with the most damage were the elbows and ankles. There was a reduction in the HJHS between the second and third measurements, statistically significant difference (p < 0.05). The items that showed significant differences were edema in elbows and muscle strength in ankles. The training program in open waters, pool and land exercise are effective to decrease the severity of hemophilic arthropathy in adolescents. Relevance: motivate patients with hemophilia to integrate into supervised sports, showing the results obtained and decreasing the myths. Originality: the type of training carried out in Mexican adolescents with hemophilia.

Keywords: open waters, exercise in hemophilia.

P2.14
Impact of hemophilic arthropathy on quality of life
R. Cuesta-Barriuso1, M. Moreno-Moreno1, A. Torres-Ortuño3
1Department of Physiotherapy, Faculty of Medicine, University of Murcia; Psychiatry and Social Psychology Department, University of Murcia, Murcia, Spain

E-mail: ruben.cuestabarriuso@gmail.com

Objective: Identify the variables that have the greatest influence on the perception of quality of life (QoL) of patients with hemophilia (PWH) and hemophilic arthropathy (HA) of knee, ankle and elbow. Methods: PWH 31 adults with hemophilic arthropathy participated in this study, being evaluated 56 ankles, 34 knees and 46 elbows. One hundred per cent of patients had HA ankle (25 bilaterally), 21 HA knee (13 bilaterally), and 27 to HA elbow (19 bilateral). Two masked reviewers assessed the range of motion (with universal goniometer), pain perception (visual analog scale, VAS), radiological damage (Petterson scale), and quality of life (QoL: Hemophilia-A36 questionnaire). Result: Descriptive characteristics of the PWH included in the study are in Table 1. Patient age and radiological damage barely influence the QoL of PWH. However, the pain is correlated with eight and four QoL variables in PWH and HA of ankle and knee, respectively. The variables that influence QoL are plantar and dorsal flexion deficits of the ankle. In the PWH with elbow HA, only radiological damage influences “difficulty with the treatment” variable. Table 2 shows the correlations observed in the study. Relevance and applicability to hemophilia care: Pain is one of the symptoms reported by PWH and HA and should be addressed as quickly as possible. A multidisciplinary approach is necessary to decrease the perception of joint pain, especially in the lower limbs, so we can improve the QoL of PWH.

Keywords: hemophilic arthropathy, quality of life

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Ankle</th>
<th>Knee</th>
<th>Elbow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>n Mean SD</td>
<td>n Mean SD</td>
<td>n Mean SD</td>
</tr>
<tr>
<td>Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemophilia A</td>
<td>31 35.29 12.877</td>
<td>21 39.48 13.493</td>
<td>27 34.48 12.99</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td>31 82.68 10.965</td>
<td>21 92.76 12.23</td>
<td>27 81.6 9.71</td>
</tr>
<tr>
<td>Radiation previous year</td>
<td>56 0.80 0.672</td>
<td>34 1.15 0.784</td>
<td>46 0.96 0.96</td>
</tr>
<tr>
<td>Radiological damage (Petterson score)</td>
<td>56 9.95 3.071</td>
<td>34 9.79 2.972</td>
<td>46 8.61 2.80</td>
</tr>
<tr>
<td>Pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PH</td>
<td>n %</td>
<td>n %</td>
<td>n %</td>
</tr>
<tr>
<td>PH</td>
<td>26 83.9</td>
<td>17 81</td>
<td>22 81.5</td>
</tr>
<tr>
<td>Hemophilia A</td>
<td>5 16.1</td>
<td>4 19</td>
<td>5 18.5</td>
</tr>
<tr>
<td>PH</td>
<td>12 67.3</td>
<td>9 42.9</td>
<td>17 63</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td>12 38.7</td>
<td></td>
<td>10 37</td>
</tr>
<tr>
<td>PH</td>
<td>17 54.8</td>
<td>12 57.1</td>
<td>15 55.6</td>
</tr>
<tr>
<td>Hemophilia A</td>
<td>14 45.2</td>
<td>9 42.9</td>
<td>12 44.4</td>
</tr>
</tbody>
</table>

In Table 1. Patient age and radiological damage barely influence the QoL of PWH. However, the pain is correlated with eight and four QoL variables in PWH and HA of ankle and knee, respectively. The variables that influence QoL are plantar and dorsal flexion deficits of the ankle. In the PWH with elbow HA, only radiological damage influences “difficulty with the treatment” variable. Table 2 shows the correlations observed in the study.

Relevance and applicability to hemophilia care: Pain is one of the symptoms reported by PWH and HA and should be addressed as quickly as possible. A multidisciplinary approach is necessary to decrease the perception of joint pain, especially in the lower limbs, so we can improve the QoL of PWH.

Keywords: hemophilic arthropathy, quality of life

<table>
<thead>
<tr>
<th>Joint</th>
<th>Variable</th>
<th>PH</th>
<th>TA</th>
<th>JS</th>
<th>JP</th>
<th>TS</th>
<th>TD</th>
<th>EF</th>
<th>MH</th>
<th>SA</th>
<th>QoL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ankle</td>
<td>Age</td>
<td>-0.265</td>
<td>0.136</td>
<td>-0.147</td>
<td>-0.164</td>
<td>0.198</td>
<td>0.048</td>
<td>0.209</td>
<td>-0.200</td>
<td>-0.086</td>
<td>-0.058</td>
</tr>
<tr>
<td></td>
<td>Radiological damage</td>
<td>-0.181</td>
<td>-0.008</td>
<td>-0.184</td>
<td>-0.175</td>
<td>0.282</td>
<td>0.122</td>
<td>0.029</td>
<td>-0.230</td>
<td>-0.211</td>
<td>-0.106</td>
</tr>
<tr>
<td></td>
<td>Flexion</td>
<td>0.166</td>
<td>0.041</td>
<td>0.398*</td>
<td>0.265*</td>
<td>-0.114</td>
<td>0.016</td>
<td>-0.246</td>
<td>-0.058</td>
<td>-0.087</td>
<td>0.055</td>
</tr>
<tr>
<td></td>
<td>Extension</td>
<td>0.181</td>
<td>-0.153</td>
<td>-0.034</td>
<td>-0.191</td>
<td>-0.295**</td>
<td>-0.401*</td>
<td>-0.358*</td>
<td>-0.069</td>
<td>0.017</td>
<td>-0.148</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>-0.502*</td>
<td>-0.380*</td>
<td>-0.411*</td>
<td>-0.301**</td>
<td>-0.028</td>
<td>-0.030</td>
<td>-0.343*</td>
<td>-0.493*</td>
<td>-0.424*</td>
<td>-0.461*</td>
</tr>
<tr>
<td>Knee</td>
<td>Age</td>
<td>-0.364</td>
<td>-0.093</td>
<td>0.210</td>
<td>-0.120</td>
<td>0.171</td>
<td>0.108</td>
<td>0.111</td>
<td>-0.382</td>
<td>-0.195</td>
<td>-0.145</td>
</tr>
<tr>
<td></td>
<td>Radiological damage</td>
<td>-0.454**</td>
<td>-0.003</td>
<td>-0.384</td>
<td>-0.206</td>
<td>0.298</td>
<td>0.257</td>
<td>-0.033</td>
<td>-0.272</td>
<td>-0.248</td>
<td>-0.199</td>
</tr>
<tr>
<td></td>
<td>Flexion</td>
<td>0.159</td>
<td>-0.286</td>
<td>0.235</td>
<td>0.062</td>
<td>-0.247</td>
<td>-0.413*</td>
<td>0.248</td>
<td>0.021</td>
<td>-0.018</td>
<td>-0.116</td>
</tr>
<tr>
<td></td>
<td>Extension</td>
<td>0.103</td>
<td>0.405**</td>
<td>0.069</td>
<td>0.154</td>
<td>0.061</td>
<td>0.199</td>
<td>0.242</td>
<td>-0.014</td>
<td>0.114</td>
<td>0.235</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>-0.387**</td>
<td>-0.009</td>
<td>-0.270</td>
<td>-0.491*</td>
<td>-0.103</td>
<td>-0.009</td>
<td>-0.222</td>
<td>-0.453*</td>
<td>-0.266</td>
<td>-0.342**</td>
</tr>
<tr>
<td>Elbow</td>
<td>Age</td>
<td>-0.179</td>
<td>0.219</td>
<td>-0.556</td>
<td>-0.041</td>
<td>0.192</td>
<td>0.058</td>
<td>0.290</td>
<td>-0.137</td>
<td>0.004</td>
<td>0.042</td>
</tr>
<tr>
<td></td>
<td>Radiological damage</td>
<td>-0.211</td>
<td>0.166</td>
<td>-0.155</td>
<td>0.075</td>
<td>0.321</td>
<td>0.437**</td>
<td>0.207</td>
<td>-0.103</td>
<td>-0.213</td>
<td>0.051</td>
</tr>
<tr>
<td></td>
<td>Flexion</td>
<td>0.246</td>
<td>-0.02</td>
<td>0.251</td>
<td>0.047</td>
<td>-0.146</td>
<td>-0.119</td>
<td>-0.105</td>
<td>-0.149</td>
<td>0.171</td>
<td>0.091</td>
</tr>
<tr>
<td></td>
<td>Extension</td>
<td>-0.136</td>
<td>-0.169</td>
<td>-0.141</td>
<td>0.075</td>
<td>0.228</td>
<td>0.228</td>
<td>0.202</td>
<td>-0.028</td>
<td>0.068</td>
<td>0.057</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>0.09</td>
<td>0.024</td>
<td>-0.115</td>
<td>-0.071</td>
<td>0.074</td>
<td>0.093</td>
<td>-0.064</td>
<td>-0.002</td>
<td>0.028</td>
<td>0.01</td>
</tr>
</tbody>
</table>

(PH: physical health; TA: treatment adherence; JS: joint state; JP: joint pain; TS: treatment satisfaction; TD: treatment difficulties; EF: emotional functioning; MH: mental health; SA: social activities; QoL: total perception of quality of life)

* Correlation is significant at the 0.01 level (bilateral) ** Correlation is significant at the 0.05 level (bilateral)
P2.15

Characteristics of orthopedic status and impact on the quality psychosocial functioning of persons with hemophilia

M. Marinic1, S. Zupancic-Salek2
1Institute of Social Sciences Ivo Pilar; 2University Hospital Centre Zagreb, Zagreb, Croatia

E-mail: marko@pilar.hr

Research on the relationship between (poor) body conditions of persons with various physical disabilities and their psychosocial functioning are not always unambiguous. While on the one hand, research shows a negative correlation between the degree of disability and the mentioned areas, the other refers to the so-called “disability paradox,” or high quality of life despite the poor state of the body. Therefore, we wanted to investigate the nature the relationship between quality orthopedic status and psychosocial functioning of persons with hemophilia. An empirical survey among adults with hemophilia was conducted in Croatia (N=135). To determine orthopedic status we used: the scale of bleeding frequency in individual joints (elbow, knee, and ankle); the scale of damage levels of each joint; the scale of pain frequency, the scale of average pain intensity and the scale of physical mobility. The quality of psychosocial functioning was measured by using the Life Satisfaction Scale, the Emotional Functioning Scale the Mental Health Scale, and the Relationships and Social Activity Scale. We also used a variety of socio-demographic variables. The results show a significant correlation of all analyzed orthopedic status domains with psychosocial functioning. Frequent bleeding in joints, greater damage to joints, greater problems with mobility, and frequent and intense pain were negatively correlated with emotional functioning, mental health, relationships and social activity, and life satisfaction. It is interesting to note that the highest correlation was found in relation to knee damage and it seems that knee problems are precisely the biggest problems for people with hemophilia. It is also interesting to note that the worst results (in all forms of psychosocial functioning) were obtained from respondents who were between 40 and 50 years old. The results, among other things, show that the poor orthopedic status of hemophilia patients is not only an indication of major problems with regard to physical functioning, but that this greatly impacts other domains of human life. Therefore, to preserve the quality of psychosocial functioning, it is extremely important to receive quality medical care to ensure health of the musculoskeletal system. Moreover, the implementation of counselling for patients about the easiest ways of coping with these problems is also necessary.

Keywords: psychosocial, hemophilia, quality of life

P2.16

Safety concerns for small children in radioisotope synovectomy for hemophilia: 12 years of experience from a single center

K. Kavakli1, S. Aydogdu2, H. Oezkilic3, C. Balkan1, D. Karapinar4, N. Karadas1, S. Senol1
1Department of Pediatric Hematology, 2Orthopedics, 3Nuclear Medicine, 4Faculty of Nursing, Pediatrics, Ege University Hospitals Dept., Izmir, Turkey

E-mail: kaan.kavakli@ege.edu.tr

Radioisotope synovectomy (RS) is defined as intra-articular injection of radioisotopes for target joints. Safety concerns related to exposure to radiation have arisen, especially for small children. We aimed to evaluate safety records for 12 years in young children aged <10 years (20% of all patients) (38 patients and 85 joints). Mean age was 8±2 (three to 10 years). All were male 33 had hemophilia A and five had hemophilia B. RS was used for 36 knees, 26 elbows, and 23 ankles. Only four cases had inhibitor (10%). All patients had prophylaxis-resistant synovitis. Target joints per patient were 1.8 (1–3). By 2005, Yttrium 90 (Y-90) was used for all joints, as of 2005, Rhenium 186 (Re-186) started for elbows and ankles, Y-90 continued for knees. Children dose for Y-90 was 2.5–3.0 mCi and 1.5–1.6 mCi for Re-186. Mean RS count was 2.2 per patient (1–6). Two consecutive RS (with six-month duration) were used for six patients. Three RS in the same joint were used for three patients. During 12 years of observation, we have not had any single patient with malignancy (0/38 patients). One patient, aged six years, with HA and inhibitor was diagnosed severe aplastic anemia after eight months of RS (Re-186 for ankle) (1/38; 2.6%). He was evaluated as co-incidence due to short time of duration. Radioisotope leakage to skin has not been seen in children. Acute inflammatory reaction was observed in two patients with inhibitors. Y-90 was used this four-year-old boy with HA (1/38; 2.6%). After 12 years of observation serious safety problems were not observed. RS has also evaluated as safe procedure for children. No doubt, firstly prophylaxis must be tried for children. Radioisotope synovectomy should be preserved for resistant cases.

P2.17

Thermographic and clinical comparison of children with hemophilia and healthy age-matched children

A. Seuser1, K. Kurnik2, C. Bidlingmaier2, A. Mahlein3
1Institute for Spectral Medicine, 2Von Hauner Hospital for Children, Munich, Germany

E-mail: axel.seuser@t-online.de

The objective of the work: Children with hemophilia have silent bleeds, often recognized too late by structural changes in MRI. They cause silent, joint-associated symptoms associated with inflammation. Inflammation increases local blood flow and heat is a cardinal symptom. This can be measured by infrared thermography. This non-invasive sensor method could be a basic instrument for early detection of silent bleeds. Material and Methods: 10 symptom-free children with severe hemophilia, no reported joint bleeds within the last two years, age four to 17 years (10.3y) and 12 healthy boys age 10 to 14 years (11.75y). Digital Thermografic camera (Vario-Scan High Resolution 3201 ST, Jenoptik Laser, Jena, Germany). Room temperature: 21.9°C (21.7–22.2°C), humidity: 62.3% (59–63.7%). Digital RGB-photos for anatomic right-left comparison. Physical examinations: silent pressure points, were compared with Hemophilia Joint Health
Score (HJHS) and Hot Spots (right–left differences in heat distribution >0.7°C). Results: See tables Conclusion: Thermography detects early, subclinical inflammatory changes in joints and ligaments. It has no side effects and is easy to apply. We see significant differences between both groups. All clinical symptoms correlated with a hot spot. The study will be carried on with higher numbers to develop an early diagnostic tool to detect and subsequently treat silent bleeds in children with hemophilia.

It is highly relevant and easily applicable for hemophilia. The originality of the work: After the first paper, in 1975, focusing on acute hemarthrosis in adults, this is the first time thermography is applied to people with hemophilia and a matched age group of healthy boys. It offers a new view of the bodies’ biochemistry and compares it with easy physical examination methods. It provides a maximum of preventative insight and can change our view of pathogenesis of hemarthrosis and its prevention.

### TABLE 1: Average results for hot spots and physical examination for all joints

<table>
<thead>
<tr>
<th>Component</th>
<th>PWH (absolute)</th>
<th>Healthy (absolute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silent symptoms / HJHS</td>
<td>7.2 / 0</td>
<td>2.5 / 0</td>
</tr>
<tr>
<td>Hot spots</td>
<td>9.0</td>
<td>2.6</td>
</tr>
</tbody>
</table>

### TABLE 2: Distribution of hot spots and silent symptoms for the different joints:

<table>
<thead>
<tr>
<th>Examination: Joint</th>
<th>PWH (absolute)</th>
<th>Healthy (absolute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silent Symptoms: Elbow</td>
<td>23.6% (1,7 from 7,2)</td>
<td>23.3% (0,6 from 2,5)</td>
</tr>
<tr>
<td>Thermography: Elbow</td>
<td>23.3% (2,1 from 9,0)</td>
<td>35.5% (0,9 from 2,6)</td>
</tr>
<tr>
<td>Silent Symptoms: Knee</td>
<td>27.8% (2,0 from 7,2)</td>
<td>20.0% (0,5 from 2,5)</td>
</tr>
<tr>
<td>Thermography: Knee</td>
<td>40.0% (3,6 from 9,0)</td>
<td>41.9% (1,1 from 2,6)</td>
</tr>
<tr>
<td>Silent Symptoms: Ankle</td>
<td>48.6% (3,5 from 7,2)</td>
<td>56.6% (1,4 from 2,5)</td>
</tr>
<tr>
<td>Thermography: Ankle</td>
<td>28.9% (2,6 from 9,0)</td>
<td>22.6% (0,6 from 2,6)</td>
</tr>
</tbody>
</table>

### Keywords: thermography, hemophilia

#### P2.18

**Obesity and metabolic syndrome in Mexican children with hemophilic arthropathy**

A. Tlacuilo-Parra¹, E. Velazquez-Jimenez², R. Garibaldi-Covarrubias³, J. Soto-Padilla⁴, E. Guevara-Gutierrez⁴

¹Medical Research Division, UMAE Hospital de Ped, Guadalajara; ²Pediatric Hematology Department, UMAE Hospital de Ped, Guadalajara; ³Dermatology Department, Instituto Dermatolog, Zapopan, Mexico

E-mail: albtlacuilo@yahoo.com

Overweight and obesity and hypertension among people with hemophilia are a well-known problem; these are core components of the metabolic syndrome (MS). There are no studies about MS in children with hemophilia. **Objective:** To establish the prevalence of overweight-obesity and metabolic syndrome in pediatric patients with hemophilic arthropathy (HA). **Methods:** The Cook pediatric criteria for MS includes: waist circumference (WC, adjusted for age and sex, >90th percentile), high blood pressure (BP, adjusted for age and sex, >90th percentile), triglycerides (TG, >110mg/dL), HDL cholesterol (HDL-c, <40md/dL) and fasting glucose (Glu, >100mg/dL), requiring at least three criteria to establish MS. **Results:** 26 children with HA were studied, mild form in three (12%), moderate 10 (38%), and severe 13 (50%), the mean age was 11 ± 3. The prevalence of overweight and obesity (according to Z score CDC-NCHS reference values) was 12% and 31%, respectively. The MS criteria distribution was: high TG 46%, low HDL-c 34%, high BP 23%, high WC 15%, high glucose 0%. Finally the prevalence of MS was 8%. Obese children had statistically significant higher WC ratio (0.91 ± 0.07 vs. 85 ± 0.03; p = 0.018) and LDL-c values (95.6 ± 16 vs. 62.5 ± 16; p = 0.007) than non-obese children. **Conclusions:** Overweight and obesity are common in our pediatric patients with HA, our obese/overweight children had a lipoprotein profile of cardiovascular risk, and additionally obese/overweight children could damage earlier weight-bearing joints, affecting the range of motion, physical functioning, sports, and quality of life. Early detection allows appropriate intervention.

**Keywords:** Obesity, pediatrics, arthropathy

#### P2.19

**Joint health and functional ability in children with hemophilia in Bosnia and Herzegovina**

J. Samardzic Predojevic¹, E. Hasanbegovic², S. Mehadzic³, B. Djurdjevic Banjac⁴, A. Latifagic⁵, D. Stimjanin⁶, L. Solomon⁷

¹Department Hematology Oncology, University Children's Hospital, Banjaluka; ²Department Hematology Oncology, University Children's Hospital, Sarajevo; ³Department Hematology Oncology, University Children's Hospital, Tuzla; ⁴Cantonal Hospital, Zenica, Bosnia & Herzegovina

E-mail: jelicasp@inecco.net

**Introduction:** Currently there is growing interest in objective measurement of health outcome in patients hemophilia. Evaluation of joint health in hemophilia patients and their limitations in performing activities of daily living are very important. This is of particular importance in Bosnia and Herzegovina, where in the last five years, great efforts were made to provide prophylactic treatment for children suffering from hemophilia. **Aim:** The aim of this study was to determine the status of the joint function and functional ability of children with hemophilia and compare it with the degree of severity of hemophilia, age of the patient, therapy (on demand, primary or secondary prophylaxis). **Methods:** This study is based on data that were collected by phone interviews with patients and their parents and data from the National Register for people with hemophilia, which is currently in the process of forming. Joint check list and questions about functional ability are made by joint HSPH and Pediatric Hemophilia Activity List and adapted for the telephone survey. **Results:**

<table>
<thead>
<tr>
<th>Severe</th>
<th>Moderate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number patients</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Mean of ages</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Hemophilia A</td>
<td>27</td>
<td>6</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>History of prophylaxis</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

**Keywords:** Hemophilia, pediatrics, arthropathy.
Conclusion: Treatment of hemophilia should be more than the use of clotting factor. Joint physical examination must be performed by hemophilia joint score and provide adequate physiotherapy and surgical treatment for patients.

Keywords: joint health

P2.20
Using the PedHAL to measure functional abilities in children with hemophilia

N. Hubert, A. Griffioen, N. Sugg, M. Bladen, K. Khair
Great Ormond Street Hospital Haemophilia Centre, London, U.K.

E-mail: nicola.hubert@gosh.nhs.uk

Clinical outcomes are important aspects of hemophilia care; these include disease-specific tools evaluating medical and social consequences. The Paediatric Hemophilia Activities List (PedHAL) is a self-reported functional outcome questionnaire, measuring the impact of hemophilia on activities of daily living. This study reports the largest cohort to date using the PedHAL in a single U.K. hemophilia centre. Questionnaires were completed by patients with all severities of hemophilia A or B when attending hemophilia reviews. The PedHAL has 53 questions in seven subsections and is completed by children and/or parents. All scores are normalized, with a score range of 0 – 100 (worst to best function). 95 questionnaires were completed. Results were analysed looking at three groups; parent only (n=33, median age six years), child only (n=8, median age 14.5 years), child parent dyads (n=54, median age 11 years). The parent only group had the highest median total score (100, 50.6-100). The child only group had the lowest median total score (82.7, 48.8-100). The child parent dyads had the same median total scores (95.1, parent 44.1-100, child 57-100). The three subsections involving the lower limb: sitting/kneeling/standing, leg function, and leisure and sport had the lowest median scores reported by the child only and child parent dyads. These PedHAL scores were at the highest end of the scale, reflecting good functional status. Lower scores were observed in older boys. Further investigation of the lower scores is important to determine influencing factors, such as the number of bleeds, disease severity, joint health, or psychosocial aspects.

P2.21
Are age, prophylaxis, history of high-titre inhibitor and recent bleeding variables that affect HJHS in children with severe hemophilia?

M. Bladen¹, E. Main², R. Liesner³, E. Koutoumanou⁴,
N. Hubert¹, K. Khair¹
¹Great Ormond St Hospital for Children NHS Foundation Trust; ²Institute of Child Health, London, UK

E-mail: Melanie.Bladen@gosh.nhs.uk

Many variables may influence the frequency and severity of bleeding leading to joint damage and physical limitations in people with hemophilia. The variables age, prophylaxis, history of high-titre inhibitors (HTI), and recent bleeding events were evaluated to see if they influenced the Hemophilia Joint Health Score (HJHS) in children. In boys with severe hemophilia, aged 4-18 years, medical and physiotherapy were reviewed to collate information about the possible variables associated with increased HJHS. Total HJHS zero scores were seen in 44/83 (53%) of boys whose median age was 11 (range 0-25). The median HJHS was 0 (mean 2.6). Variables: age, number of recent bleeds, and tolerated status were all significant. History of a HTI demonstrated higher HJHS than those boys in the non-HTI group. A significant relationship was identified with number of recent bleeds, tolerated status, and age. The score rose on average by 28% for every year of age and by 76% for non-tolerized boys. In the non-HTI group, the HJHS for boys on late prophylaxis was 2.68 times higher than those who started early; the HJHS was on average 10% higher for every additional recent bleed. In this group, the odds of having a zero score fell by 30% for every year increase in age. Early prophylaxis and immune-tolerance are important outcome variables as evidenced from this study. Monitoring joint scores is essential to clinical management; the HJHS offers such an outcome measure. Advances in hemophilia care may pose challenges to understanding the HJHS given the likely rise in zero scores.

Keywords: HJHS and children

P2.22
Long-term follow-up of boys with severe hemophilia in one hemophilia centre

M. Bladen¹, N. Hubert¹, K. Khair¹, P. McLaughlin³,
S. Classey¹, F. Hall¹, E. Main¹
¹Great Ormond St Hospital For Children NHS Foundation Trust; ²The Royal Free Hospital; ³Guys and St Thomas Hospital; ⁴University Hospital of Wales, London, U.K., ¹Institute of Child Health, London, U.K.

E-mail: Melanie.Bladen@gosh.nhs.uk

The Hemophilia Joint Health Score (HJHS) is one method of evaluating long-term joint status in people with hemophilia, which is important for management. HJHS (v2.1) scores at transition to adult care from Great Ormond Street Hospital were

<table>
<thead>
<tr>
<th>Primary prophylaxis</th>
<th>Moderate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Secondary prophylaxis</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>No joint problems</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Joint loss/impaired function</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 joint</td>
</tr>
<tr>
<td>2 joints</td>
</tr>
<tr>
<td>3 joints or and more</td>
</tr>
<tr>
<td>Surgical procedures</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Functional ability score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excellent (5)</td>
</tr>
<tr>
<td>Good (3-5)</td>
</tr>
<tr>
<td>Bad (0-3)</td>
</tr>
<tr>
<td>Regular physiotherapy</td>
</tr>
<tr>
<td>Home exercise</td>
</tr>
</tbody>
</table>
Abstracts

P2.23

Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization

L. Nieuwenhuizen1,3, R. Schutgens1, K. Coeleveld1, S. Mastbergen2, G. Roosendaal1, D. Biesma1, F. Lafeber2

1Hematology & Van Creveldkliniek; 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

E-mail: L.nieuwenhuizen@umcutrecht.nl

Background: Joint bleedings result in iron-mediated synovitis and cartilage destruction. Monocyte/macrophage polarization affects their role in iron homeostasis: M1 cells have limited iron recycling capacities, whereas M2 cells have effective iron recycling capacities. Objective: The aim of this study was to evaluate the effects of hemarthrosis on monocyte/macrophage polarization. Methods: Using a murine hemophilia model of acute joint bleeding and flow cytometry, we evaluated monocyte/macrophage polarization in blood, spleen, synovium, and knee lavage at day 1, 2, and 7 following the induction of hemarthrosis. Results: Induction of hemarthrosis resulted in a transient shift of blood monocytes towards a M1 type (control 13 vs. 1847 counted cells at day 1; p<0.01), a temporary decrease of spleen M1 monocytes (control 2841 vs. 1086 counted cells at day 1; p=0.02), and a sustained decrease of spleen M2 red pulp macrophages (control 1853 vs. 673 counted cells at day 7; p=0.01). In addition, an increase in M1 (control 119 vs. 592 counted cells at day 1; p=0.04) and M2 (control 247 vs. 650 counted cells at day 1; p=0.02) synovial macrophages was noted. In the joint lavage, a temporary increase in M1 monocytes (control 20 vs. 125 counted cells at day 1; p=0.04) and a more sustained increase in M2 monocytes (control 73 vs. 186 counted cells at day 2; p<0.01) was observed. Conclusion: This study demonstrates for the first time alterations in monocyte/macrophage polarization, following hemarthrosis, resulting in a blood monocyte M1 phenotype and a combined M1-M2 monocyte/macrophage phenotype in the joint. Based on the different capabilities of M1 and M2 cells in iron homeostasis, modulating polarization of distinct monocyte/macrophage populations might represent interesting prophylactic or therapeutic approaches for joint bleedings.

Keywords: hemostasis, monocyte/macrophage polarization

P2.24

Antiplasmin, but not amiloride, prevents synovitis and cartilage destruction following hemarthrosis in hemophilic mice

L. Nieuwenhuizen1,3, G. Roosendaal1, K. Coeleveld1, D. Biesma1, F. Lafeber2, R. Schutgens1

1Hematology & Van Creveldkliniek; 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

E-mail: L.nieuwenhuizen@umcutrecht.nl

Introduction: In this study, we evaluate the alterations in synovitis and cartilage destruction following the induction of a joint bleeding in hemophilic mice treated with placebo, amiloride (a specific inhibitor of uPA), or antiplasmin. Methods: The right knees of hemophilic mice were punctured to induce hemarthrosis. Hemophilic synovitis and cartilage destruction were determined by two blinded observers according to Valentino and Glasson. An increase in Valentino and Glasson score represents an increase in hemophilic synovitis and cartilage destruction, respectively. Treatment with amiloride or antiplasmin was compared with control. Categorical data were analyzed by loglinear analysis and Pearson Chi-Square. Results: No significant alterations in synovitis and cartilage destruction were found when comparing the intra-articular amiloride group with the oral control group, and when comparing the intra-articular amiloride group with the intra-articular control group. In contrast, intra-articular treatment with antiplasmin resulted in a statistical significant (p<0.01) reduction in synovitis, as assessed by the Valentino score, when comparing the intra-articular control group to the intra-articular antiplasmin group: 1 (0% vs. 11.1%), 2 (4.2% vs. 11.1%), 3 (16.7% vs. 61.1%), 4 (29.2% vs. 5.6%), 5 (20.8% vs. 11.1%), 6 (8.3% vs. 7.7%), 7 (8.3% vs. 0%), and 8 (12.5% vs. 0%). Conclusions: Intra-articular treatment with antiplasmin following the induction of a joint bleeding prevented synovitis and cartilage destruction in hemophilic mice. Oral and intra-articular treatment with amiloride failed to attenuate synovitis and cartilage destruction. Given that complete prevention of joint bleeds in hemophilia is not feasible at the moment despite the prophylactic use of factor replacement, the data presented herein offer promise for the use of antiplasmin as a new therapeutic intervention.

Keywords: synovitis, antiplasmin
### Chair and Speaker Index

<table>
<thead>
<tr>
<th>Letter</th>
<th>Name</th>
<th>Affiliation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Ambroziak P.</td>
<td></td>
<td>A4.1</td>
</tr>
<tr>
<td>B</td>
<td>Bias V.</td>
<td>OC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blamey G.</td>
<td>A2, A4, C2.4</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Caviglia H.</td>
<td>A3.3, A4.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chen L.</td>
<td>B3.5, B4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Czepa D.</td>
<td>B4.2</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>Daffunchio C.</td>
<td>A4.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dange R.</td>
<td>PDW-Physio, B2.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>de Kleijn P.</td>
<td>PDW-Physio, B3</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>El-Ekiaby M.</td>
<td>B1, B3.4</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>Forsyth A.</td>
<td>PDW-Physio, OC, A1, B4.4, B4.7</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>Goddard N.</td>
<td>PDW-Ortho, B2, B3.3, C2.2</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>Haffar A.</td>
<td>OC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heijnen L.</td>
<td>PDW-Physio, A2, C2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heim M.</td>
<td>C2.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hilliard P.</td>
<td>C1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hoffman M.</td>
<td>A1.3</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td>Jankovic N.</td>
<td>PDW-Physio, A3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jayandharan G.</td>
<td>A1.1</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td>Lillicrap D.</td>
<td>B1.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Llinás A.</td>
<td>A3.2, A4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Luck J.</td>
<td>A3.1, B3</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>Manco-Johnson M.</td>
<td>A1.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>McLaughlin P.</td>
<td>A2, B4.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monahan P.</td>
<td>B2.1, B4.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moore M.</td>
<td>A4.4</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>Narayan P.</td>
<td>PDW-Physio, B2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nieuwenhuizen L.</td>
<td>B4.8</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>Pasta G.L.</td>
<td>C2</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td>Querol F.</td>
<td>B4.3</td>
<td></td>
</tr>
<tr>
<td>R</td>
<td>Reiss U.</td>
<td>B2.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rodriguez-Merchán C.</td>
<td>A1, B2.4</td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>Sabbour A.</td>
<td>PDW-Physio, B3.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sayers L.</td>
<td>A4.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Silva M.</td>
<td>PDW-Ortho, PH, A2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simpson M.</td>
<td>A1.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solimeno L.P.</td>
<td>A2, A3, A4.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Srivastava A.</td>
<td>OC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephensen D.</td>
<td>PDW-Physio , B3.1, B4.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Strauss A.</td>
<td>A4.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sun J.</td>
<td>B4.10</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>Thomas S.</td>
<td>A4.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toledo S.</td>
<td>PDW-Physio</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>Valentino L.</td>
<td>A2, B2.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>van Vulpen L.F.D.</td>
<td>A4.6, A4.10</td>
<td></td>
</tr>
<tr>
<td>W</td>
<td>Weill A.</td>
<td>OC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wells A.</td>
<td>B4.5</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>Young N.</td>
<td>C1.1</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td>Zourikian N.</td>
<td>B4, C2.3</td>
<td></td>
</tr>
</tbody>
</table>
Arthopathy and Arthroplasty

P1.01 Utility of the arthroscopic debridement in chronic arthropathy in hemophilic patients

P1.02 Repeated autologous intra-articular blood injections as an animal model for joint pain in hemophilic arthropathy
M. Boettger 1,2,3, S. Kruecker 1, M. Gajda 2, H. Schäuble 1, T. Hilberg 2
1Institute of Physiology I - University Hospital, Friedrich-Schiller University, Jena; 2Department of Sports Medicine - University Wuppertal, Wuppertal; 3Current address - Bayer Pharma AG, Wuppertal; 4Institute of Pathology, University Hospital Jena, Jena, Germany

P1.03 Arthroscopic treatment of hemophilic ankle arthropathy
G. Pastia 1, M. Mancuso 2, E. Cristini 1, P. Gozzi 2, E. Santagostino 1, L. Solimeno 1
1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico, 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy

P1.04 Standardized ultrasonography of joints and correlation with joint function in children and young adults with hemophilic arthropathy
M. Sigl-Kraetzig 1, A. Seuser 1, M. Wendel 1
1IPFW - Institute for pediatric research and further education, Blaubeuren; 2Pediatric practice and haemophilia treatment center, Blaubeuren; 3Institute for motion analysis (IBQ), Bonn, Germany

P1.05 Early complications after total knee replacement in people with hemophilia
P. Zbikowski 1, P. Ambroziak 1, J. Windygá 1, A. Miśka 2, M. Maruzewski 1, I. Kotela 1
1Central Clinical Hospital of the Ministry of Interior, Warsaw; 2Institute of Hematology and Transfusion Medicine, Warsaw; 3The Jan Kochanowski University in Kielce, Kielce, Poland

P1.06 Simultaneous bilateral knee arthroplasty in hemophilia patients: report of two cases

P1.07 Functionality and quality of life of hemophilic persons undergoing a bilateral total knee arthroplasty
C. Lorenzato 1, P. Prado 2, A. Wolff 3, L. Rocha Loures Pacheco 3
1Hemepar - Haemocentre from Paraná, Brazil; 2University of São Paulo - USP, Brazil; 3UFPR-Federal university from Paraná, Curitiba, Brazil

P1.12 Joint distraction results in clinical and structural improvement of hemophilic ankle arthropathy: a series of three cases
L.F.D. van Vulpén 1,2, M.E.R. Van Meegeren 1,2, K. van Veghel 1, P. de Kleijt 1, P.M. van Roermund 3, D.H. Biesma 4, G. Roosendaal 1, S.C. Mastbergen 1, P.P.J. Lenaers 1
1Rheumatology & Clinical Immunology; 2Haemophilia and Ven Creveld Clinic, Orthopaedic Surgery, University Medical Center Utrecht, The Netherlands

P1.13 Musculoskeletal status of adult Saudi patients with severe hemophilia
A.K. Almomen 1, F. Aljasim 1, M. Alfarhan 1
1Center of Excellence in Thrombosis and Hemostasis, College of Medicine; 2Department of Physical Therapy, King Khalid University Hospital; 3Department of Radiology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

P1.14 Peripelvic myositis ossificans in a hemophilic adolescent
D.Y. Petratos 1, H. Pergantou 2, T. Almonte 3, A. Chan 3, K. Decker 3, R. Goldsmith 4, T. Owaidah 1, M. Alfarhan 1, F. Aljassir 1, A.K. Almomen 1, 7Aristotle University of Thessaloniki, Thessaloniki, Greece; 6Novo Nordisk A/S, Søborg, Denmark; 8The University of Iowa Carver College of Medicine, Iowa City, U.S.A.

P1.15 ACL reconstruction in active athlete with factor VII deficiency: Case Report
J. Walawski 1,2, T. Tomasz Wrzak 3, M. Kołasa-Nowicka 4
1MSW Hospital Lublin; Private Practice Ortomax, Lublin; 2Orthopaedic and Traumatology Department, Medical University, Lublin; 3Department of Disorders of Haemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw Poland

Care Delivery

P1.23 Interdisciplinary musculoskeletal clinic for persons with inherited bleeding disorders (PWBD)
1Hamilton Niagara Regional Bleeding Disorders Program, Hamilton Health Sciences, Hamilton, Canada

Inhibitors

P1.17 Hemostatic management of children with severe hemophilia, A, B and von Willebrand disease (VWD) and high responding inhibitors undergoing orthopedic surgeries
H. Pergantou 1, G. Matison 1, D.Y. Petratos 2, J. Anastasopoulos 3, H. Platokouki 4
1Haemophilia Centre/Haemostasis Unit; 22nd Orthopedic Department, Agia Sophia Children’s Hospital, Athens, Greece

P1.18 Elective orthopedic surgery in hemophilic patients with inhibitors
L.P. Solimeno 1, M. Mancuso 2, E. Santagostino 2, T. Donzelli 2, P. Techio 2, G. Pastia 2
1Ortho-Trauma Unit, Fondazione IRCCS Granda Ospedale Maggiore Policlinico, 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine, Milan, Italy

P1.24 Efficacy and safety of rFVIIa, used as comparator in development of a new rFVIIa analogue: data from a phase 3 trial on vatreptacog alfa in hemophilia patients with inhibitors
J. Windygá 1, J. Miahluangi 2, P. Abdul Karim 1, Tatiana Andreeva 4, Marina Economou 3, Silke Ehrenforth 5, Steven Lente 2, on behalf of the adept 2 investigators
1Institute of Hematology and Transfusion Medicine, Warsaw, Poland; 2University of the Witwatersrand, Johannesburg, South Africa; 3National Blood Centre, Kuala Lumpur, Malaysia; 4Republican Center for Hemophilia Treatment, St. Petersburg, Russia; 5Aristotle University of Thessaloniki, Thessaloniki, Greece; 6Novo Nordisk A/S, Søborg, Denmark; 7The University of Iowa Carver College of Medicine, Iowa City, U.S.A.

Orthopedic Issues
**Poster Index**

**P1.16** Surgical and non-surgical management of Pelvifemoral bone bridges in patients with hemophilia
S. Aydogdu, C. Kavakli, C. Balkan, G. Saydam
Departments of Orthopededics, Pediatric Haematology, Adult Haematology, Ege University Hospital Izmir, Turkey

**P1.19** The diagnosis of Acute Compartment Syndrome (ACS) in hemophilia
S. Classey
Guy's and St Thomas' Foundation Trust Hospital, London, UK

**P2.1.21** Factors influencing on functional independence score in hemophilia
1Orthopedic Department, Ghaem Hospital; 2Sheikh Hospital for Children, Orthopedic and Trauma Research Center, Ghaem Hospital Mashhad University of Medical Sciences, Mashhad, Iran

**Outcome Measures**

**P2.20** Using the PediHAL to measure functional abilities in children with hemophilia
N. Hubert, A. Grifflon, N. Sugg, M. Bladen, K. Khair
Great Ormond Street Hospital Haemophilia Centre, London, UK

**P2.21** Are age, prophylaxis, history of high-titre inhibitor and recent bleeding variables that affect HJHS in children with severe hemophilia?
M. Bladen, E. Main, R. Lienzer, E. Koutoumanos, N. Hubert, K. Khair
1Great Ormond St Hospital for Children NHS Foundation Trust, 2Institute of Child Health, London, UK

**P2.22** Long-term follow up of boys with severe hemophilia in one hemophilia centre
M. Bladen, N. Hubert, K. Khair, P. McLaughlin, S. Classey, F. Hall, E. Main
1Great Ormond Street Hospital Haemophilia Centre, London, UK

**Pediatric Issues**

**P2.16** Safety concerns for small children in radioisotope synovectomy for hemophilia: 12 years of experience from a single center
K. Kavakli, S. Aydogdu, H. Ozkirci, C. Balkan, D. Karapinar, N. Karadas, S. Senol
Departments of Orthopedics, Pediatric Haematology, Nuclear Medicine, Faculty of Nursing, Pediatrics, Ege University Hospitals Dept., Izmir, Turkey

**P2.17** Thermographic and clinical comparison of children with hemophilia and healthy age matched children
A. Seuser, K. Kurnik, C. Bidlingmaier, A. Mahlein
1Institute for Spectral Medicine, 53225 Bonn; 2Von Hauner Hospital for Children, Munich, Germany

**P2.18** Obesity and metabolic syndrome in Mexican children with hemophilic arthropathy
A. Taculco-Parra, E. Velaquez-Jimenez, R. Garibaldi-Covarrubias, J. Soto-Padilla, E. Guerra-Gutierrez
1Medical Research Division, UMAE Hospital de Ped, Guadalajara; 2Pediatric Hematology Department, UMAE Hospital de Ped, Guadalajara; 3Dermatology Department, Instituto Dermatolog, Zapopan, Mexico

**P2.19** Joint health and functional ability in children with hemophilia in Bosnia and Herzegovina
1Department Hematology Oncology, University Children's Hospital, Banjaluka; 2Department of Hematology Oncology, University Children's Hospital, Sarajevo, 3Department Hematology Oncology, University Children's Hospital, Tuzla; 4Cantonal Hospital, Zenica, Bosnia & Herzegovina

**Physiotherapy Issues**

**P2.01** The effect of a home-based exercise program on postural balance in children with hemophilia: two case studies
F. Melo Bessa De Souza, B. Romanelli Ortiz, M. VerÁssimo Oliveira, C. Mendes Carmo, M. Helena Mello, P. Villa, C. Tanaka
1Physical Therapy Service, Clinical Hospital; 2Hemophilia Center, Clinical Hospital, University of Sao Paulo, Sao Paulo, Brazil

**P2.02** Physiotherapy is an important element of the modern hemophilia treatment
S. Halimeh, M. Rosenthal
1GZRR Coagulation Centre Rhine/Ruhr; 2GZRR Coagulation Centre Rhine/Ruhr, Duisburg, Germany

**P2.03** Effects of cold application on pain sensitivity in hemophilia knee - results of a randomized controlled study
D. Czepe, I. Kirstein, S. Krueger, E. Staueber, H. Stephan, T. Miliszewski, T. Hilberg
Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany

**P2.04** Physical strength, architecture and neuromuscular function in adolescent boys with hemophilia, following lower limb joint hemarthrosis
L.B. Suckling, D. Stephens, M.C. Cramp, W.L. Drechsler
1School of Health, Sport and Bioscience, University of East London, Stratford, London, UK; 2Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, United Kingdom

**P2.05** Effectiveness of joint traction and PNF in hemophilic arthropathy of elbow
R. Cuesta-Barriloso, M. Moreno-Moreno, D. Garcia-Diego
1Department of Physiotherapy, Faculty of Medicine, University of Murcia, Murcia; 2Service of Hematology, University Hospital Virgen de la Arrixaca, Murcia; 3Spanish Federation of Haemophilia, Madrid; 4Instituto Universitario Ortega y Gasset, Madrid, Spain

**P2.06** Improved ambulation and weight bearing in hemophilia patients with affected lower limbs using the SmartStep® Gait System
R. Tikitsky, G. Kenet, M. Heim, U. Martinowitz
National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
P2.07
Building evidence into practice: proposed evidence-based updates to the Canadian physiotherapists in hemophilia care (CPHC) standards of care
1Hamilton Health Sciences, McMaster Children’s Hospital, Hamilton, ON; 2McMaster University, School of Rehab Science, Hamilton, ON; 3Health Sciences North, Sudbury, ON; 4TWO Health Centre, Halifax, NS; 5Adult Inherited Bleeding Disorder Program of B.C., St. Paul’s Hospital, Vancouver, BC; 6Centre de traitement de l’hémophilie pour l’Est du Québec, CHU de Québec, Québec, QC, Canada

P2.08
Physiotherapy, physical activity and sport in a program of prophylaxis of arthropathy in adult hemophilia patient
S. Pérez-Alenda1,2, F. Querol2,3, L.M. González1, M. Jaca1, J.A. Vila1, C. Aznar4
1Institute of Social Sciences Ivo Pilar; 2University of Murcia; 3Department of Physiotherapy, Faculty of Medicine, University of Murcia; 4Radiology Service University and Polytechnic Hospital La Fe, Valencia, Spain

P2.09
Incidence of bone mass deficit in the hemophilic patient: aspects related to physiotherapy and quality of life
F. Querol1,2, S. Pérez-Alenda1,2, F. Aparisi1, M. Jaca1, C. Vila1, J.A. Aznar4
1University of Valencia; 2Haemostasis and Thrombosis Unit, University and Polytechnic Hospital La Fe, Valencia, Spain

Pseudo-tumor
P1.20
Surgical resection of a pseudotumour in Myanmar
S. Htut1,2, A. Myo Thant2, K. Thu Tun2, K. Nwe Oo1, A. A. Khaing3
1Department of Orthopaedics, Yangon Orthopedic Hospital; 2Department of Haematology, Yangon Children Hospital, Yangon, Myanmar

Quality of Life
P2.14
Impact of hemophilic arthropathy on quality of life
R. Cuesta-Barriloso1, M. Moreno-Moreno1, A. Turriz-Ortuño1
1Department of Physiotherapy, Faculty of Medicine, University of Murcia; 2Service of Hematology, University Hospital Virgen de la Arrixaca; 3Psychiatry and Social Psychology Department, University of Murcia, Murcia, Spain

P2.15
Characteristics of orthopedic status and their impact on the quality of life of the psychosocial functioning of persons with hemophilia
M. Marinic1, S. Zaguncic-Salek2
1Institute of Social Sciences Ivo Pilar; 2University Hospital Centre Zagreb, Zagreb, Croatia

Rehabilitation
P2.11
Posturgical mobility of total knee replacement in patients with hemophilia (PWH) operated without tourniquet
C. Daffunchio1,2, G. Galatro3,4, N. Moretti5, H. Cavagnola6, M. Candela7, P. Salgado8
1Fundación de la Hemofilia, 2Hospital Juan A. Fernández, Servicio de Ortopedia y Traumatología, 3Academia Nacional de Medicina, Buenos Aires, Argentina

P2.12
Fisiccare: a new approach to physiotherapy based on self-treatment
E. Forneris1, M. Messina2, C. Bruno3, E. Boccalandro4
1Center for Rehabilitation of the Republic of Mexico, México; 2Haemophilia Centre; Policlinico, Bari- Italy

Research
P2.23
Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization
L. Nieuwenhuizen1,2, R. Schutgens3, K. Coeckelbergh3, S. Mastbergen1, G. Roosendaal4, D. Biesma3, F. Lefever3
1Hematology & Van Creveldkliniek; 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

P2.24
Antiplasmin, but not amiloride, prevents synovitis and cartilage destruction following hemarthrosis in hemophilic mice
L. Nieuwenhuizen1,2, G. Roosendaal3, K. Coeckelbergh3, D. Biesma3, F. Lefever3
1Hematology & Van Creveldkliniek; 2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

Synovectomy
P1.08
Surgical synovectomy in pediatric patients with severe factor VII deficiency
S. Peltier, S. Kearney, M. Heisel-Kurth
Children’s Hospitals and Clinics of Minnesota, Center for Bleeding and Clotting Disorders, Minneapolis, MN, USA

P1.09
The economic effect of tandem arthroscopic synovectomy for hemophilic patients
Y. Inagaki1, Y. Tanaka1, K. Murata1, Y. Sakamoto1, T. Kuma1, K. Uemastu2, A. Taniguchi3, M. Ogawa4, H. Nakai4, S. Omokawa5, K. Nomura5, M. Shima2
1National Haemophilia Center and Haemostasis Department, Budapest, Hungary; 2Department of Orthopaedic Surgery, St. Paul’s Hospital, Vancouver, BC

P1.10
Radiosynoviorthesis in the treatment of chronic hemophilic synovitis
I. Szerb1, L. Bartha1, L. Nemes3
1University Medical Center Utrecht, Utrecht, The Netherlands; 2Hematology & Van Creveldkliniek; 3Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

Sports and hemophilia
P2.13
Effectiveness of training program in open waters, pool, and land exercise in adolescents with hemophilia arthropathy
A. Gibraltar Conde1, M. Osorio Guzmán2, M.A. Gutierrez Agasmo3
1UMAF “Dr. Victorio de la Fuente Narvaez”. Uisty of Physical Medicine and Rehabilitation North, ** ** UNAM Facultad de Estudios Superiores Iztacala, ***Hemophilia Federation of the Republic of Mexico, Mexico
For a chance to win a complimentary one-year WFH Membership, sign up or renew during the WFH 13th International Musculoskeletal Congress 2013.

The MSK Committee requires that all voting members during the Annual General Assembly must be a current WFH Member.

Together, we will Close the Gap.

www.wfh.org/membership
WFH MEMBERSHIP FORM

YES!
I WANT TO SUPPORT THE WFH AND TREATMENT FOR ALL.

Please sign me up as a(n):
☐ Sustaining member: US$100
☐ Individual member: US$60
☐ Person with bleeding disorder/Family member: US$30

Please sign my HTC/organization/company up as an:
☐ Associate/Organizational member: US$300 (On a separate sheet, please provide contact information for the six individuals from your organization who will receive membership benefits.)

I would like to give a gift of membership
☐ Gift of WFH membership: US$50

ABOUT YOU

☐ Dr. ☐ Mr. ☐ Mrs. ☐ Ms. ☐ Miss ☐ Other

First name ____________________________________________
Last name ____________________________________________
Organization __________________________________________
Address ______________________________________________
City ______________________ State/Province ______________
Zip/Postal Code ___________ Country _________________
E-mail _______________________________________________
Telephone __________________ Fax ___________________

GIFT MEMBERSHIP

☐ Dr. ☐ Mr. ☐ Mrs. ☐ Ms. ☐ Miss ☐ Other

First name ____________________________________________
Last name ____________________________________________
Organization __________________________________________
Address ______________________________________________
City ______________________ State/Province ______________
Zip/Postal Code ___________ Country _________________
E-mail _______________________________________________
Telephone __________________ Fax ___________________

This gift is for a: ☐ Person with a bleeding disorder ☐ Family member
☐ Friend ☐ Student ☐ Other

PROFILE

Please indicate all the categories that apply to you:
☐ Dental professional
☐ General practitioner
☐ Hematologist
☐ Laboratory personnel
☐ NMO staff/volunteer
☐ Nurse
☐ Occupational therapist
☐ Orthopedist
☐ Pediatrician
☐ Physiatrist
☐ Physiotherapist
☐ Researcher/scientist
☐ Rheumatologist
☐ Social worker/psychologist
☐ Student
☐ Other _________________________________________

I work for:
☐ Treatment centre or hospital
☐ Industry
☐ Government or regulatory agency
☐ Non-profit organization
☐ Other ________________________________

Preferred language:
☐ English ☐ Spanish ☐ French

WFH publication preference:
☐ Print ☐ Electronic

PAYMENT INFORMATION

Total memberships fees ______________________________________

☐ My cheque or money order is enclosed, payable to the World Federation of Hemophilia in US dollars drawn from a US bank or the US correspondent of my local bank.

I wish to pay by: ☐

Credit card number _________ - _________ - _________ - _________
Expiration __________________________________________
Name on card (please print) __________________________________
Signature _____________________________________________

You can also go to www.wfh.org and follow the membership link to a secure form.
WFH MEMBERSHIP FORM

YES! I WANT TO SUPPORT THE WFH AND TREATMENT FOR ALL.

Please sign me up as a(n):

¨ Sustaining member: US$100
¨ Individual member: US$60
¨ Person with bleeding disorder/Family member: US$30

Please sign my HTC/organization/company up as an:

¨ Associate/Organizational member: US$300 (On a separate sheet, please provide contact information for the six individuals from your organization who will receive membership benefits.)

I would like to give a gift of membership

¨ Gift of WFH membership: US$50

ABOUT YOU

¨ Dr.
¨ Mr.
¨ Mrs.
¨ Ms.
¨ Miss
¨ Other

First name  __________________________________________________
Last name   __________________________________________________
Organization   ________________________________________________
Address   ___________________________________________________
City   ______________________  State/Province   __________________
Zip/Postal Code   ____________  Country   _______________________
E-mail   _____________________________________________________
Telephone  _________________  Fax   ___________________________

GIFT MEMBERSHIP

¨ Dr.
¨ Mr.
¨ Mrs.
¨ Ms.
¨ Miss
¨ Other

First name  __________________________________________________
Last name   __________________________________________________
Organization   ________________________________________________
Address   ___________________________________________________
City   ______________________  State/Province   __________________
Zip/Postal Code   ____________  Country   _______________________
E-mail   _____________________________________________________
Telephone  _________________  Fax   ___________________________

This gift is for a:

¨ Person with a bleeding disorder
¨ Family member
¨ Friend
¨ Student
¨ Other

PROFILE

Please indicate all the categories that apply to you:

¨ Dental professional
¨ General practitioner
¨ Hematologist
¨ Laboratory personnel
¨ NMO staff/volunteer
¨ Nurse
¨ Occupational therapist
¨ Orthopedist
¨ Pediatrician
¨ Physiatrist
¨ Physiotherapist
¨ Researcher/scientist
¨ Rheumatologist
¨ Social worker/psychologist
¨ Student
¨ Other   ___________________________________________________

I work for:

¨ Treatment centre or hospital
¨ Industry
¨ Government or regulatory agency
¨ Non-profit organization
¨ Other   ___________________________________________________

Preferred language:

¨ English
¨ Spanish
¨ French

WFH publication preference:

¨ Print
¨ Electronic

PAYMENT INFORMATION

Total memberships fees   _______________________________________

¨ My cheque or money order is enclosed, payable to the World Federation of Hemophilia in US dollars drawn from a US bank or the US correspondent of my local bank.

I wish to pay by:

¨ ¨ Credit card number  _________ - _________ - _________ -  ___________
Expiration   __________________________________________________
Name on card (please print)   ____________________________________
Signature   __________________________________________________

You can also go to www.wfh.org and follow the membership link to a secure form.

Some see inhibitors as a lifetime of tests, bleeds, and complications.
Novo Nordisk helps them see a lifetime of possibilities.

We help provide the financial, educational, and community support he needs.

The financial, educational, and community support programs offered by Novo Nordisk have helped people with hemophilia A or B with inhibitors live more normal lives.
To find out how Novo Nordisk can help change your patients’ possibilities, visit ChangingPossibilities-US.com.

Novo Nordisk Inc., 100 College Road West, Princeton, New Jersey 08540 U.S.A.
Changing Possibilities in Hemophilia® is a registered trademark owned by Novo Nordisk Health Care AG.
© 2012 Novo Nordisk  Printed in the U.S.A.  0212-00007699-1  April 2012
WFH 2014 WORLD CONGRESS
THE LARGEST INTERNATIONAL MEETING FOR THE GLOBAL BLEEDING DISORDERS COMMUNITY
MELBOURNE, AUSTRALIA • MAY 11-15

www.wfh2014congress.org